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1. FeMALe SexUALITy AND FeMALe SexUAL DySFUNCTION
Sexual reproduction is one of the most universal, fundamental and essential 
processes that all species have in common. Sexuality in humans, however, 
goes far beyond the basic principles of reproduction and entails complex 
interactions of biological, psychological and sociocultural variables. Few other 
biological systems are as multifaceted as sexuality. Beyond neurobiological 
factors that influence sexual function, several studies, including the National 
Health and Social Life Survey (NHSLS) that was conducted in the United 
States [1], point out that sexuality in women is closely linked to psychological 
factors, quality of their relationship with a partner and lifestyle [2-7], and that 
all are influenced by cultural, family and personal expectations [2, 3; 8-10]. 
Ultimately, sexuality serves a basic emotional health need for all individuals. 
Despite this understanding, sexual function in general, and female sexual 
function in particular, remains a relatively understudied area of scientific and 
clinical investigation, although pharmacotherapeutic interest has intensified 
research in recent years [11].
Masters and Johnson (1966) were among the first to describe and 
characterize female sexual function by proposing a linear, four stage model of 
the human sexual response. This traditional view divides a woman’s sexual 
response into four sequential stages, starting with spontaneous sexual 
desire that leads to sexual arousal, and that is then followed by orgasm and 
resolution [12]. Later observations made it evident that this view of the female 
sexual response is just one of several normal variants in sexual responses in 
women [13]. For example, studies of women in established relationships show 
that desire by itself is not a frequent reason to engage in sexual activity [14], 
while other reasons such as the nurture of emotional closeness with a partner, 
the increase of their own sense of well-being, or the avoidance of negative 
consequences of sexual inactivity are commonly reported to also play a role 
[2, 3, 9, 10]. Other reports suggest that that female sexual desire and sexual 
arousal are overlapping concepts that women find difficult to separate [13]. At 
the same time, functional imaging studies in women reveal that subjectively 
perceived sexual arousal is often unrelated to objectively measured sexual 
arousal (reviewed in [6, 7, 15]). These and other observations led to novel 
views on women’s sexuality and spurred the development of alternative 
models of the female sexual response cycle, centering around sociocultural 
and relationship factors [2, 8]. The model proposed by Basson (Figure 1, [8]) 
may be the most accurate for women with a history of sexual problems [16].
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Following the groundbreaking work by Masters and Johnson, the Diagnostic 
and Statistical Manual of Mental Disorders (DSM) implemented a classification 
system for female sexual dysfunctions (FSDs) that is based on the female 
sexual response stages. Sexual problems are divided into disorders of desire 
(hypoactive sexual desire disorder (HSDD), sexual aversion), arousal, orgasm 
and pain (dyspareunia and vaginismus). In the 4th edition (DSM-IV) and text-
revised 4th edition (DSM-IV-TR), attention is paid to psychological factors such 
as interpersonal distress, which must be subjectively perceived by the female 
patient for the diagnosis of certain sexual dysfunctions, including HSDD. 
The NHSLS reveals that sexual dysfunction is prevalent across the entire 
demographic population and found in 43% of the women who participated in 
the NHSLS study at some point in their lives [1]. Among female sexual desire 
subgroups, low sexual desire is the most frequently reported complaint in 
women (32%; Figure 2). Clinically relevant, personally distressing occurrence 
of HSDD is reported in approximately 1 in 10 women [6, 7, 17]. With the 
exception of estrogen therapy for impaired genital vasocongestion in response 
to sexual stimulation and, in some countries, testosterone formulations for 
reduced desire, there are currently no approved drugs for the treatment of 
sexual dysfunction in women despite their high prevalence [18].




Sexual desire and sexual arousal have traditionally been regarded as two 
distinct though related phenomena, a concept which seems to fit the sexual 
experience in men, but less in women [19]. In fact, some women find it difficult 
to differentiate arousal from desire [13]. Bancroft and Graham [13] describe 
sexual desire and sexual arousal as overlapping concepts. They suggest that 
sexual arousal involves (i) information processing of sexual stimuli involving 
unconscious and conscious cognitive mechanisms, (ii) incentive motivation 
that includes activation of the dopaminergic incentive motivational system, 
(iii) induction of generalized central nervous system (CNS) arousal, and 
(iv) genital response. The state of sexual desire, in contrast, involves only 
some of these components (usually components (i) and (ii)). The DSM-IV-
TR defines HSDD as persistent or recurrent deficiency or absence of sexual 
fantasies and thoughts, and/or desire for, or receptivity to, sexual activity, 
which causes personal distress or interpersonal difficulties and is not caused 
by a medical condition or drug. Distress is an integral part of HSDD diagnosis. 
A diagnosis of HSDD requires a clinical evaluation, taking into account factors 
that affect sexual functioning, such as age and the context of the woman’s life 
[20]. Despite of its prevalence, the acronym HSDD is poorly understood by 
clinicians, and the current DSM-IV-TR definition of HSDD has been criticized. 
There is an ongoing debate for combining arousal and desire into one disorder, 
and to include duration, intensity, and frequency to the definition of HSDD in 
the upcoming DSM-5 edition [20, 21]. The debate, however, goes beyond the 
scope of this thesis and its outcome neither affects objectives nor results of 
the experimental chapters presented in this book (Chapters 2-5).
Figure 2. Prevalence of sexual dysfunction in women. Adapted from the National Health 
and Social Life Survey (NHSLS) [1].
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2. THe NeUROBIOLOGy OF FeMALe SexUAL BeHAVIOR
Following the principle that animal and human behavior is based on an 
underlying neurobiological substrate, neuroscientists are facing the challenge 
of dissecting and reducing the multifaceted behavior of female sexuality into 
separate components that can be studied individually. Health psychologists 
and ethologists, on the other hand, are equally challenged with the integration 
of complex etiological factors to explain the behavioral expression of female 
sexuality. The display of female sexual behavior, as well as the lack thereof, 
is the net result of motivational states, sensory stimuli, hormonal and 
neurochemical environments, previous experience, cultural influences and 
many other factors.
For practical and ethical reasons, many studies attempting to unravel the 
neurobiology of female sexual behavior have been performed in animals, and 
mostly in rodents. Pfaff and colleagues succeeded in describing the complete 
neural circuit of a primary reproductive behavior, lordosis behavior, in the female 
rat [22]. Lordosis behavior is a sexual response of the female to male tactile 
stimulation and consists of a ventral arching of the spine, thus allowing for 
copulation. In short, somatosensory stimulation of the female’s flanks, tailbase 
and perineum by the male’s paws and penis activate pressure receptors that 
signal via ascending spinal neurons to nuclei in the brain stem (medullary 
reticular formation and lateral vestibular nucleus), midbrain (midbrain reticular 
formation and periaqueductal gray, PAG) and hypothalamus (medial preoptic 
area, mPOA, medial anterior and ventromedial hypothalamus, VMH), where 
estradiol and progesterone are necessary to facilitate the behavior. Integrated 
signals are projected via the brain stem nuclei to descending pathways of the 
lumbar spinal cord, leading to the contraction of deep back muscles to elicit 
lordosis behavior [22]. Further studies in rodents applying lesion, electrical 
stimulation, tract-tracing and Fos-immunoreactivity (Fos-IR) techniques 
revealed other brain structures involved in different aspects of female sexual 
behavior.  Following mating, Fos-IR is not only activated in the mPOA, VMH, 
and PAG, but also in the bed nucleus of the stria terminalis (BNST) and central 
tegmental field (CTF) [23-27]. Chemosensory investigation of the anogenital 
area induces Fos-IR in the posteromedial part of the BNST only [28], while 
vaginocervical stimulation either by a high number of penile intromissions 
or manual probing induces Fos-IR in the mPOA and BNST, and also in the 
medial amygdala and parvocellular subparafascicular nucleus [25, 26, 28, 
29]. Importantly, combined estrogen and progesterone treatment in female 
rodents activates Fos-IR in most of the same brain areas that are activated 
after mating, including the pivotal VMH and mPOA, confirming the high density 




and environmental signals relevant to sexual function may converge in these 
brain structures to determine the expression of female sexual behavior.
In female cats, a similar neural circuit to rats has been found to control 
lordosis behavior. Neurons in the nucleus retroambiguus (NRA), located in 
the brain stem, send descending projections to lumbosacral motoneurons that 
control the lower limbs and trunk to produce the copulatory posture. The NRA 
receives sensory information from the midbrain central gray, which in turn is a 
projection area for hypothalamic, amygdaloid and cortical neurons. Estradiol 
regulates the strength of the NRA-lumbosacral connection, explaining why 
lordosis behavior only occurs when the female cat is in estrous [31].
While experiments as described above are limited in their applicability to 
animal studies, more recent advances in functional imaging methods provide 
a window into the conscious human mind and allow for the study of neural 
correlates of human behavior. Both functional magnetic resonance imaging 
(fMRI) and positron emission tomography (PET) approaches have attempted 
to investigate the brain activity during different sexual states, ranging from 
sexual interest to arousal and orgasm. fMRI studies in women show that 
several cortical areas (medial prefrontal, anterior cingulate, orbitofrontal, 
insular, entorhinal and occipitotemporal cortices) as well as the amygdala 
and ventral striatum are activated in response to the visual presentation 
of erotic video clips [32, 33]. Interestingly, the peripheral sexual response 
seems not to be correlated to either the subjective sexual response or brain 
activation patterns [33]. In a H215O PeT study, clitoral stimulation of women 
by their partners leads to activation of the medial areas of the somatosensory 
and somatomotor cortices, which represent the pelvic region. These same 
regions are also activated during orgasm, although in a less pronounced 
fashion. Orgasm is furthermore characterized by an activated rostromedial 
cerebellum [31, 34]. Most strikingly, while some brain areas are activated 
during sexual stimulation and orgasm, much larger areas are deactivated, 
especially during orgasm. Clitoral stimulation deactivates the amygdala and 
the posterior temporal lobe mainly in the left hemisphere, and these same 
structures, together with large areas of the ventral temporal lobe and ventral 
prefrontal cortex, are also deactivated during orgasm. This study, together 
with an fMRI study that demonstrates greater activation of the medial frontal 
and right inferior frontal gyri in women with HSDD when watching erotic video 
clips [33], suggests that the deactivation of certain neural processes involved 
in alertness and thought processing is important for the experience of sexual 
arousal and orgasm, while HSDD patients may allocate more attention to 
monitoring and evaluating their sexual responses.
Of equal importance as the description of anatomical structures involved in 
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the regulation of female sexual behavior, including female sexual desire, is the 
characterization of neurochemical and hormonal mediators that orchestrate 
the neural activity within and between these brain regions. In a recent review 
publication [35], Pfaus applies the concept of separate but interactive neural 
systems for behavioral excitation and inhibition of female sexual behavior 
(Figure 3) and stresses that behavior can commence either because of direct 
excitation, or through a process of disinhibition. Neurobiological mechanisms 
of this dual control model for sexual behavior include, on the excitatory side, 
the central dopamine (DA) and norepinephrine (NE) neurotransmitter systems, 
as well as the neuropeptides oxytocin (OT) and melanocortin (MC), and the 
steroid hormones estradiol (E2) and testosterone (T). DA facilitates sexual 
excitement via mesolimbic/mesocortical, nigrostriatal and incertohypothalamic 
pathways. The mesolimbic/mesocortical pathway sends projections from the 
ventral tegmental area (VTA) to the nucleus accumbens (NAcc), amygdala 
and frontal cortex [35]. The medial prefrontal cortex (mPFC) is of particular 
interest as it is a key region implicated in executive control and behavioral 
inhibition [36, 37].
 
The nigrostriatal pathway sends projections from cell bodies in the substantia 
nigra to the striatum, while in the incertohypothalamic pathway, dopaminergic 
cell bodies in the zona incerta send projections to the mPOA. In estradiol and 
progesterone primed ovariectomized female rats, DA levels increase in the 
NAcc when the females are exposed to a sexually active male, and even more 
Figure 3. Excitatory-inhibi-
tory model of female sexual 
behavior. Adapted from [35]. 
5-HT, serotonin; eCBs, endog-
enous cannabinoids; DA, dopa-
mine; Ne, norepinephrine; OT, 
oxytocin; MCs, melanocortins; 




during copulation. Copulation also elevates DA in the dorsal striatum [38]. 
DA antagonists generally inhibit proceptive, or appetitive, sexual behavior in 
female rats [39]. When D1 and D2 agonists are directly administered to the 
mPOA of estradiol primed ovariectomized rats, proceptive sexual behavior 
is selectively increased or decreased, depending on the specificity of the 
administered ligands to D1 or D2 receptors. This study suggests that it is the 
ratio of DA D1/D2 activity within the mPOA that influences the expression of 
proceptive sexual behavior [40].
The activation of the melanocortin receptors MC3R and MC4R in the brain 
increase female proceptive behavior in the rat, without affecting receptive 
(lordosis) behavior [41]. Peripheral administration of the MC3R and MC4R 
agonist bremelanotide induces c-fos expression in the mPOA and other 
hypothalamic and limbic brain regions. Direct infusion of bremelanotide into the 
mPOA facilitates proceptive, but not receptive, sexual behavior in the female 
rat, while administration to the VMH is without effect [42]. Subcutaneous 
administration of bremelanotide to ovariectomized and hormonally primed 
females also increases DA selectively in the mPOA, but not in the NAcc or VMH, 
suggesting that bremelanotide’s effect on female sexual behavior is mediated 
by DA in the mPOA, a hypothesis that is supported by the observation that D1 
antagonist administration to the mPOA reverses the effect of bremelanotide 
[Gelez H, Pfaus JG, personal communication].
The central serotonin (5-HT) neurotransmitter system is a key component 
in sexual inhibition, though there is evidence that activation of certain 5-HT 
receptor subtypes facilitates female sexual behavior [43-48]. The regulation of 
female sexual function by the serotonin neurotransmitter system is the main 
focus of this thesis, and a more detailed introduction to serotonin is presented 
in section 3.
Alongside the neural control of sexual function, steroid hormones play an 
important role in the regulation (in rodents) or modulation (in primates) of sexual 
behavior. Estrogens, progesterone and androgens have been recognized 
to be excitatory on sexual behavior in both humans and rodents [49], while 
glucocorticoids secreted in response to a stressful environment generally 
inhibit sexual behavior [49-52]. Thus, disorders of both ovarian function and 
the hypothalamic-pituitary-adrenal (HPA) axis, the latter responsible for the 
secretion of glucocorticoids from the adrenal glands, are associated with 
decreased sexual desire and arousal in women [53, 54]. In addition to direct 
endocrine effects on sexual behavior, steroid hormones modulate the central 
neurotransmitter systems involved in sexual function and may thus indirectly 
regulate sexual behavior. 
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3. THe ROLe OF SeROTONIN IN FeMALe SexUAL FUNCTION
Pharmacological modulation of 5-HT neurotransmission is a common 
cause of diminished female sexual activity. Multiple clinical reports show 
that up to 75% of patients prescribed selective serotonin reuptake inhibitors 
(SSRIs) experience a treatment-induced detriment in sexual satisfaction, such 
as delayed or inhibited orgasm, or decreased sexual desire [55-60]. These 
studies provide evidence for the involvement of 5-HT in diminishing sexual 
behavior in women, however, without elucidating underlying brain circuitries 
as 5-HT modulates a wide range of neural, neuroendocrine and behavioral 
functions [61].
To date, there are 14 known 5-HT receptors, each of which exhibits 
considerable variation in brain distribution and physiological effects upon 
activation [61]. The 5-HT receptors are grouped in 7 families (5-HT1-7). except 
for the 5-HT3 receptor subtype, which is a ligand-gated ion channel, 5-HT 
receptors are G-protein coupled receptors. While serotonergic projections in 
the brain are diffuse, most of them originate from the raphé nuclei, a neuronal 
cluster located in the midbrain and the brain stem that contains the cell bodies 
of 5-HT neurons (Figure 4). A negative feedback mechanism regulates the 
Figure 4. The central serotonin neurotransmitter system. Serotonergic neurons diffusely 
project from the Raphé nuclei to cortical, limbic and hypothalamic areas. mPFC, medial 







activity of serotonergic neurons and acts mostly through presynaptically 
located autoreceptors of the 5-HT1A and 5-HT1B subtypes. Activation of 
5-HT1A receptors located on soma and dendrites opens potassium channels 
and thus inhibits 5-HT cell firing. Activation of 5-HT1B receptors on the nerve 
terminals also inhibits 5-HT release. A negative feedback mechanism via 
postsynaptic 5-HT receptors might also play a role in regulating central 5-HT 
neurotransmission. This mechanism likely acts via the prefrontal cortex, 
where an activation of glutamatergic and GABAergic neurons that project 
back to the raphé nuclei leads to an inhibition of further 5-HT neural firing 
[62]. Serotonin transporters (5-HTT, or alternatively SeRT) also partake in the 
negative feedback mechanism by actively transporting 5-HT from the synaptic 
cleft into presynaptic 5-HT neurons. The rapid removal of 5-HT released into 
the synaptic cleft by 5-HTT allows for the control of magnitude, duration and 
spatial distribution of signals reaching 5-HT receptors following neuronal 
stimulation [63].
Serotonin exerts a generally inhibitory tone on female sexual behavior. 
Studies in female rodents, however, have shown that 5-HT receptor specific 
agonists or antagonists can either facilitate or inhibit sexual activity, depending 
on the 5-HT receptor subtype activated. Lordosis is inhibited by 5-HT1A receptor 
activation and 5-HT3 receptor antagonism [43, 44, 47, 64], but is facilitated 
by 5-HT2A/C receptor activation [46, 65]. While the inhibitory effect of 5-HT1A 
agonists on female receptivity is clear, less is known as to where in the brain 
these receptors are located. Lesion studies and local administration of the 
5-HT1A receptor agonist R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-
DPAT) into different brain areas highlight the importance of both pre- and 
post-synaptic 5-HT1A receptor function in the serotonergic regulation of female 
sexual behavior, involving a circuitry that comprises the presynaptic raphé 
nuclei and the postsynaptic VMH, mPOA and PAG [44, 66-71]. The central 5-HT 
system furthermore interacts with the excitatory DA and NE neurotransmitter 
systems [72, 73], thus providing the possibility that a manipulation of 5-HT 
neurotransmission could affect sexual behavior both directly and indirectly by 
modulation of DA and NE.
The 5-HT system is also intertwined with endocrine systems. estrogens 
and glucocorticoids modulate 5-HT receptor density in a receptor subtype and 
brain region specific manner in both rodents and primates [74-76]. Conversely, 
the central 5-HT system generally exerts a stimulatory function on HPA axis 
activity [77-79], and depletion of 5-HT reduces the responsiveness of the HPA 
axis to stress [80]. Liposits et al. [81] provide an anatomical context for the 
involvement of 5-HT in activating the HPA axis by showing that serotonergic 
nerve terminals and corticotropin-releasing hormone (CRH) neurons are 
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synaptically linked in the paraventricular hypothalamic nucleus (PVN). CRH 
containing neurons in the PVN that regulate HPA axis activity express 5-HT1A 
and 5-HT2A receptors [81, 82], and activation of either receptor type stimulates 
the HPA axis to release ACTH from the pituitary, and cortisol (in primates) or 
corticosterone (in rodents) from the adrenal cortex [82-85]. Thus, it seems 
plausible that sexual behavior could be indirectly modulated by 5-HT-regulated 
HPA axis activity and glucocorticoid secretion.
4. FLIBANSeRIN – A NOVeL PHARMACOTHeRAPeUTIC 
APPROACH FOR THe TReATMeNT OF HyPOACTIVe SexUAL 
DeSIRe DISORDeR IN WOMeN
Recently, flibanserin (2H-benzimidazol-2-one, 1,3-dihydro-1-[2-[4-[3-
(trifluoromethyl) phenyl]-1-piperazinyl]ethyl]), an agonist of 5-HT1A and 
antagonist of 5-HT2A receptors [86, 87], demonstrates the ability to stimulate 
female sexual behavior in rats [88] and to improve sexual desire in women 
with either HSDD or major depressive disorder [89-91]. The positive actions 
of flibanserin on sexual functioning were first discovered serendipitously while 
studying flibanserin in patients with major depressive disorder. Flibanserin 
is ineffective as antidepressant, but increases the scores of women on the 
Arizona Sexual experiences Scale [89]. These findings led to further clinical 
evaluations of flibanserin. In phase-III clinical trials designed to investigate 
the efficacy of flibanserin as first pharmacotherapeutic treatment of HSDD 
in women (the BOUQUET studies), premenopausal women with HSDD 
report increased satisfying sexual events, increased desire and decreased 
distress following chronic flibanserin treatment over several weeks [90, 91]. 
With exception of the experiments described in this thesis (Chapters 2-5), 
flibanserin has not been tested in any nonhuman primate.
Flibanserin crosses the blood-brain barrier by diffusion, and brain exposure 
is therefore expected to be similar to that in blood and peripheral organs. 
In rodents, flibanserin shows functional preference for cortical 5-HT1A and 
5-HT2A receptors over other brain regions [92, 93]. While both flibanserin and 
8-OH-DPAT, a prototypical 5-HT1A agonist [94, 95], decrease neuronal firing 
in the prefrontal cortex (PFC), this decrease is eliminated when the neurons 
of the dorsal raphé nucleus (DRN) are lesioned in 8-OH-DPAT treated rats, 
but not in flibanserin treated rats [96]. These findings provide evidence that 
while 8-OH-DPAT exerts its action on neuronal firing by binding to presynaptic 
5-HT1A receptors (autoreceptors), flibanserin seems to activate a postsynaptic 
mechanism as all 5-HT1A autoreceptors on serotonergic neurons in the 




activates 5-HT1A receptors in the PFC and hippocampus, but does not activate 
presynaptic 5-HT1A receptors in the DRN [92], thus confirming the postsynaptic 
binding preference of flibanserin. While in rats flibanserin stimulates female 
sexual behavior [88], it is of particular interest that 8-OH-DPAT induces the 
opposite effect and contrasts with flibanserin with regard to female sexual 
behavior [43, 44, 47].
5. MODeLING FeMALe SexUAL BeHAVIOR IN ANIMALS
Much of our understanding of female sexual function has been gained from 
the study of animal models that display nonhuman counterparts to desire, 
arousal, orgasm and satiety [97]. Importantly, these aspects of female sexuality 
can be assessed in animals both qualitatively and quantitatively. For example, 
the female rat displays a distinct set of behaviors, referred to as proceptive 
hops and darts [98], to solicit copulation from the male (sexual proceptivity), 
while others, such as lordosis, signal her readiness for copulation (sexual 
receptivity). Sexual proceptivity and receptivity behaviors are flexible in regard 
to frequency and intensity and can be altered by pharmacological manipulation, 
a critical prerequisite for a rational approach to pharmacotherapy for female 
sexual dysfunction.
In animals, sexual desire can be inferred from certain appetitive behaviors 
that occur during copulation. The occurrence of such behaviors can be 
experimentally tested and pharmacologically manipulated. For example, 
female rats that show high motivation to press a lever to gain access to a 
male, or to run back and forth from behind an opaque barrier, release 
increased DA in the striatum and nucleus accumbens compared to females 
with low motivation (reviewed in [97]). The rate at which female rats solicit 
and pace their copulatory contact with males is another example of an 
analogous behavior of desire. Pharmacological manipulation of melanocortin 
and serotonin receptors has been demonstrated to be effective in altering 
this pacing behavior in female rodents [41, 88]. Furthermore, the willingness 
to engage in sexual intercourse, expressed as lordosis in female rodents, 
is mediated by estrogen and progesterone, and modulated by hypothalamic 
dopamine, norepinephrine, oxytocin and opioid receptor activation [98].
Sexual arousal, as mentioned above in Section 2, additionally involves 
induction of generalized CNS arousal and genital arousal. While generalized 
CNS arousal is regulated by the neurotransmitters DA, Ne, 5-HT and 
acetylcholine [99], the genital response includes increased vaginal blood flow, 
clitoral, labial and vestibular bulb engorgement, and vaginal smooth muscle 
contraction and relaxation, which are under parasympathetic (cholinergic) and 
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sympathetic (adrenergic, cholinergic) control and also influenced by vasoactive 
intestinal polypeptide (VIP), nitric oxide synthase (NOS), neuropeptide Y 
(NPY), and other mediators (see [97] for a comprehensive review).
Value and importance of animal models to study female sexual function 
have been recognized, though a vast majority of the studies that aimed to 
investigate the animal counterparts of human sexual behavior have been 
performed in rodents. The translation of rodent data to human behavior, 
however, entails problems. Unlike in humans, certain aspects of female sexual 
function in rodents are under strict control of hormonal status. Lordosis, for 
example, is a highly estrogen-dependent behavior. Ovariectomy of the female 
rat abolishes the behavior, while estradiol and progesterone [100, 101] or 
estradiol and testosterone replacement [102] restore proceptive and receptive 
sexual behavior.
In humans, and in primates generally, sex hormones play an important role 
in the modulation of sexual behavior. They are however not essential [103], and 
sex in women is abolished neither by menopause nor by a surgical removal 
of the ovaries [104]. As outlined in Section 1, sexual behavior in women is 
strongly associated with physical and emotional factors, such as feelings of 
happiness and satisfaction, quality of their relationship with the partner and 
lifestyle, and it is influenced by sociocultural, family and personal expectations 
[2-10]. Sexual behavior in women thus entails the net output of an interplay 
between hormonal, neural and psychosocial factors and involves, on the 
neurobiological level, hypothalamic and limbic brain structures that are under 
close cortical control. In this respect, nonhuman primate models of female 
sexual function may be a valuable and sensible alternative to rodent models 
due to their emancipation of sexual behavior from strict hormonal control 
[103, 105] and their phylogenetic proximity to humans, including advanced 
corticalization [106, 107]. Considering the advantages of nonhuman primates 
as animal models for female sexual function and dysfunction, the common 





6. THe COMMON MARMOSeT MONKey: A SeNSIBLe CHOICe 
All experiments presented in this thesis, designed to explore the role of the 
central 5-HT neurotransmitter system in the regulation of female sexual function, 
were conducted in the common marmoset monkey (Figure 5). Suitability of the 
common marmoset to study exogenous compounds regulating female sexual 
behavior has previously been demonstrated [108]. Unlike the multiple-mating 
social structures of rats and most nonhuman primates, such as macaques 
and baboons, marmoset sexual behavior most commonly occurs within stable 
male-female pairs [109, 110]. The frequency and pattern of sexual behavior 
can vary greatly between marmoset pairs, as does the quality of their social 
interactions, as manifest by allogrooming and aggressive behavior [111]. Similar 
to humans, several aspects in the repertoire of marmoset sexual behavior 
are controlled by both partners. During most stages of the species-specific 
sequence of sexual behaviors, including sexual solicitation, acceptance and 
rejection of the partner’s sexual advances, and the execution and permission 
of an ejaculatory mount, both male and female partner have the ability to 
promote or to interrupt the sexual interaction. As a further parallel to human 
sexual physiology, but in contrast to some nonhuman primate [112-115] and 
many non-primate species [116, 117], the female marmoset’s display of sexual 
Figure 5. The common marmoset 
(Callithrix jacchus). Adult marmo-
sets form stable male-female





behavior is not limited to the periovulatory period. While marmoset sexual 
behavior increases across the first half of the ovarian cycle, peaking just prior 
to ovulation, it also occurs throughout the ovarian cycle, reinforcing the bond 
between partners [118]. Ovariectomy reduces, but does not abolish sexual 
behavior or the female’s sexual attractiveness to the male [119]. Lesion of the 
anteromedial hypothalamus, which overlaps with the mPOA, blocks sexual 
proceptivity in female marmosets, but not sexual receptivity [120]. Finally, the 
availability of a well-characterized behavioral ethogram of marmoset sexual 
proceptivity and sexual receptivity [121, 122] permits validated quantification 
of marmoset sexual behavior. 
Female marmosets display sexual proceptivity by rapid protrusion and 
retraction of the tongue (proceptive tongue flick) and stares directed at the 
male pairmate while their ear tufts are flattened (proceptive stare). Receptive 
sexual behaviors include female acceptance of male mounts and mount 
attempts (accept mount), frequently by pressing herself to the ground in a 
frozen position (receptive freeze posture, Figure 6), thus permitting the male to 
intromit his erect penis (erection, intromission), to which the female commonly 
responds with a head turn and nuzzling or biting of the male (receptive 
head turn). A successful mount is completed by male ejaculation within the 
vagina, which is normally followed by the male licking his penis (ejaculation). 
Grooming behavior between partners (allogrooming) is normally a sign of 
a stable and close pair-bond between male and female pairmates, while 
aggressive interactions signal disagreement and conflict between partners. 
Male marmosets sniff and lick the ano-genital region of the female pairmate 
(ano-genital sniff/lick), thus obtaining sensory information of the female’s 
ovarian cycle status [123]. Ano-genital sniff/lick also signals sexual interest by 
the male pairmate (adapted from [121, 122]).
Figure 6. Marmoset copulatory behav-
ior. The female partner (to the right) ac-
cpted the male partner’s mount attempt. 
The male is in a mounting position, while 
the female’s posture indicates a recep-




7. SCOPe OF THe THeSIS
Objectives
The central theme of this thesis is the serotonergic regulation of female 
sexual behavior in a nonhuman primate that is characterized by a pairmate 
social setting comparable to humans. The experimental agents employed 
in the study are (1) flibanserin, a 5-HT1A agonist, 5-HT2A antagonist and 
putative pharmacotherapeutic treatment for hypoactive sexual desire disorder 
in women, and (2) 8-OH-DPAT, a prototype 5-HT1A agonist. In the thesis, 
flibanserin data are presented as they relate to two of the four Objectives key 
to this thesis (Objectives 1 and 2 in Chapters 2 and 3), while 8-OH-DPAT data 
are related to all four Objectives (Chapters 2 – 5).
The First Objective is to assess the effects of chronic flibanserin and 
8-OH-DPAT on sexual and social interactions between female-male marmoset 
pairs. Based on the results from human clinical trials and rodent experimental 
data, we hypothesize that female marmoset sexual behavior is facilitated by 
flibanserin and diminished by 8-OH-DPAT.
The Second Objective is to test whether chronic flibanserin and 8-OH-
DPAT alter the hypothalamic-pituitary-adrenal axis and thus indirectly modulate 
female sexual function through a suppressive endocrine mechanism. Central 
activation of 5-HT1A and 5-HT2A receptors stimulates the HPA axis. We 
consequently hypothesize that the 5-HT1A agonist 8-OH-DPAT increases HPA 
axis activity and thus suppresses female sexual behavior, while flibanserin, 
through concurrent inhibition of 5-HT2A receptors, displays a more moderate 
effect on HPA axis activity and therefore does not suppress female sexual 
behavior.
The Third Objective is to measure brain activity correlates of 8-OH-
DPAT induced alterations of female sexual behavior and social interactions 
between pairmates. We hypothesize that chronic 8-OH-DPAT alters neural 
activity in brain regions with high 5-HT1A density, and in regions that have 
been associated with female sexual behavior: (1) dorsal raphé nucleus (DRN) 
with its serotonergic cell bodies, (2) medial prefrontal cortex (mPFC) as 
executive and inhibitory behavioral regulator, (3) medial preoptic area of the 
hypothalamus (mPOA) as a region essential for the generation of marmoset 
female sexual behavior, (4) ventromedial hypothalamic nucleus (VMH), a key 
regulator of female sexual receptivity, and (5) CA1 field of the hippocampus 
(CA1), involved in sexually relevant memory processes.
The Fourth Objective is to investigate the brain region-specific changes in 
gene expression induced by chronic 8-OH-DPAT to discover neural molecular 
mechanisms that may underlie suppressed female sexual behavior. We 
hypothesize that 8-OH-DPAT alters functional gene classes and pathways in 
24
the same brain regions determined in objective 3: (1) DRN, (2) mPFC, (3) 
mPOA and (4) CA1. The VMH was not studied.
Experimental approach
Sixteen adult common marmoset females will be pair housed with male 
partners for 8-20 months before study onset. Eight of the 16 females will be 
assigned to test the effects of flibanserin, while the remaining 8 females will 
be assigned to test the effects of 8-OH-DPAT. Females will be housed with the 
same male partner for the entire study and will be ovariectomized and primed 
with either mid-follicular phase estradiol levels or no estradiol before study 
onset. Estradiol status will remain the same throughout the study for each 
individual animal, except for the final 16 weeks prior to brain tissue collection, 
when all females will be primed with estradiol to increase group size for the 
gene expression experiment. All in vivo experiments (behavior, Chapter 2; 
endocrine, Chapter 3; brain imaging, Chapter 4) will be conducted using a 
counterbalanced, cross-over design that will apply within-subject comparisons 
to measure the effect of chronic flibanserin and 8-OH-DPAT against respective 
vehicle treatment. Figure 7 shows a detailed visual representation of the 
complete study design. The transcriptomic experiment (Chapter 5) will employ 
a between-subject comparison to measure the effects of 8-OH-DPAT against 
vehicle treatment.
To investigate the effects of flibanserin and 8-OH-DPAT on pair behavior 
in Chapter 2, behavioral observations will be conducted using a validated 
experimental setup that encourages a standardized, modest baseline of 
sexual activity induced by a 90-minute separation of the pairmates prior
Figure 7. Study design. Drug treatment and estradiol replacement
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to a 30-min pair test. In addition to sexual and social behavior observed 
during the pair tests, additional experiments described in this chapter 
will also explore behavioral responses to acute flibanserin and 8-OH-
DPAT (serotonin behavioral syndrome), and the 24-hour pharmacokinetic 
profiles of circulating drug levels at 15 min, 30 min, 60 min, 3h, 6h 
and 24 h of drug administration during the chronic treatment phase.
Chapter 3 will assess female marmoset HPA axis properties following 
chronic treatment with flibanserin and 8-OH-DPAT. Baseline plasma cortisol 
levels will be measured before starting chronic treatments, and again after 3 
and 6 weeks of daily treatment. Using a 5-HT1A agonist challenge test, it will be 
determined whether the responsiveness of the HPA axis to 5-HT1A activation 
will be affected by chronic 5-HT1A activation/5-HT2A inhibition (flibanserin), 
or by chronic 5-HT1A activation alone (8-OH-DPAT). To further test whether 
altered HPA axis function may contribute to changes in female interactions 
with male pairmates, a 30-minute restraint test will be administered to test the 
marmosets’ stress responsiveness after chronic flibanserin and 8-OH-DPAT 
treatment. Timed blood samples will be drawn for all tests, and plasma ACTH 
and cortisol levels will be measured using radioimmunoassays.
To associate 8-OH-DPAT induced changes in pair behavior to brain 
function, a PET imaging experiment will be conducted in Chapter 4. Female 
marmosets will be infused with radiolabeled fluorodeoxyglucose (FDG) 
immediately prior to a pair test with their male pairmates. The majority of FDG 
uptake into brain tissue occurs within the first 30 minutes of infusion. The FDG 
signal will thus reflect glucose metabolism during pair behavior, with the most 
active brain regions trapping the highest concentration of radiolabeled FDG.

































After pair test, the females will be anesthetized and imaged by PeT. Whole 
brain normalized PeT images will be analyzed with anatomically defined 
regions of interest derived from overlaid structural MRI images and scanned 
marmoset brain atlas images, and by whole brain voxelwise mapping. 
Finally, FDG signal differentials will be correlated with behavioral changes.
In a large-scale gene expression experiment described in Chapter 5, 
transcriptomic changes induced by chronic 8-OH-DPAT will be analyzed in 
brain tissues of 8-OH-DPAT and vehicle treated female marmosets. Due to 
great transcriptomic heterogeneity between brain regions, the mPFC, mPOA, 
CA1 and DRN will be excised using high-precision laser-microdissection. RNA 
will be isolated, amplified and hybridized to the marmoset-specific eUMAMA 
microarray. Real-time quantitative PCR (RT-qPCR) will be used to validate 
the microarray results, and a candidate gene approach will be employed 
to measure the expression of serotonin receptor and transporter genes by 
RT-qPCR. Enriched functional gene classes will be determined, possibly 
representing underlying molecular markers and mechanisms of suppressed 
female sexual function.
In Chapter 6, the combined experimental results from Chapters 2 – 5 will be 
considered and the abilities of flibanserin and 8-OH-DPAT to regulate female 
sexual function will be discussed in the context of pharmacological modes 
of action and future pharmacotherapeutic perspectives for the treatment of 
hypoactive sexual desire disorder in women.
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A B S T R A C T
Introduction. Psychopathological origins of personally distressing, 
hypoactive sexual desire disorder (HSDD) in women are unknown, but 
are generally attributed to an inhibitory neural regulator, serotonin (5-HT). 
Flibanserin, a 5-HT1A agonist and 5-HT2A antagonist, shows promise as a 
treatment for HSDD.
Aim. To test the hypothesis that female marmoset sexual behavior is 
enhanced by flibanserin and diminished by 8-OH-DPAT, in order to evaluate 
the efficacy of serotonergic modulation of female sexual behavior in a pairmate 
social setting comparable to humans.
Methods. Sexual and social behavior were examined in eight female 
marmoset monkeys receiving daily flibanserin (15 mg/kg), 8-OH-DPAT (0.1 
mg/kg), or corresponding vehicle for 15–16 weeks in a counterbalanced, 
withinsubject design, while housed in long-term, stable male–female pairs.
Main Outcome Measures. Marmoset pairmate interactions, including 
sexual and social behavior, were scored during weeks 5–6 of daily flibanserin, 
8-OH-DPAT or vehicle treatment. 24-hour pharmacokinetic profiles of the 
drugs and their metabolites, as well as drug-induced acute symptoms of the 
5-HT behavioral syndrome were also assessed.
Results. Two-way analysis of variance reveals that flibanserin-treated 
females attract more male sexual interest (P = 0.020) and trigger increased 
grooming (P = 0.001) between partners. In contrast, 8-OH-DPAT-treated 
females show increased rejection of male sexual advances (P = 0.024), a 
tendency for decreased male sexual interest (P = 0.080), and increased 
aggression with their male pairmates (P = 0.049).
Conclusions. While 8-OH-DPAT-treated female marmosets display 
decreased sexual receptivity and increased aggressive interactions with their 
male pairmates, flibanserin-treated female marmosets demonstrate increased 
affiliative behavior with their male pairmates. Such pro-affiliation attributes 
may underlie flibanserin’s effectiveness in treating HSDD in women.
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INTRODUCTION
In an estimated 10% of women [1], marked distressand interpersonal 
difficulty arise from unwanted, persistent or recurrent low sexual desire 
(hypoactive sexual desire disorder, HSDD; American Psychiatric Association’s 
Diagnostic and Statistical Manual, DSM-IV-TR). Psychopathogenesis of 
HSDD is not known, but neurotransmitter dysfunction has been proposed 
involving the excitatory regulators dopamine (DA) and norepinephrine (NE), 
as well as inhibitory serotonin (5-HT) [2,3]. 5-HT is a key neurotransmitter 
involved in female sexual inhibition [2]. Pharmacological manipulation of 
5-HT commonly results in diminished female sexual satisfaction and activity, 
particularly in women prescribed selective serotonin reuptake inhibitors 
(SSRIs) for depression [4]. Animal studies that apply 5-HT receptor subtype 
specific ligands permit mechanistic examination of 5-HTmediated effects on 
sexual behavior. There are seven known 5-HT receptor families, each with its 
own specific brain distribution, as well as effects on behavior and physiology 
[5]. For example, in rodents, the sexually receptive female lordosis posture is 
inhibited by 5-HT1A receptor activation [6,7] and 5-HT3 receptor antagonism 
[8], but is facilitated by 5-HT2A/C receptor activation [9].
Recently, flibanserin (2H-benzimidazol-2-one, 1,3-dihydro-1-[2-[4-[3-
(trifluoromethyl) phenyl]- 1-piperazinyl]ethyl], an agonist of 5-HT1A and 
antagonist of 5-HT2A receptors [11,12], has been shown to stimulate sexual 
solicitation and receptivity in female rats [13] and to improve sexual desire 
in women with major depression [14]. Women with HSDD report increased 
satisfying sexual events, increased desire and decreased distress following 
flibanserin treatment [15]. R-(+)-8-hydroxy-2-(di-n-propylamino)-tetralin 
hydrobromide (8-OH-DPAT), however, a selective 5-HT1A receptor agonist 
[16], diminishes female sexual receptivity in rats [17]. Thus, despite the shared 
5-HT1A agonist activity between flibanserin and 8-OH-DPAT, the contrasting 
effects of the two drugs on rodent female sexual behavior provides us with 
an opportunity to examine whether such contrasting behavioral outcomes 
translate to a nonhuman primate model, the common marmoset, in a well-
established male– female pairmate social environment.
Female marmoset monkeys present an opportunity to contrast the effects 
of flibanserin and 8-OH-DPAT in an animal model that readily translates to 
humans because marmosets form and display modest amounts of sexual 
behavior [19]. Unlike the multiple-mating social structures of rats and many 
nonhuman primates, such as macaques and baboons, marmoset sexual 
behavior most commonly occurs within stable male–female pairs [18,20]. 
During acceptance or rejection of a pairmate’s sexual advances, female 
marmosets can readily promote, prevent, or terminate sexual interactions [21], 
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and our recent development of a standardized behavioral testing paradigm 
permits repeatable, quantitative exploration of neurally active compounds that 
enhance or diminish female marmoset sexual behavior [19].
AIMS
The aim of the present study was to test the hypothesis that female 
marmoset sexual behavior is enhanced by flibanserin and diminished by 
8-OH-DPAT, in order to evaluate the efficacy of serotonergic modulation of 
female sexual behavior in a pairmate social setting comparable to humans.
MeTHODS
Study animals
This study was conducted in accordance with the recommendations of the 
Guide for the Care and Use of Laboratory Animals and the Animal Welfare 
Act and its subsequent amendments. All animal procedures were reviewed 
and approved by the Graduate School Animal Care and Use Committee 
of the University of Wisconsin-Madison. The Wisconsin National Primate 
Research Center (WNPRC) is accredited by the Association for Assessment 
and Accreditation of Laboratory Animal Care as part of the University 
of Wisconsin-Madison Graduate School. Sixteen adult (age 2–5 years) 
nulliparous captive-born common marmoset (Callithrix jacchus) females were 
pair housed with similarly aged male partners at the WNPRC for 8–20 months 
before onset of this study. Females were housed with the same male partner 
for the entire study, as previously described [22], and were ovariectomized 
and primed with either mid-follicular phase estradiol levels or no hormone [19] 
before study onset. This model allows us to provide a repeatable estrogen 
replete (estradiol capsules implanted) or estrogen deficient (empty capsules 
implanted) hormonal environment in which sex hormone levels are stable and 
reflect, respectively, the equivalent of an estrogen-dominant, pre-ovulatory 
stage in the ovarian cycle or a post-menopausal stage.
Experimental design
A counterbalanced, crossover study that applied within-subject 
comparisons was designed to examine the effects of chronic (15–16 weeks) 
daily (12:00pm–2:00pm) administration of flibanserin (N = 8; 15 mg/kg, orally 
(PO) in 1 mL/kg vehicle; Boehringer Ingelheim Pharma GmbH & Co. KG, 
Biberach an der Riss, Germany), 8-OH-DPAT (N = 8; 0.1 mg/kg in 0.4 mL/kg 
vehicle, injected subcutaneously (SC); Sigma-Aldrich St. Louis, MO, USA), or 
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respective vehicles (for flibanserin, 98.5% of 0.5% hydroxycellulose solution 
and 1.5% of 1% polysorbate 80 solution, 1.0 mL/kg PO; for 8-OH-DPAT, 0.4 
mL saline, SC). The study focused on two major behavioral outcomes: (i) 
sexual and social interactions between pairmates; and (ii) acute manifestation 
of the 5-HT behavioral syndrome providing quantitative indication of continued 
drug efficacy.
As flibanserin was not previously administered to female marmosets, we 
performed an initial dose response study comparing male–female interactions 
observed after 5–6 weeks of oral dosing of 10 mg/kg (N = 4) or 30 mg/kg (N = 
4) flibanserin to behavior observed during baseline male–female interactions 
made prior to these flibanserin treatments. We observed changes in selected 
behaviors (Table S1) in our male–female testing paradigm, described in later 
discussion, 16–24 hours after daily flibanserin administration, compared to 
baseline. Blood samples assessing pharmacokinetics of both doses (Figure 
S1) were obtained after 3–4 weeks. As similar results were obtained from both 
doses for behavioral and pharmacokinetic assessments, we decided to employ 
an intermediate dose of 15 mg/kg for the main study. The scaled equivalent in 
humans of 15 mg/kg flibanserin administered to marmosets is ~2.4 mg/kg [23] 
and approximately similar to ~1.7 mg/kg flibanserin administered to women in 
clinical trials (100 mg/ day, assuming 60 kg body weight [24].
8-OH-DPAT has previously been administered to marmosets in i.p. 
injections of 0.3 mg/kg, resulting in pronounced expression of the serotonin 
behavioral syndrome immediately following each treatment. 8-OH-DPAT at 
a dose of 0.3 mg/kg also induces scratching and diarrhea [25]. To minimize 
the latter responses and to remain within a dose range previously used to 
consistently diminish female sexual behavior in rats (0.025–1.0 mg/kg, SC or 
IP [6,17,26], we selected 0.1 mg/kg SC for this study.
Bilateral ovariectomy
Females were injected intramuscularly (IM) with ketamine (15 mg/kg), 0.02–
0.04 mg/kg atropine and 0.01 mg/kg buprenorphine, and were maintained on 
isofluorane (2%; 0.6 liter/min oxygen). each ovary was isolated through a 
ventral midline incision and exteriorized for visualization of the fallopian tube 
and ovarian pedicle. Subsequent histological examination confirmed complete 
ovarian removal.
Estradiol replacement
One week before the start of daily treatment, females were implanted 
SC with silastic capsules that were either estradiol-filled (N = 4 per active 
compound/vehicle) or empty (N = 4 per active compound/vehicle). Plasma 
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estradiol levels were determined every 2 weeks whenever capsules were 
implanted. Treatment with active compound/vehicle started at (i) either 7 
weeks after ovariectomy or 7 weeks after removal of capsules; and (ii) 1 week 
after implantation or re-implantation of capsules that occurred at 6 weeks after 
ovariectomy or 6 weeks after removal of previous capsules, resulting in a 
constant intertreatment interval of 7 weeks. Estradiol status was maintained 
throughout treatment for each female.
Estradiol levels in blood samples that were collected by femoral puncture 
[22] were determined using celite column chromatography and a validated 
estradiol radioimmunoassay (RIA) for marmoset plasma [27]. Assay sensitivity 
was 4.6 pg/tube (30.4 pg/mL), and intra- and inter-assay assay coefficients of 
variation (CVs), respectively, were 5.0% and 14.0%.
Ovariectomized females implanted with estradiol-filled capsules (N = 8) had 
higher (P < 0.003) circulating estradiol levels (396.0  30.6 pg/mL) compared 
to females implanted with empty capsules (67.5 5.2 pg/mL), and circulating 
estradiol values in the former females were comparable to those previously 
reported for female marmosets in the mid-follicular phase of the ovarian cycle 
[19]. Estradiol replacement is thus below the mid-cycle, peri-ovulatory levels 
used in some previous studies [28] and thus supports modest [19] rather than 
maximal [29] expression of female marmoset sexual behavior.
Pharmacokinetic assessment of flibanserin and 8-OH-DPAT 
administration
Treatment-induced systemic exposure to circulating levels of flibanserin and 
two common flibanserin metabolites, 1-(3-trifluoromethylphenyl) piperazine 
(TFMPP) and 6-hydroxy-flibanserin (BIMA 23 BS), and to 8-OH-DPAT, was 
assessed during study weeks 40 to 42 by validated high performance liquid 
chromatography coupled to tandem mass spectrometry (LC-MS/MS). Serial 
blood samples were collected at 0.25, 0.5, 1, 3, 6, and 24 hours after flibanserin 
or 8-OH-DPAT administration (N = 4 for each compound).
Behavioral observation of sexual and social behavior
In order to stimulate social and sexual interactions upon reunion [19], 
females andmales were separated for 90 minutes prior to each of four, 
30-minute behavioral tests at 7:00am–1:00pm (16–24 hours after daily 
administration of active compound/ vehicle), 5–6 weeks after treatment 
onset. This time window for observations was chosen to assess the chronic 
changes induced by flibanserin and 8-OHDPAT when circulating levels of 
drugs were minimal, thus avoiding potential acute effects driven by elevated 
circulating concentrations of the drug preparations and active metabolites. 
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Potential behavioral changes are thus consequences of longterm adaptation 
to treatment that may involve changes in gene and protein expression [30].
At the start of the behavioral test, the male was introduced to the female 
by remote door operation, and behavior was manually and digitally recorded 
by two observers from behind a one-way window (Table 1). Behavioral tests 
were reanalyzed in a random fashion from the digitally stored recordings by 
two observers blinded with respect to treatment. The reanalyzed data were 
compared with those obtained on the day of the test to confirm final values 
and to generate behavioral data not originally scored during live observations 
(for aggression and self-grooming). Inter-observer reliability scores for 
behavioral data collection averaged 90.6%, and within-observer reliability 
scores averaged 96.1%.
Monitoring of the 5-HT behavioral syndrome
Locomotor behaviors indicative of the 5-HT behavioral syndrome, 
i.e., “random rapid limb movements” and “wet-dog shakes” [16,25], were 
monitored once per week (0.5 hour) at 0–0.5 hour and at 16–24 hours after 
administration of active compound/vehicle treatment, during weeks 1 to 4 of 
treatment (Table 1). Females were placed in a test cage for the duration of 
the test (8-OH-DPAT/vehicle), or returned to their home cage (flibanserin/
vehicle). In addition, sprawling behavior (females lying down in prone position, 
monitored during flibanserin or respective vehicle treatment only), a possible 
non-locomotor component of the 5-HT behavioral syndrome [32], and self-
scratching behavior, a locomotor behavior not specifically linked to 5-HT 
neurotransmission, were scored.
Data analysis
Observed levels of female proceptive sexual behavior (Table 1) were too 
infrequent to permit statistical analysis. Female sexual receptivity was quantified 
by frequency of female acceptance of male ejaculatory mounts. Female 
refusal of male sexual advances was quantified by frequency of rejection of 
male mounts and mount attempts. Sexual arousal of the male was quantified 
by frequency of penile erection. Analyses of all behavior were performed 
on transformed frequency data square root (1 + x)] to achieve homogeneity 
of variance and to increase linearity of data. This transformation generates 
positive numbers, permitting appropriate analysis of behavioral frequency 
data as square root transformation in which the variance is independent of the 
mean [33]. Mean values of the frequencies were analyzed by two-way anova 
incorporating repeated measures design, with Treatment (active compound, 
vehicle) and Observations (observation 1–4) as within-subject factors. Data 
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are presented as backtransformed mean values (95% confidence intervals). A 
P value less than 0.05 was considered significant.
Initial analyses of behavioral data were performed using the same mixed 
design anova with Estradiol supplementation and Order of treatment as 
between-subject factors, and Treatment as within-subject factor. As Estradiol 
supplementation and Order of treatment consistently failed to affect (P > 
0.05) any behavioral variable, both factors were omitted in the final analyses 
reported here.
Results
Systemic Exposure to Flibanserin, Flibanserin
Metabolites, and 8-OH-DPAT during Chronic
Drug Treatment
Maximal plasma concentrations of flibanserin,
TFMPP and BIMA 23 BS (C(max)) of 628 
225 ng/mL (mean  SEM), 46.0  17.0 ng/mL
and 149  38.7 ng/mL, respectively, were reached
at 0.5–1 hour after oral administration, decreasing
rapidly to low levels by 24 hours, providing a cir-
culating half-life for flibanserin of 2.8 hours
(Figure 1). For 8-OH-DPAT, C(max) of 69.7 
19.8 nmol/L was reached by 0.25–0.5 hour after






Proceptive female sexual behavior*
Proceptive tongue flicking 0 0.03  0.06 0 0
Proceptive staring 0 0 0 0
Proceptive freeze posture/Sprawling position 0.16  0.28 0.12  0.14 0.05  0.06 0.06  0.09
Receptive female sexual behaviors*
Acceptance of mounts 0.61  0.58 0.75  0.75 0.23  0.27 0.64  0.57
Rejection of mount attempts and mounts** 0.19  0.28 0.25  0.29 0.62  0.75 1.49  1.50
Receptive freeze posture 0.29  0.28 0.45  0.56 0.23  0.27 0.58  0.55
Receptive tongue flicking 0 0 0 0
Receptive head turning/biting 0.40  0.35 0.35  0.30 0.20  0.23 0.29  0.24
Male sexual behaviors*
Penile erection 0.78  0.65 1.12  0.98 0.89  0.73 1.05  0.46
Mounting 0.61  0.58 0.71  0.69 0.23  0.27 0.64  0.57
Mounting attempts** 0.19  0.28 0.26  0.27 0.63  0.83 1.63  1.59
Intromitting 0.43  0.37 0.48  0.43 0.17  0.20 0.35  0.27
Ejaculating 0.28  0.31 0.26  0.27 0.17  0.20 0.21  0.15
Social odors*
Genital investigation by female 0.03  0.06 0.06  0.08 0.28  0.66 0.08  0.17
Genital investigation by male¶ 1.76  1.54 2.62  1.89 1.12  0.74 0.49  0.39
Scent marking by female 2.54  2.53 3.15  2.67 3.50  3.95 4.36  5.17
Scent marking by male 3.52  4.71 3.39  3.07 5.18  5.23 3.69  2.62
Social interactions*
Grooming by female 1.29  1.57 2.19  2.15 2.77  3.57 1.79  2.60
Grooming by male¶ 2.21  2.02 3.97  3.27 1.09  0.57 0.76  0.47
Total allogrooming¶ 3.94  2.22 6.91  3.20 4.07  3.74 2.71  2.69
Aggression by female 0.94  1.17 0.78  1.07 0.92  1.03 1.66  1.76
Aggression by male 0.06  0.08 0.17  0.23 0.18  0.18 0.53  0.62
Total aggression** 0.99  1.21 0.91  1.27 1.09  1.14 2.23  1.98
Contact within arm-length 5.54  1.23 5.42  1.04 7.71  2.04 6.27  1.75
Direct body contact/huddling 8.69  1.72 10.37  2.60 9.42  2.84 9.77  2.48
Total contact 14.30  2.07 15.87  3.07 17.62  1.55 16.19  3.30
Initiating contact by female 11.14  5.67 10.99  3.41 20.13  8.08 16.99  7.84
Breaking contact by female 15.60  5.99 15.03  7.71 21.09  6.46 14.27  7.20
Following by female 1.60  1.66 1.67  1.39 3.00  2.52 2.60  2.33
Avoiding contact by female 1.69  1.15 1.53  1.22 1.60  1.00 1.15  0.61
Self-directed behavior by female*
Self-grooming¶ 2.75  1.86 3.96  1.95 1.00  0.55 1.89  1.25
Genital inspection/Genital self-grooming¶ 1.87  1.58 4.18  2.95 0.45  0.43 0.33  0.23
Scratching 12.74  8.73 11.50  4.94 8.44  5.09 10.95  3.56
Locomotion and movement by female*
Mobile in locomotion 2.50  0.74 1.93  0.53 3.07  1.15 2.39  1.03
Mobile while stationary 4.45  1.55 5.33  1.64 4.06  1.95 4.14  1.41
Mobile total 6.97  2.14 7.29  1.92 7.25  2.47 6.67  1.63
Immobile, incl. sprawling position 22.72  2.09 22.47  1.77 22.33  2.59 23.14  1.59
Acute behavioral changes†
Scratching* 7.32  2.40 5.23  2.32 1.50  0.90 5.56  4.49
Random rapid limb movements‡** 0 0 0 6.89  4.32
“Wet-dog” shakes‡** 0.24  0.16 0.11  0.18 0 17.44  11.90
Latency to sprawling position§¶ 19.47  4.19 14.58  4.71 Not scored Not scored
A zero value indicates complete absence of behavior. Bold numbers indicate significant changes compared to vehicle treatment. 8-OH-DPAT, R-(+)-8-hydroxy-2-
(di-n-propylamino)-tetralin
*Adapted from Stevenson and Poole [21]. Behavior was recorded at 16–24 hours after daily drug/vehicle administration during weeks 5–6 of daily treatment
†Behavior was recorded at 0–0.5 hours after drug/vehicle administration during weeks 1–4 of daily treatment
‡Behavior indicative of the 5-HT behavioral syndrome. Elliott et al. [25]
§Behavior resembling the rodent flat-body posture. Tricklebank et al. [31]
¶Significantly altered by flibanserin administration (P < 0.05)
**Significantly altered by 8-OH-DPAT administration (P < 0.05)
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MAIN OUTCOME MEASURES
Marmoset pairmate interactions, including sexual and social behavior, were 
scored atweeks 5–6 of daily flibanserin, 8-OH-DPAT or vehicle treatment. In 
addition, 24-hour pharmacokinetic profiles of flibanserin, TFMPP, BIMA 23 
BS, and 8-OH-DPAT, as well as drug-induced acute symptoms of the5-HT 
behavioral syndrome, were assessed.
RESULTS
Systemic exposure to flibanserin, flibanserin metabolites, and 8-OH-
DPAT during chronic drug treatment
Maximal plasma concentrations of flibanserin, TFMPP and BIMA 23 BS 
(C(max)) of 628 ± 225 ng/mL (mean ± SEM), 46.0 ± 17.0 ng/mL and 149 ± 
38.7 ng/mL, respectively, were reached at 0.5–1 hour after oral administration, 
decreasing rapidly to low levels by 24 hours, providing a circulating half-life 
for flibanserin of 2.8 hours (Figure 1). For 8-OH-DPAT, C(max) of 69.7 ± 19.8 
nmol/L was reached by 0.25–0.5 hour after SC injection, and values dropped 
rapidly to 3.4 ± 2.6 nmol/L after 3 hours, providing a circulating half-life of 8-OH-
DPAT of 0.6 hour (Figure 1). No cumulative effects of chronic 8-OH-DPAT and 
Figure 1. 24-hour pharmacokinetic profiles of flibanserin and 8-OH-DPAT in female 
marmoset monkeys. Pairmate observations were performed at 16-24 hours after administration, 
when exposure to circulating drug concentrations was low or absent, while observations of the 
5-HT behavioral syndrome was performed at 0-0.5 hour after administration, when circulating 
drug concentrations were high. 8-OH-DPAT, R-(+)-8-hydroxy-2-(di-n-propylamino)-tetralin; 
5-HT, serotonin.
SC injection, and values dropped rapidly to
3.4  2.6 nmol/L after 3 hours, providing a circu-
lating half-life of 8-OH-DPAT of 0.6 hour
(Figure 1). No cumulative effects of chronic
8-OH-DPAT and flibanserin administration were
apparent. The results confirm a substantial sys-
temic exposure to flibanserin, BIMA 23 BS,
TFMPP and 8-OH-DPAT during observations
for 5-HT behavioral syndrome, but not during
pairmate observations. Thus, treatment-induced
changes during pairmate observations are most
likely attributable to the long-term consequences
of flibanserin and 8-OH-DPAT exposure, and not
to acute effects elicited by elevated circulating
levels of active drug.
Chronic Effects of 8-OH-DPAT and Flibanserin on
Sexual, Social and Self-Directed Behavior
Five to six weeks of daily oral administration of
flibanserin to female marmosets noticeably
increased female genital area self-grooming
(F(1,7) = 31.28, P = 0.001; Figure 2A) and male
pairmate sniffing/licking of their female’s genital
area (F(1,7) = 8.91, P = 0.020; Figure 2B). No
other sexually related behavior was altered by fli-
banserin (Table 1). In contrast, 5–6 weeks of daily
SC administration of 0.1 mg/kg 8-OH-DPAT
strikingly increased female rejection of male pair-
mate mount attempts and mounts compared to
corresponding vehicle (F(1,7) = 8.24, P = 0.024;
Figure 3). 8-OH-DPAT-induced female rejection
Figure 1 24-hour pharmacokinetic
profiles of flibanserin and 8-OH-
DPAT in female marmoset monkeys.
Pairmate observations were per-
formed at 16–24 hours after adminis-
tration, when exposure to circulating
drug concentrations was low or
absent, while observation of the 5-HT
behavioral syndrome was performed
at 0–0.5 hour after administration,
when circulating drug concentrations
were high. 8-OH-DPAT, R-(+)-8-
hydroxy-2-(di-n-propylamino)-tetralin;
5-HT, serotonin.
Figure 2 Investigation of female genital area. Frequencies (backtransformed mean) of (A) female genital area self-
grooming and (B) male inspection of female genital area per 30 minutes during 5–6 weeks following the onset of flibanserin,
flibanserin vehicle, 8-OH-DPAT, or 8-OH-DPAT vehicle administration. *** P = 0.001 vs. flibanserin vehicle (F(1,7) = 31.3),
* P = 0.020 vs. flibanserin vehicle (F(1,7) = 8.9), † P = 0.080 vs. 8-OH-DPAT vehicle (F(1,7) = 4.2). Each symbol indicates
the same individual female marmoset receiving estradiol (solid symbols) or no estradiol (open symbols). 8-OH-DPAT,
R-(+)-8-hydroxy-2-(di-n-propylamino)-tetralin.
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flibanserin administration were apparent. The results confirm a substantial 
systemic exposure to flibanserin, BIMA 23 BS, TFMPP and 8-OH-DPAT 
during observations for 5-HT behavioral syndrome, but not during pairmate 
observations. Thus, treatment-induced changes during pairmate observations 
are most likely attributable to the long-term consequences of flibanserin and 
8-OH-DPAT exposure, and not to acute effects elicited by elevated circulating 
levels of active drug.
Chronic effects of 8-OH-DPAT and flibanserin on sexual, social and self-
directed behavior
Five to six weeks of daily oral administration of flibanserin to female 
marmosets noticeably increased female genital area self-grooming (F(1,7) 
= 31.28, P = 0.001; Figure 2A) and male pairmate sniffing/licking of their 
female’s genital area (F(1,7) = 8.91, P = 0.020; Figure 2B). No other sexually 
related behavior was altered by flibanserin (Table 1). In contrast, 5–6 weeks 
of daily SC administration of 0.1 mg/kg 8-OH-DPAT strikingly increased 
female rejection of male pairmate mount attempts and mounts compared to 
corresponding vehicle (F(1,7) = 8.24, P = 0.024; Figure 3). 8-OH-DPAT-induced 
female rejection of male sexual advances also increased male attempts to 
mount their female pairmate (F(1,7) = 6.93, P = 0.034). The male pairmates 
Figure 2. Investigation of female genital area. Frequencies (backtransformed mean) of (A) 
female genital area selfgrooming and (B) male inspection of female genital area per 30 minutes 
during 5–6 weeks following the onset of flibanserin, flibanserin vehicle, 8-OH-DPAT, or 8-OH-
DPAT vehicle administration. *** P = 0.001 vs. flibanserin vehicle (F(1,7) = 31.3), * P = 0.020 
vs. flibanserin vehicle (F(1,7) = 8.9), † P = 0.080 vs. 8-OH-DPAT vehicle (F(1,7) = 4.2). each 
symbol indicates the same individual female marmoset receiving estradiol (solid symbols) or no 
estradiol (open symbols). 8-OH-DPAT, R-(+)-8-hydroxy-2-(di-n-propylamino)-tetralin.
SC injection, and values dropped rapidly to
3.4  2.6 nmol/L after 3 hours, providing a circu-
lating half-life of 8-OH-DPAT of 0.6 hour
(Figure 1). No cumulative effects of chronic
8-OH-DPAT and flibanserin administration were
apparent. The results confirm a substantial sys-
temic exposure to flibanserin, BIMA 23 BS,
TFMPP and 8-OH-DPAT during observations
for 5-HT behavioral syndrome, but not during
pairmate observations. Thus, treatment-induced
changes during pairmate observations are most
likely attributable to the long-term consequences
of flibanseri and 8-OH-DPAT exposure, and not
to acute effects elicited by elevated circulating
levels of active drug.
Chronic Effects of 8-OH-DPAT and Flibanserin on
Sexual, Social and Self-Directed Behavior
Five to six weeks of daily oral administration of
flibanserin to female marmosets noticeably
increased female genital area self-grooming
(F(1,7) = 31.28, P = 0.001; Figure 2A) and male
pairmate sniffing/licking of their female’s genital
area (F(1,7) = 8.91, P = 0.020; Figure 2B). No
other sexually related behavior was altered by fli-
banserin (Table 1). In contrast, 5–6 weeks of daily
SC administration of 0.1 mg/kg 8-OH-DPAT
strikingly increased female rejection of male pair-
mate mount attempts and mounts compared to
corresponding vehicle (F(1,7) = 8.24, P = 0.024;
Figure 3). 8-OH-DPAT-induced female rejection
Figure 1 24-hour pharmacokinetic
profiles of flibanserin and 8-OH-
DPAT in female marmoset monkeys.
Pairmate observ tions were per-
formed at 16–24 hours after adminis-
tration, when exposure to circulating
drug concentrations was low or
absent, while observation of the 5-HT
behavioral syndrome was performed
at 0–0.5 hour after administration,
when circulating drug concentrations
were high. 8-OH-DPAT, R-(+)-8-
hydroxy-2-(di-n-propylamino)-tetralin;
5-HT, serotonin.
Figure 2 Investigation of female genital area. Frequencies (backtransformed mean) of (A) female genital area self-
grooming and (B) male inspection of fe ale genital area per 30 minutes during 5–6 weeks following the onset of flibanserin,
flibanserin vehicle, 8-OH-DPAT, or 8-OH-DPAT vehicle administration. *** P = 0.001 vs. flibanserin vehicle (F(1,7) = 31.3),
* P = 0.020 vs. flibans rin vehicle (F(1,7) = 8.9), † P = 0.080 vs. 8-OH-DPAT v hicle (F(1,7) = 4.2). E ch symbol indicate
the same individual female marmoset receiving estradiol (solid symbols) or no estradiol (open symbols). 8-OH-DPAT,
R-(+)-8-hydroxy-2-(di-n-propylamino)-tetralin.
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of 8-OH-DPAT treated females also tended to sniff/lick their female pairmate’s 
genital area less (F(1,7) = 4.20, P = 0.080; Figure 2B), and decreased male 
genital sniffing was correlated with female rejection of male mount attempts 
and mounts (r = -0.747, P = 0.033). No other sexually related behavior was 
altered (Table 1).
Such opposing effects of flibanserin and 8-OHDPAT were also observed in 
social interactions between male and female pairmates. Flibanserin increased 
Figure 3. Female sexual rejection. Frequency 
(backtransformed mean) of female rejection 
of male mounts and mount attempts per 30 
minutes during 5–6 weeks of flibanserin, 
flibanserin vehicle, 8-OH-DPAT, or 8-OH DPAT 
vehicle administration. * P = 0.024 vs. 8-OH-
DPAT vehicle (F(1,7) = 8.2). each symbol 
indicates the same individual female marmoset 
receiving estradiol (solid symbols) or no 
estradiol (open symbols). 8-OH-DPAT, R-(+)-8-
hydroxy-2- (di-n-propylamino)-tetralin.
Figure 4. Pairmate allogrooming and aggression. Frequencies (backtransformed mean) of 
(A) allogrooming and (B) aggressive interactions between pairmates per 30 minutes during 5–6 
weeks of flibanserin, flibanserin vehicle, 8-OH-DPAT, or 8-OH-DPAT vehicle administration. *** 
P = 0.001 vs. flibanserin vehicle (F(1,7) = 34.2), † P = 0.079 vs. 8-OH-DPAT vehicle (F(1,7) 
= 4.2), * P = 0.049 vs. 8-OH-DPAT vehicle (F(1,7) = 5.6). each symbol indicates the same 
individual female marmoset receiving estradiol (solid symbols) or no estradiol (open symbols). 
8-OH-DPAT, R-(+)-8-hydroxy-2-(di-n-propylamino)-tetralin.
of male sexual advances also increased male
attempts to mount their female pairmate
(F(1,7) = 6.93, P = 0.034). The male pairmates of
8-OH-DPAT treated females also tended to sniff/
lick their female pairmate’s genital area less
(F(1,7) = 4.20, P = 0.080; Figure 2B), and
decreased male genital sniffing was correlated with
female rejection of male mount attempts and
ounts (r = -0.747, P = 0.033). No other sexually
related behavior was altered (Table 1).
Such opposing effects of flibanserin and 8-OH-
DPAT were also observed in social interactions
between male and female pairmates. Flibanserin
increased allogrooming between pairmates
(F(1,7) = 34.25, P = 0.001; Figure 4A), mostly
male grooming of their female pairmates
(F(1,7) = 6.25, P = 0.041). 8-OH-DPAT, in con-
trast, tended to diminish allogrooming between
males and females (F(1,7) = 4.23, P = 0.079;
Figure 4A), including a trend toward diminished
male grooming of female pairmates
(F(1,7) = 4.92, P = 0.062). Frequency of aggres-
sive interactions between the pairmates was
increased by 8-OH-DPAT (F(1,7) = 5.65,
P = 0.049; Figure 4B), but not by flibanserin
(F(1,7) = 0.09, P = 0.778). This 8-OH-DPAT
induced increase in aggression positively corre-
lated with increased female rejection of male
mount attempts and mounts (r = 0.941,
P < 0.001), and correlated negatively with male
genital sniffing (r = -0.834, P = 0.010). No other
changes in social behavior were induced by fli-
banserin or 8-OH-DPAT (Table 1).
Female self-grooming behavior was increased
by flibanserin (F(1,7) = 7.13, P = 0.032), but not by
8-OH-DPAT (F(1,7) = 3.02, P = 0.126). There
Figure 3 Female sexual rejection. Frequency (backtrans-
formed mean) of female rejection of male mounts and
mount attempts per 30 minutes during 5–6 weeks of fli-
banserin, flibanserin vehicle, 8-OH-DPAT, or 8-OH-DPAT
vehicle administration. * P = 0.024 vs. 8-OH-DPAT vehicle
(F(1,7) = 8.2). Each symbol indicates the same individual
female marmoset receiving estradiol (solid symbols) or no
estradiol (open symbols). 8-OH-DPAT, R-(+)-8-hydroxy-2-
(di-n-propylamino)-tetralin.
Figure 4 Pairmate allogrooming and aggression. Frequencies (backtransformed ean) of (A) allogrooming and (B)
aggressive interactions between pairmates per 30 minutes during 5–6 weeks of flibanserin, flibanserin vehicle, 8-OH-DPAT,
or 8-OH-DPAT vehicle administration. *** P = 0.001 vs. flibanserin vehicle (F(1,7) = 34.2), † P = 0.079 vs. 8-OH-DPAT vehicle
(F(1,7) = 4.2), * P = 0.049 vs. 8-OH-DPAT vehicle (F(1,7) = 5.6). Each symbol indicates the same individual female marmoset
receiving estradiol (solid symbols) or no estradiol (open symbols). 8-OH-DPAT, R-(+)-8-hydroxy-2-(di-n-propylamino)-tetralin.
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of male sexual advances also increased male
at empts to ount their female pairmate
(F(1,7) = 6.93, P = 0.034). The male pairmates of
8-OH-DPAT treated females also tended to sniff/
lick their female pairmate’s genital area less
(F(1,7) = 4.20, P = 0.080; Figure 2B), and
decreased male genital sniffing was correlated with
female rejection of male mount attempts and
mounts (r = -0.747, P = 0.033). No other sexually
related behavior was altered (Table 1).
Such opposing effects of flibanserin and 8-OH-
DPAT were also observed in social interactions
between male and female pairmates. Flibanserin
increased allogrooming between pairmates
(F(1,7) = 34.25, P = 0.001; Figure 4A), mostly
male grooming of their female pairmates
(F(1,7) = 6.25, P = 0.041). 8-OH-DPAT, in con-
trast, tended to diminish allogrooming between
males and females (F(1,7) = 4.23, P = 0.079;
F gur 4A), including a trend toward dimini hed
male grooming of female pairmates
(F(1,7) = 4.92, P = 0.062). Frequency of aggres-
sive interactions etween the pairmates was
increased by 8-OH-DPAT (F(1,7) = 5.65,
P = 0.049; Figure 4B), but not by flibanserin
(F(1,7) = 0.09, P = 0.778). This 8-OH-DPAT
induced increase in aggression positively corre-
lated with increased female rejection of male
mount attempts and mounts (r = 0.941,
P < 0. 01), and co related negatively with male
genital sniffing (r = -0.834, P = 0.010). No other
changes in social behavior were induced by fli-
bans rin or 8-OH-DPAT (Tabl 1).
Female self-grooming behavior was increased
by flibanserin (F(1,7) = 7.13, P = 0.032), but not by
8-OH-DPAT (F(1,7) = 3.02, P = 0.126). There
Figure 3 Female sexual rejection. Frequency (backtrans-
formed mean) of female rejection of male mounts and
mount attempts per 30 minutes during 5–6 weeks of fli-
banserin, flibanserin vehicle, 8-OH-DPAT, or 8-OH-DPAT
vehicle administration. * P = 0.024 vs. 8-OH-DPAT vehicle
(F(1,7) = 8.2). Each symbol indicates the same individual
female marmoset receiving estradiol (solid symbols) or no
estradiol (open symbols). 8-OH-DPAT, R-(+)-8-hydroxy-2-
(di-n-propylamino)-tetralin.
Figure 4 Pairmate allogrooming and aggression. Frequencies (backtransformed mean) of (A) allogrooming and (B)
aggressive interactions between pairmates per 30 minutes during 5–6 weeks of flibanserin, flibanserin vehicle, 8-OH-DPAT,
or 8-OH-DPAT vehicle administration. *** P = 0.001 vs. flibanserin vehicle (F(1,7) = 34.2), † P = 0.079 vs. 8-OH-DPAT vehicle
(F(1,7) = 4.2), * P = 0.049 vs. 8-OH-DPAT vehicle (F(1,7) = 5.6). Each symbol indicates the same individual female marmoset
receiving estradiol (solid symbols) or no estradiol (open symbols). 8-OH-DPAT, R-(+)-8-hydroxy-2-(di-n-propylamin )-tetralin.
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allogrooming between pairmates (F(1,7) = 34.25, P = 0.001; Figure 4A), 
mostly male grooming of their female pairmates (F(1,7) = 6.25, P = 0.041). 
8-OH-DPAT, in contrast, tended to diminish allogrooming between males 
and females (F(1,7) = 4.23, P = 0.079; Figure 4A), including a trend toward 
diminished male grooming of female pairmates (F(1,7) = 4.92, P = 0.062). 
Frequency of aggressive interactions between the pairmates was increased 
by 8-OH-DPAT (F(1,7) = 5.65, P = 0.049; Figure 4B), but not by flibanserin 
(F(1,7) = 0.09, P = 0.778). This 8-OH-DPAT induced increase in aggression 
positively correlated with increased female rejection of male mount attempts 
and mounts (r = 0.941, P < 0.001), and correlated negatively with male genital 
sniffing (r = -0.834, P = 0.010). No other changes in social behavior were 
induced by flibanserin or 8-OH-DPAT (Table 1).
Female self-grooming behavior was increased by flibanserin (F(1,7) = 7.13, 
P = 0.032), but not by 8-OH-DPAT (F(1,7) = 3.02, P = 0.126). There were no 
other behavioral effects of either drug on self-directed behaviors (Table 1). 
estradiol supplementation, in both 8-OH-DPAT and flibanserin groups, was 
without effect on pairmate behavior.
Effects of flibanserin and 8-OH-DPAT on acute induction of the 5-HT 
behavioral syndrome
During pairmate observations to assess sexual and social behavior 
(7:00am–1:00pm, 16–24 hours following daily drug administration), neither 
8-OH-DPAT nor flibanserin resulted in females displaying symptoms of the 
potentially disruptive 5-HT behavioral syndrome.
Directly (0–0.5 hour) following administration, however, flibanserin 
shortened the latency to the first occurrence of sprawling or prone behavior 
(Figure 5, F(1,7) = 11.90, P = 0.011), without affecting the frequency of this 
behavior (F(1,7) = 0.44, P = 0.528). Furthermore, in contrast to 8-OH-DPAT, 
flibanserin first increased (weeks 1–3) female scratching behavior 0–0.5 hour 
Figure 5. Sprawling behavior. Latency (minutes; 
backtransformed mean) to the first occurrence of sprawling 
behavior by female marmosets during pairmate observation 
after 5–6 weeks of flibanserin or flibanserin vehicle. * P = 0.011 
vs. flibanserin vehicle (F(1,7) = 11.90). each symbol indicates 
the same individual female marmoset receiving estradiol (solid 
symbols) or no estradiol (open symbols).
were no other behavioral effects of either drug on
self-directed behaviors (Table 1). Estradiol supple-
mentation, in both 8-OH-DPAT and flibanserin
groups, was without effect on pairmate behavior.
Effects of Flibanserin and 8-OH-DPAT on Acute
Induction of the 5-HT Behavioral Syndrome
During pairmate observations to assess sexual and
social behavior (7:00am–1:00pm, 16–24 hours fol-
lowing daily drug administration), neither 8-OH-
DPAT nor flibanserin resulted in females display-
ing symptoms of the potentially disruptive 5-HT
behavioral syndrome.
Directly (0–0.5 hour) following administration,
however, flibanserin shortened the latency to the
first occurrence of sprawling or prone behavior
(Figure 5, F(1,7) = 11.90, P = 0.011), without
affecting the frequency of this behavior
(F(1,7) = 0.44, P = 0.528). Furthermore, in con-
trast to 8-OH-DPAT, flibanserin first increased
(weeks 1–3) female scratching behavior 0–0.5 hour
after administration (F(3,21) = 5.64, P = 0.005),
and then diminished scratching behavior over
the remaining weeks of flibanserin treatment
compared to corresponding vehicle treatment
(Treatment ¥ Week interaction [F(3,21) = 7.21,
P = 0.002]).
In contrast to flibanserin, 8-OH-DPAT consis-
tently induced locomotor components of an acute,
transient 5-HT behavioral syndrome in female
marmosets 0–0.5 hour after administration, which
persisted over the entire time course (15–16 weeks)
of chronic treatment. In 8-OH-DPAT-treated
female marmosets, the acute 5-HT behavioral syn-
drome involved displays of “random rapid limb
movements” (Figure 6A, F(1,7) = 16.67, P = 0.005)
and “wet-dog shakes” (Figure 6B, F(1,7) = 19.81,
P = 0.003). In addition, frequency of scratching
behavior tended to be elevated 0–0.5 hour after
8-OH-DPAT administration (Figure 6C, F(1,7) =
5.46, P = 0.052), but there was a Treatment ¥ Week
interaction (F(1,7) = 15.39, P < 0.001). Post hoc
analysis indicated that female marmosets demon-
Figure 5 Sprawling behavior. Latency (minutes; back-
transformed mean) to the first occurrence of sprawling
behavior by female marmosets during pairmate observation
after 5–6 weeks of flibanserin or flibanserin vehicle.
* P = 0.011 vs. flibanserin vehicle (F(1,7) = 11.90). Each
symbol indicates the same individual female marmoset
receiving estradiol (solid symbols) or no estradiol (open
symbols).
Figure 6 Acute induction of the 5-HT behavioral syndrome. Frequency (backtransformed mean) of female (A) “rapid,
random limb movements” behavior (B) “wet dog shake” behavior, and (C) scratching behavior per 30 minutes during 5–6
weeks of flibanserin, flibanserin vehicle, 8-OH-DPAT, or 8-OH-DPAT vehicle and following 0–0.5 hours of treatment admin-
istration. ** P < 0.01 vs. 8-OH-DPAT vehicle (“rapid, random limb movements”: F(1,7) = 16.7; “wet dog shakes”:
F(1,7) = 19.8), † P = 0.052 vs. 8-OH-DPAT vehicle (F(1,7) = 5.46). Each symbol indicates the same individual female
marmoset receiving estradiol (solid symbols) or no estradiol (open symbols). 8-OH-DPAT, R-(+)-8-hydroxy-2-(di-n-
propylamino)-tetralin.
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after administration (F(3,21) = 5.64, P = 0.005), and then diminished scratching 
behavior over the remaining weeks of flibanserin treatment compared to 
corresponding vehicle treatment (Treatment × Week interaction [F(3,21) = 
7.21, P = 0.002]).
In contrast to flibanserin, 8-OH-DPAT consistently induced locomotor 
components of an acute, transient 5-HT behavioral syndrome in female 
marmosets 0–0.5 hour after administration, which persisted over the entire 
time course (15–16 weeks) of chronic treatment. In 8-OH-DPAT-treated 
female marmosets, the acute 5-HT behavioral syndrome involved displays 
of “random rapid limb movements” (Figure 6A, F(1,7) = 16.67, P = 0.005) 
and “wet-dog shakes” (Figure 6B, F(1,7) = 19.81, P = 0.003). In addition, 
frequency of scratching behavior tended to be elevated 0–0.5 hour after 
8-OH-DPAT administration (Figure 6C, F(1,7) = 5.46, P = 0.052), but there 
was aTreatment × Week interaction (F(1,7) = 15.39, P < 0.001). Post hoc 
analysis indicated that female marmosets demonstrated an acute onset of 
scratching behavior during the first week of 8-OH-DPAT treatment (week 1), 
but not during subsequent weeks. As found with 5-HT behavioral syndrome 
behaviors, there was no effect of 8-OH-DPAT treatment on scratching behavior 
at 16–24 hours following drug administration (F(1,7) = 1.75, P = 0.227) when 
pairmate behavioral observations were conducted.
Figure 6. Acute induction of the 5-HT behavioral syndrome. Frequency (backtransformed 
mean) of female (A) “rapid, random limb movements” behavior (B) “wet dog shake” behavior, 
and (C) scratching behavior per 30 minutes during 5–6 weeks of flibanserin, flibanserin vehicle, 
8-OH-DPAT, or 8-OH-DPAT vehicle and following 0–0.5 hours of treatment administration. ** P < 
0.01 vs. 8-OH-DPAT vehicle (“rapid, random limb movements”: F(1,7) = 16.7; “wet dog shakes”: 
F(1,7) = 19.8), † P = 0.052 vs. 8-OH-DPAT vehicle (F(1,7) = 5.46). each symbol indicates 
the same individual female marmoset receiving estradiol (solid symbols) or no estradiol (open 
symbols). 8-OH-DPAT, R-(+)-8-hydroxy-2-(di-npropylamino)- tetralin.
were no other behavioral effects f either drug on
self-directed behaviors (Table 1). Estradiol supple-
mentation, in both 8-OH-DPAT and flibanserin
groups, was without effect on pairmate behavior.
Effects of Flibanserin and 8-OH-DPAT on Acute
Induction of the 5-HT Behavioral Sy drom
During pairmate observations to assess sexual and
social behavior (7:00am–1:00pm, 16–24 hours fol-
lowing daily drug administration), neither 8-OH-
DPAT nor flibanserin resulted in females display-
ing symptoms of the potentially disruptive 5-HT
behavioral syndrome.
Directly (0–0.5 hour) following administration,
however, flibanserin shortened the latency to the
first occurrence of sprawling or prone behavior
(Figure 5, F(1,7) = 11.90, P = 0.011), without
affecting the frequency of this behavior
(F(1,7) = 0.44, P = 0.528). Furthermore, in con-
trast to 8-OH-DPAT, flibanserin first increased
(weeks 1–3) female scratching behavior 0–0.5 hour
after administration (F(3,21) = 5.64, P = 0.005),
and then diminished scratching behavior over
the remaining weeks of flibanserin treatment
compared to corresponding vehicle treatment
(Treatment ¥ Week interaction [F(3,21) = 7.21,
P = 0.002]).
In contrast to flibanserin, 8-OH-DPAT consis-
tently induced locomotor components of an acute,
transient 5-HT behavioral syndrome in female
marmosets 0–0.5 hour after administration, which
persisted over the entire time course (15–16 weeks)
of chronic treatment. In 8-OH-DPAT-treated
female marmosets, the acute 5-HT behavioral syn-
drome involved displays of “random rapid limb
movements” (Figure 6A, F(1,7) = 16.67, P = 0.005)
and “wet-d g shakes” (Figure 6B, F(1,7) = 19.81,
P = 0.003). In addition, frequency of scratching
behavior tended to be elevated 0–0.5 hour after
8-OH-DPAT administration (Figure 6C, F(1,7) =
5.46, P = 0.052), but there was a Treatment ¥ Week
interaction (F(1,7) = 15.39, P < 0.001). Post hoc
analysis indicated that female marmosets demon-
Figure 5 Sprawling behavior. Latency (minutes; back-
transformed mean) to the first occurrence of sprawling
behavior by female marmosets during pairmate observation
after 5–6 weeks of flibanserin or flibanserin vehicle.
* P = 0.011 vs. flibanserin vehicle (F(1,7) = 11.90). Each
symbol i dicates the same individual female marmoset
receiving estradiol (solid symbols) or no estradiol (open
symbols).
Figure 6 Acute induction of the 5-HT behavioral syndrome. Frequency (backtransformed mean) of female (A) “rapid,
random limb movements” behavior (B) “wet dog shake” behavior, and (C) scratching behavior per 30 minutes during 5–6
weeks of flibanserin, flibanserin vehicle, 8-OH-DPAT, or 8-OH-DPAT vehicle and following 0–0.5 hours of treatment admin-
istration. ** P < 0.01 vs. 8-OH-DPAT vehicle (“rapid, random limb movements”: F(1,7) = 16.7; “wet dog sh kes”:
F(1,7) = 19.8), † P = 0.052 vs. 8-OH-DPAT vehicle (F(1,7) = 5.46). Each symbol indicates the same individual female
marmoset receiving estradiol (solid symbols) or no estradiol (open symbols). 8-OH-DPAT, R-(+)-8-hydroxy-2-(di-n-
propylamino)-tetralin.
Flibanserin Alters Primate Pairmate Relations 701
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DISCUSSION
Despite the prevalence of HSDD among women [1,3], its psychopathogenesis 
is unknown. Pharmacological manipulation of 5-HT, however, commonly 
induces an HSDD-like condition, especially in women chronically treated with 
SSRIs for depression [4], likely involving 5-HT1A receptors [34]. Flibanserin, 
a 5-HT1A postsynaptic receptor agonist and 5-HT2A antagonist, presents a 
pharmacological opportunity to ameliorate psychosexual distress in women. 
Flibanserin improves sexual desire in women with major depression [14], and 
in women with HSDD it has been demonstrated to increase satisfying sexual 
events, sexual desire, and decreases distress [15]. Female marmosets, 
already established as a mechanistic model for neural regulation of female 
sexual behavior [19,28], form stable, long-term, male–female relationships 
[18] that allow for the examination of the pharmacological efficacy of flibanserin 
with regard to female sexual behavior.
Chronic administration of flibanserin to female marmoset pairmates 
stimulates male inspection of female genital area and increases female 
genital self-grooming. Female sexual behavior, however, is otherwise 
unaltered, possibly because we employ well-established male–female pairs 
without a history of infrequent-to-absent sexual behavior. Enhancement of 
proceptive and receptive aspects of female marmoset sexual behavior can 
be quantified using our behavioral testing paradigm, as previously shown 
following administration of gonadotropin releasing-hormone II and respective 
analogues [19]. In contrast, 8-OH-DPAT (a 5-HT1A pre- and postsynaptic 
receptor agonist) administered to female marmoset pairmates tends to 
diminish male inspection of female genitalia and increases female rejection 
of male-initiated sexual advances, thus diminishing female sexual receptivity 
toward their long-standing male pairmate. The comparability of behavioral 
responses in both estrogen and “no hormone replaced” ovariectomized 
female marmosets used in this study suggests applicability of our results to 
both pre- and post-menopausal conditions in women, as found in a previous 
marmoset study [19].
The differential effects of flibanserin and 8-OH-DPAT on female marmoset 
sexual behavior resemble findings in female rats. Female rats given 
flibanserin increase expression of proceptive and receptive sexual behavior 
and receive increased genital sniffing by the male pairmate [13], whereas 
female rats given 8-OH-DPAT exhibit diminished female sexual receptivity 
[17]. These contrasting effects of flibanserin and 8-OH-DPAT on marmoset 
and rodent behavior are surprising since both compounds are described as 
5-HT1A agonists. However, while both flibanserin and 8-OH-DPAT activate 
postsynaptic 5-HT1A receptors, flibanserin is functional only as a postsynaptic 
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receptor agonist [15], whereas 8-OH-DPAT activates both pre- and 
postsynaptic 5-HT1A receptors. This difference in biological action results in 
fundamental differences in pharmacology and the abilities of flibanserin and 
8-OH-DPAT to induce functional changes in a brain region-specific manner. 
For example, flibanserin inhibits forskolin-stimulated cAMP formation in the 
cortex, while 8-OHDPAT does not affect cortical cAMP accumulation [10]. 
Flibanserin decreases neuronal firing rate in the rat cortex regardless of 
whether the presynaptic receptor-containing dorsal raphé nucleus is intact, 
while the effects of 8-OH-DPAT are dependent upon intact raphé serotonergic 
neurons [11]. Taken together, flibanserin and 8-OH-DPAT display a different 
regional selectivity, and they differentially affect neuronal function in 5-HT 
projection sites.
These functional differences are particularly evident in pyramidal 
neurons in the prefrontal cortex, a key site for flibanserin’s mode of action 
in affecting female sexual behavior, as these neurons are an important part 
of regulatory networks that coordinate the release of 5-HT, DA and Ne in 
a brain region-specific manner [15]. Additional 5-HT2A antagonist effects of 
flibanserin, which 8-OH-DPAT lacks, have been shown to enhance 5-HT1A 
agonist effects on pyramidal neurons of the prefrontal cortex, thus creating 
a biochemical environment in flibanserin-exposed prefrontal cortex that is 
clearly different from 8-OH-DPAT exposure. 8-OH-DPAT is thus not likely to 
directly affect cortical neurocircuitries [10], but will suppress female sexual 
behavior by acting on 5-HT1A receptors in postsynaptic hypothalamic areas, 
such as the ventromedial hypothalamus [35] and medial preoptic area [36], or 
in presynaptic raphé nuclei [37]. Thus,flibanserin’s effects on female sexual 
behavior are likely mediated by altering cortical neurocircuitries, while 8-OH-
DPAT likely inhibits female sexual behavior by activation of hypothalamic or 
midbrain 5-HT1A receptor populations. The inhibitory effects of 8-OH-DPAT 
occur immediately and do not require chronic administration in rats [6]. Chronic 
administration seems not to lead to either tolerance or sensitization of sexual 
behavior, at least in male rats [38]. Flibanserin, in contrast, might regulate 
female sexual behavior by affecting pyramidal neurons in the prefrontal cortex 
and establishing a new monoamine neurotransmitter balance in a brain region-
specific manner [15]. Chronic elevations in prefrontal cortex levels of DA and 
Ne in rats are reported after 21 days of repeated flibanserin administration, 
consistent with the duration needed for flibanserin to facilitate female sexual 
behavior in rats [13].
Flibanserin’s enhancement of interest in treated female marmosets’ genitals 
is reminiscent of its effects when administered twice daily to female rats (45 mg/
kg, PO) for 2–3 weeks. Flibanserintreated female rats attract increased male 
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inspection of their genital area [13]. In both rats and marmosets, female genital 
odor is important for activation of male sexual arousal [rat: [39]; marmoset: 
[40]], particularly, female genital odor from the peri-ovulatory period when 
female sexual proceptivity and receptivity are maximal [rat: [41]; marmoset: 
[42]]. 5-HT regulates likely mediators of genital olfactory attractiveness, 
such as oxytocinergic (OT) and vasopressinergic (AVP) neurons [43] that 
innervate female external genitalia, possibly in conjunction with the central DA 
neurotransmitter system [44]. Neuro-regulated changes in vaginal odor may 
also be a consequence of 5-HT-mediated alterations in genital vasodilatation 
[44] or salt-water regulation [45]. Increased female interest in genital self-
grooming and selfgrooming, in general, could involve 5-HT mediated changes 
in OT, as central administration of OT (and AVP) to female rats increases 
selfgrooming, particularly of the genital area [46].
Perhaps the most intriguing finding of this marmoset study, the opposing 
effects of flibanserin and 8-OH-DPAT on the quality of male–female pair 
interactions, raises the possibility that female sexuality is strongly influenced by 
the perceived quality of the relationship with their partner (e.g., [3,47]). Social 
attachment and maintenance of proximity, allogrooming and pair-bonding, 
function to facilitate reproduction [48] and sexual behavior may contribute 
toward maintenance of a close male–female relationship [49]. In marmosets, 
affiliative behavior between females and males co-occurs with sexual behavior, 
while aggressive behavior between pairmates impedes sexual interaction 
[50,51]. Thus, the aggression-inducing effect of 8-OH-DPAT and the affiliation-
enhancing effect of flibanserin may create relationship environments that 
either diminish or facilitate sexual interactions between marmoset pairmates, 
respectively, likely mediated by neurotransmitter systems implicated in 
the regulation of social behavior, such as 5-HT [52], DA [53], AVP and OT 
[54,55]. Flibanserin selectively activates postsynaptic 5-HT1A receptors while 
antagonizing 5-HT2A receptors [11]. Gerretsen et al. [56] recently reported a 
negative association between the desire for social relationships in humans 
and 5-HT2A binding in the prefrontal cortex. Furthermore, flibanserin’s distinct 
receptor binding profile induces long-lasting increases in basal DA in the 
prefrontal cortex, while not changing basal levels in other tested brain areas, 
including the hypothalamus and nucleus accumbens [57,58]. If replicated in 
flibanserin-treated female marmosets, such increases in prefrontal cortex 
DA would be expected to enhance prefrontal cortex-guided attention to male 
behavioral cues and to more readily elicit female responses based on previous 
experience [58]. Improved efficiency of DAmediated neural processing is 
proposed as one aspect of therapeutic efficacy for a variety of drugs that 
improve disorders of PFC dysfunction, possibly including HSDD [59,60].
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Beyond neurobiological factors that influence sexual function, several 
studies, including the National and Social Life Survey [61], point out that 
sexual behavior in women is closely linked to psychosocial factors and quality 
of their relationship with a partner [47]. The complex interplay of these factors 
with hormonal and neural environments is a challenge for any animal model 
of female sexual function. The translation of rodent findings to humans, for 
example, is difficult in light of their strict circadian hormonal control of female 
sexual function [62]. Studies in non-primate mammals are thus not likely able 
to capture the multifactorial environment in which sexual behavior is expressed 
in nonhuman primates and humans [63]. In contrast, our observations in the 
marmoset monkey emulate the human situation more closely and highlight 
the importance of pairbond quality in female sexual behavior. Our findings 
are likely based within an important set of marmoset-typical characteristics, 
including welldeveloped social behavior, long-term female–male pairings and 
a degree of emancipation of female sexual behavior from strict hormonal 
control [28] that permit a significant influence of the social environment on the 
shaping of sexual behavior.
The strong and consistent, but transient, expression of a 5-HT behavioral 
syndrome induced in female marmosets by 8-OH-DPAT administration is likely 
mediated by activation of postsynaptic 5-HT1A receptors [64,65]. Flibanserin, 
in contrast, does not elicit shaking or rapid limb movements despite its 
postsynaptic 5-HT1A agonist characteristic. This may be due to flibanserin’s 
5-HT2A antagonist property, as 5-HT1A and 5-HT2A receptors are functionally 
linked and show reciprocal modulation [66]. Indeed, pretreatment with 5-HT2A 
antagonists reduces 8-OH-DPAT-induced 5-HT behavioral syndrome in rats 
[31]. It is possible that flibanserin increases the expression of brain-derived 
neurotrophic factor (BDNF) in the cerebral cortex and hippocampus, which, 
in rats, diminishes the 5-HT behavioral syndrome induced by 8-OH-DPAT 
[67]. A shortened latency to sprawl induced by flibanserin may be equivalent 
to the flat-body posture component of the 5-HT behavioral syndrome [32]. 
Sprawling, however, is also commonly observed when marmosets solicit 
allogrooming from a partner [21]. Thus, a shortened latency to sprawling 
behavior may indicate another pro-social effect of flibanserin rather than a 
flibanserin-induced component of the 5-HT behavioral syndrome. Neither 
sprawling in flibanserin treated females, nor the 5-HT behavioral syndrome 
displayed by 8-OH-DPAT treated females, are likely related to 5-HT toxicity (or 
5-HT syndrome) described in humans, a potentially life-threatening condition 
induced by excess 5-HT [68]. 5-HT toxicity can result from combinations of 
antidepressant treatments, such as monoamine oxidase inhibitors (MAOIs) 
and SSRIs, causing clonus (involuntary muscle contraction and relaxation) 
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and hyperthermia [68] apparently due to 5-HT2 receptor-mediated effects [69]. 
Activation of 5-HT1A receptors, in contrast, commonly leads to hypothermia 
in rodents and humans [70,71]. Flibanserin, a 5-HT1A agonist and 5-HT2A 
receptor antagonist, and 8-OH-DPAT, a 5-HT1A agonist, are thus both unlikely 
to cause hyperthermic responses. Furthermore, both flibanserin and 8-OH-
DPAT administered to rodents selectively decrease 5-HT synthesis in several 
brain regions [72], further indicating the unlikelihood of either contributing to 
5-HT toxicity.
Similar to a previous observation indicating that low-level estradiol 
supplementation is not required for the efficacy of gonadotropin-releasing 
hormone II to stimulate sexual behavior in ovariectomized female marmosets 
[19], our present study, applying the same design in regard to estradiol 
replacement, demonstrates that behavioral changes due to chronic flibanserin 
and 8-OH-DPAT treatments are independent of estradiol status. This finding 
might be somewhat surprising in light of welldocumented interactions of 
estrogens with the central serotonin system [73] and contrast with a previous 
study conducted by Kendrick and Dixson [29]. Kendrick and Dixson [29], 
however, applied high levels of estradiol supplementation equivalent to pre-
ovulatory peak levels (~940 pg/mL). The much lower circulating estradiol levels 
in our study (average with estradiol supplementation: 396 pg/mL), chosen to 
facilitate a low to modest baseline of sexual behavior, may be responsible for 
the lack of obvious estradiol-induced behavioral changes in the present study.
CONCLUSIONS
Our findings are the first to demonstrate differential and potentially 
bi-directional regulation of female sexual behavior (diminished versus 
unchanged) and social behavior (diminished versus enhanced) in a nonhuman 
primate through prolonged serotonergic modulation, supporting the central 
5-HT system as a promising target for pharmacotherapy of sexual dysfunction 
in women. Our model applies species-appropriate settings in which female 
partners can control sexual and social interactions. We show that female 
marmoset sexual behavior is suppressed by selective chronic stimulation of 
5-HT1A receptors by 8-OH-DPAT. In contrast, through its distinctively different 
5-HT receptor binding profile, and potential additional abilities to enhance DA 
levels (and possibly other neurotransmitters) in a brain region specific manner 
[57,58], flibanserin increases pro-social interactions in male and female 
marmoset pairmates without obvious enhancement of female sexual behavior. 
While these findings suggest that flibanserin’s effects may not translate from 
female marmosets to women in every respect, they do show that flibanserin 
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enhances species-specific, intimate aspects of partner interactions. These 
are manifest by increased intimate affiliative engagement between marmoset 
pairmates and improved sexual relationships between women and their 
partners [14]. Thus, the putative beneficial effect of flibanserin on sexual well-
being in women, otherwise distressed about low sexual desire, may arise 
from its ability to positively influence the quality of relationship with long-term 
partners. Our observations of female marmosets may therefore suggest the 
need to integrate mechanistic, neurochemical explanations of female sexual 
behavior with holistic views of health psychology, including emotional and 
relational aspects of female sexuality, in order to successfully contribute novel 
therapeutic approaches to female sexual well-being.
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SUPPORTING INFORMATION
Figure S1. 24-hour pharmacokinetic profiles of 10 mg/kg and 30 mg/kg flibanserin in 
female marmoset monkeys. Flibanserin was administered PO at doses of 10 mg/kg or 30 
mg/kg. Blood samples were taken at 0.25 h, 0.5 h, 1 h, 3 h, 6 h and 24 h after flibanserin 
administration and analyzed for circulating flibanserin concentrations. Flibanserin doses did not 
significantly differ (P > 0.05; N = 4).
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Table S1. In a dose-response study, the behavioral effects of 10 mg/kg or 30 mg/kg flibanserin, 
administered to female marmosets, were compared to respective baseline behavior of each 
individual. Difference between flibanserin doses were assessed by three-way anova including 
the dose of flibanserin as between-subject factor.
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ABSTRACT
Background. Flibanserin, a novel serotonin (5-HT)1A agonist and 5-HT2A 
antagonist, has been shown to increase sexual desire and reduce distress 
in women with Hypoactive Sexual Desire Disorder (HSDD). In marmoset 
monkeys, flibanserin has demonstrated pro-social effects on male-female 
pairmates, while the classic 5-HT1A agonist 8-OH-DPAT suppresses female 
sexual behavior and increases aggressive interactions between pairmates. 
Activation of 5-HT1A and 5-HT2A receptors is known to stimulate the 
hypothalamic-pituitary-adrenal (HPA) axis. This study aims to characterize 
the effects of repeated flibanserin and 8-OH-DPAT administration on the 
marmoset HPA axis and to elucidate endocrine correlates of altered marmoset 
pair behavior.
Methods. Adrenocorticotropic hormone (ACTH) and cortisol were examined 
at baseline and during 5-HT1A agonist and restraint challenges in 8 female 
marmoset monkeys receiving daily flibanserin (15 mg/kg) and an additional 
8 female marmosets receiving 8-OH-DPAT (0.1 mg/kg) for 15-16 weeks. 
Corresponding vehicle treatments were administered in a counterbalanced, 
within-subject design. All females were housed in stable male-female pairs. 
Treatment-induced changes in ACTH and cortisol levels were correlated with 
previously assessed marmoset pair behavior.
Results. While morning basal cortisol levels and HPA responses to a 
5-HT1A agonist challenge were not altered by chronic flibanserin or 8-OH-
DPAT, both treatments increased the responsiveness of the marmoset HPA 
axis to restraint. enhanced ACTH responses to restraint correlated with 
reduced sexual receptivity and increased aggression in 8-OH-DPAT-, but not 
in flibanserin-treated female marmosets.
Conclusions. Unaltered HPA responses to a 5-HT1A agonist challenge 
after chronic flibanserin and 8-OH-DPAT treatments indicate little or no de-
sensitization of the HPA axis to repeated 5-HT1A manipulation. Chronic 8-OH-
DPAT, but not flibanserin, leads to aggravated ACTH responses to stress that 
may contribute to anti-sexual and anti-social behavior between 8-OH-DPAT-
treated females and their male pairmates. Despite similar flibanserin and 
8-OH-DPAT induced ACTH responses to restraint stress, flibanserin-treated 
females show unchanged cortisol profiles. This is possibly due to flibanserin’s 
regional selectivity in 5-HT1A activation and concurrent 5-HT2A inhibition. The 
contrasting restraint-related cortisol responses emulate contrasting behavioral 
phenotypes of diminished pair-bond of 8-OH-DPAT-treated females compared 
to the more affiliative pair-bond of flibanserin-treated females.
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INTRODUCTION
Hypoactive sexual desire disorder (HSDD), a distressing condition affecting 
an estimated 10% of women (Clayton, 2010), has no approved pharmacological 
treatment. Recently, flibanserin (2H-benzimidazol-2-one, 1,3-dihydro-1-[2-
[4-[3-(trifluoromethyl) phenyl]-1-piperazinyl]ethyl]), an agonist of serotonin 
(5-HT)1A and antagonist of 5-HT2A receptors (Borsini et al., 1995a; Borsini 
et al., 2002), demonstrated an ability to stimulate female sexual behavior 
in rats (Gelez et al., 2010) and to improve sexual desire in women with 
either HSDD (Derogatis et al., 2012; Thorp et al, 2012) or major depression 
(Kennedy, 2010). We have tested the long-term effects of flibanserin on 
sexual and social behavior in female common marmoset monkeys (Callithrix 
jacchus) housed with long-term male pairmates, and compared flibanserin-
induced behavioral outcomes with those induced by R-(+)-8-hydroxy-2-(di-
n-propylamino)-tetralin hydrobromide (8-OH-DPAT), a classic 5-HT1A agonist 
(Arvidsson et al., 1981). We found that flibanserin-treated females attracted 
more sexual interest from male pairmates and enhanced the frequency of 
grooming interactions between pairmates. In contrast, 8-OH-DPAT-treated 
females showed increased rejection of male sexual advances and increased 
aggression with male pairmates (Aubert et al., 2011).
Pharmacological manipulations of the central serotonin neurotransmitter 
system alter functioning of the hypothalamic-pituitary-adrenal (HPA) axis 
(Fuller, 1996; Jørgensen, 2007). Such HPA changes play important roles 
in behavioral modulation (de Kloet 2000; Sapolsky et al., 2000) and may 
contribute to the alteration of sexual and social behavior observed in our 
flibanserin and 8-OH-DPAT studies. Stress glucocorticoid levels generally 
inhibit female reproduction and sexual behavior in most species (De Catanzaro 
and Gorzalka, 1980; Sapolsky et al., 2000). Interestingly, stress is one of 
the most commonly perceived factors that contribute to low sexual desire in 
women diagnosed with HSDD (Maserejian et al., 2010), and disorders of the 
HPA axis are frequently associated with altered sexual desire and arousal in 
women (Starkman and Schteingart, 1981; erichsen et al., 2010).
The central 5-HT system generally exerts a stimulatory function on 
HPA axis activity (Feldman et al., 1987; Dinan, 1996; Jørgensen, 2007). 
Activation of 5-HT1A and 5-HT2A receptor subtypes, which are both 
expressed on corticotropin-releasing hormone (CRH) containing neurons 
in the paraventricular hypothalamic nucleus (PVN) (Liposits et al., 1987), 
stimulates the HPA axis to release adrenocorticotropic hormone (ACTH) and 
subsequently glucocorticoids (Rittenhouse et al., 1994; Osei-Owusu, 2005; 
Van de Kar et al., 2001). Conversely, the responsiveness of the HPA axis to 
stress is reduced following 5-HT depletion (Feldman and Weidenfeld, 1998). 
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5-HT induced regulation of HPA axis activity may thus underlie glucocorticoid 
influence on female sexual behavior.
The effects of chronic flibanserin administration on HPA axis functioning 
are not known. Repeated injections of 8-OH-DPAT for 21 days elevate basal 
circulating corticosterone, but not ACTH levels, in rats (Owens et al., 1990). 
A single systemic injection of 8-OH-DPAT acutely increases circulating 
ACTH and corticosterone levels (Owens et al., 1990; Raap et al., 2002) 
and inhibits sexual behavior in female rodents (Uphouse et al., 1991). No 
information regarding primate HPA axis function following chronic 8-OH-DPAT 
administration is currently available.
In female marmosets housed with long-term male pairmates, we previously 
reported pro-social outcomes during chronic flibanserin treatment in contrast 
to anti-social and anti-sexual effects of chronic 8-OH-DPAT administration 
(Aubert et al., 2012). The present study aims to investigate the effects of 
chronic flibanserin and 8-OH-DPAT (1) on the well-established stimulatory 
effect of 5-HT1A agonism on HPA function and (2) on the HPA response to 
restraint stress. Aim (1) will thus determine whether the responsiveness of the 
HPA axis to 5-HT1A activation is impacted by chronic 5-HT1A activation/5-HT2A 
inhibition (flibanserin), or by chronic 5-HT1A activation alone (8-OH-DPAT), 
while aim (2) will determine how flibanserin and 8-OH-DPAT affect marmoset 
HPA function during restraint stress. Such changes in HPA function may 




This study was conducted in accordance with the recommendations of the 
Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act 
and its subsequent amendments. All animal procedures were reviewed and 
approved by the Graduate School Animal Care and Use Committee of the 
University of Wisconsin-Madison. The Wisconsin National Primate Research 
Center (WNPRC) is accredited by the Association for Assessment and 
Accreditation of Laboratory Animal Care as part of the University of Wisconsin-
Madison Graduate School. Sixteen adult (age 2-5 yr) nulliparous captive-born 
common marmoset (Callithrix jacchus) females were pair housed with similarly 
aged male partners at the WNPRC for 8-20 months before onset of this study. 
eight of the 16 females were assigned to test the effects of flibanserin, while 
the remaining 8 females were assigned to test the effects of 8-OH-DPAT. 
Females were housed with the same male partner for the entire study and 
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were ovariectomized and primed with either mid-follicular phase estradiol 
levels or no estradiol before study onset. Estradiol status remained the same 
throughout the study for each individual animal. Surgical procedures, estradiol 
priming and study design with regard to estradiol priming were performed as 
described in Barnett et al. (2006).
Experimental design
A counterbalanced, cross-over study, that applied within-subject 
comparisons, was designed to examine the effects of chronic (15-16 weeks) 
daily (12:00h-14:00h) administration of flibanserin (n=8; 15 mg/kg, orally (PO) 
in 1ml/kg vehicle; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an 
der Riss, Germany) or 8-OH-DPAT (n=8; 0.1 mg/kg in 0.4ml/kg vehicle, injected 
subcutaneously (SC); Sigma-Aldrich St. Louis, MO, USA), with respective 
vehicles (for flibanserin, 98.5% of 0.5% hydroxycellulose solution and 1.5% 
of 1% polysorbate 80 solution, 1.0 ml/kg PO; for 8-OH-DPAT, 0.4 ml saline, 
SC). The study focused on three aspects of HPA axis functioning: (1) morning 
basal levels of cortisol, (2) following an acute 5-HT1A agonist challenge, and 
(3) during and after acute restraint-induced increases in plasma ACTH and 
cortisol levels.
Blood sampling and hormone assays
Within 3 min of home-cage entry, blood samples were collected by femoral 
puncture during brief restraint in a marmoset restraint tube (Hearn, 1977). 
This minimizes circulating ACTH and cortisol responses to the sampling 
procedures (Saltzman et al., 1994). Samples to be analyzed for ACTH were 
stored at -80°C while those for cortisol and estradiol were stored at -20°C until 
hormone assay.
Hormone assays were fully validated previously for use with marmoset 
plasma (Saltzman et al., 1994; Saltzman et al., 1998; Saltzman et al., 
2004). Plasma concentrations of ACTH and cortisol were determined by 
radioimmunoassay (RIA), and for estradiol by RIA following extraction with 5 
ml ethyl ether and celite column chromatography.  Assay sensitivity was 0.05 
ng/tube (1.0 ng/ml) for ACTH, 18.3 pg/tube (1.8 μg/dl) for cortisol, and 4.6 
pg/tube (30.4 pg/ml) for estradiol. Intra- and inter-assay assay coefficients 
of variation (CVs), respectively, were 4.6% and 12.4% for ACTH, 3.6% and 
17.2% for cortisol, and 5.0% and 14.0% for estradiol.
Morning basal cortisol levels (08:45-09:15h)
Basal circulating cortisol was assessed prior to treatment (0 wk) and at 3 
and 6 weeks of daily flibanserin, 8-OH-DPAT or respective vehicle treatment. 
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Neuroendocrine tests
Neuroendocrine tests assessing both cortisol and ACTH responses were 
performed during week 7 (5-HT1A agonist challenge test) and week 9 (restraint 
test) of daily treatment, at least 22 h after the previous daily administration of 
8-OH-DPAT, flibanserin, or vehicle. The time between 5-HT1A agonist challenge 
and restraint tests was 13 ± 0.5 days (mean ± SEM).
a) 5-HT1A agonist challenge test. Blood samples (0.3ml) were taken 0, 15 
and 180 min after a SC injection of 8-OH-DPAT (0.1 mg/kg), or vehicle 
(0.4ml/kg saline), administered at 12:00h-13:00h.
b) Restraint test. Animals were restrained for 30 min. A baseline blood 
sample (0.3ml, 0 min) was drawn immediately prior to restraint onset, and 
additional samples were taken at t=15 and t=30 min during restraint, and 3 
h after return to the home cage (210 min). 
Behavioral testing
Sexual and social behavior of the pairmates was observed after a 90-minute 
separation. Four 30-minute behavioral tests were conducted at 07:00h-13:00h 
(16-24 hours after daily administration of active serotonergic ligand/vehicle), 
5-6 weeks after treatment onset. Pair behavior was stable during the 2 weeks 
of testing. Procedural details are described in Aubert et al. (2012).
Data analysis
Analyses of circulating ACTH, cortisol and estradiol levels were performed 
on untransformed data when normality of data distribution was confirmed, or on 
log transformed data to normalize data distribution. To assess morning basal 
levels, a 2-way ANOVA with Drug Treatment (test compound, vehicle) and 
Time (0 wk, 3 wk, 6 wk) as within-subject factors was applied. For the 5-HT1A 
agonist challenge test, a 3-way ANOVA was employed, with Drug Treatment 
(test compound, vehicle), Challenge Type (5-HT1A agonist challenge, saline 
challenge) and Time (0 min, 15 min, 180 min) as within-subject factors. For the 
restraint test, a 2-way ANOVA was used, with Drug Treatment (test compound, 
vehicle) and Time (0 min, 15 min, 30 min, 210 min) as within-subject factors. 
Significant main effects of Time were specified post-hoc by contrast analysis. 
Data are presented as mean ± S.E.M. 
Initial analyses were performed using the same mixed design ANOVA with 
Estradiol supplementation and Order of treatment as additional between-
subject factors. As both factors consistently failed to affect (p>0.05) any test 
variable, they were omitted in the final analyses reported here.
To investigate the relationship between flibanserin and 8-OH-DPAT induced 
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behavioral changes (Aubert et al., 2012) and HPA axis function, all behaviors 
that were significantly altered by flibanserin or 8-OH-DPAT were post-hoc 
correlated to significantly altered endocrine responses, using two-tailed 
Pearson’s tests on the differential [serotonergic ligand – respective vehicle] 
for each selected variable, after normality of the bivariate distributions was 
confirmed. 
For all results, a p-value below 0.05 was considered significant. Behaviors 
analyzed are described in Aubert et al. (2012).
RESULTS
Chronic effects of 8-OH-DPAT and flibanserin on HPA axis functioning
Morning basal cortisol
Neither chronic flibanserin (Treatment: F(1,7) = 0.17, p = .694; Treatment x 
Time interaction: F(2,14) = 0.36, p = .704) nor chronic 8-OH-DPAT (Treatment: 
F(1,7) = 2.76, p = .140; Treatment x Time interaction: F(2,14) = 0.99, p = .397) 
altered morning basal cortisol levels compared to respective vehicle (Tab. 1).
5-HT1A agonist challenge test
The 5-HT1A agonist challenge test elicited ACTH and cortisol responses 
in all female groups (Fig. 1A), without influence of chronic daily flibanserin or 
8-OH-DPAT. In response to a 5-HT1A agonist challenge, flibanserin-, 8-OH-
DPAT- and vehicle-treated female marmosets all exhibited increased plasma 
ACTH levels at 15 min post-challenge compared to a saline challenge. Plasma 
cortisol levels were also elevated following 5-HT1A agonist challenge, at 180 







0 wk 221 ± 30.4 200 ± 27.0 167 ± 19.3 175 ± 23.9
3 wk 234 ± 16.8 235 ± 25.6 156 ± 13.3 196 ± 22.9




Table 1. Morning basal cortisol levels. Plasma concentrations of cortisol (μg/dl; mean ± 




Thirty minutes of restraint led to acute increases in plasma ACTH levels 
15 min and 30 min following restraint onset. Both chronic daily flibanserin 
Figure 1. 5-HT1A challenge test, effect of Challenge. Plasma concentrations of (A) ACTH (pg/
ml; mean±SeM) and (B) cortisol (µg/dl; mean±SeM) at 0, 15, and 180 min following an acute 
5-HT1A challenge (square dots) at 7 weeks of daily flibanserin, 8-OH-DPAT or corresponding 
vehicle treatment. ACTH flibanserin group (upper left graph): p=0.045 vs. saline challenge 
(circular dots; F(1,7) = 6.0); ACTH 8-OH-DPAT group (upper right graph): p=0.008 vs. saline 
challenge (F(1,7) = 13.5); cortisol flibanserin group (lower left graph): p=0.014 vs. saline 
challenge (F(1,7) = 8.1), p<0.001 Challenge x Time interaction (F(2,14) = 17.8); cortisol 8-OH-
DPAT (lower right graph): p=0.038 vs. saline challenge (F(1,7) = 6.5), p<0.001 Challenge x 
Time interaction (F(2,14) = 13.9); * p<0.05, ** p<0.01, *** p<0.001 vs. saline challenge (circular 
dots); # p<0.05 vs. 0min (Time effect). ACTH, adrenocorticotropic hormone; 8-OH-DPAT, R-(+)-
8-hydroxy-2-(di-n-propylamino)-tetralin.
3.1. Morning basal cortisol
Neither chronic flibanserin (Treatment: F(1,7) = 0.17,
p = .694; Treatment  Time interaction: F(2,14) = 0.36,
p = .704) nor chronic 8-OH-DPAT (Treatment: F(1,7) = 2.76,
p = .140; Treatment  Time interaction: F(2,14) = 0.99,
p = .397) altered morning basal cortisol levels compared to
respective vehicle (Table 1).
3.2. 5-HT1A agonist challenge test
The 5-HT1A agonist challenge test elicited ACTH and cortisol
responses in all female groups (Fig. 1A), without influence of
chronic daily flibanserin or 8-OH-DPAT. In response to a 5-HT1A
agonist challenge, flibanserin-, 8-OH-DPAT- and vehicle-trea-
ted female marmosets all exhibited increased plasma ACTH
levels at 15 min post-challenge compared to a saline chal-
lenge. Plasma cortisol levels were also elevated following 5-
HT1A agonist challenge, at 180 min post-challenge (Fig. 1B),
without influence of chronic daily flibanserin or 8-OH-DPAT.
3.3. Restraint test
Thirty minutes of restraint led to acute increases in plasma
ACTH levels 15 min and 30 min following restraint onset. Both
chronic daily flibanserin and chronic daily 8-OH-DPAT
enhanced restraint-induced increase in plasma ACTH levels
(Fig. 2A). 8-OH-DPAT increased ACTH levels at both 15 and
30 min of restraint, while flibanserin increased ACTH at
30 min only. At 210 min, or 3 h after the animals were
returned to their home cages following restraint, plasma
ACTH levels in both flibanserin and 8-OH-DPAT treated
females were comparable to respective vehicle treated con-
trols.
In flibanserin treated females, elevated ACTH levels at
30 min of restraint (the only significantly different time
points from vehicle control responses) were not correlated
to any behavior altered by flibanserin, including female
genital area self-grooming, male investigation of the
+ Models
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Fig. 1 5-HT1A challenge test, effect of challenge. Plasma concentrations of (A) ACTH (pg/mL; mean  SEM) and (B) cortisol (mg/dl;
mean  SEM) at 0, 15, and 180 min following an acute 5-HT1A challenge (square dots) at 7 weeks of daily flibanserin, 8-OH-DPAT or
corresponding vehicle treatment. ACTH flibanserin group (upper left graph): p = 0.045 vs. saline challenge (circular dots; F(1,7) = 6.0);
ACTH 8-OH-DPAT group (upper right graph): p = 0.008 vs. saline challenge (F(1,7) = 13.5); cortisol flibanserin group (lower left graph):
p = 0.014 vs. saline challenge (F(1,7) = 8.1), p < 0.001 Challenge  Time inte ction (F(2,14) = 17.8); cortisol 8-OH-DPAT (lower right
graph): p = 0.038 vs. saline challenge (F(1,7) = 6.5), p < 0.001 Challenge  Time interaction (F(2,14) = 13.9); *p < 0.05, **p < 0.01,
***p < 0.001 vs. saline challenge (circular dots); #p < 0.05 vs. 0 min (Time effect). ACTH, adrenocorticotropic hormone; 8-OH-DPAT, R-
(+)-8-hydroxy-2-(di-n-propylamino)-tetralin.
Table 1 Morning basal cortisol levels. Plasma concentra-
tions of cortisol (mg/dl; mean  SEM) at 0, 3 and 6 weeks of







0 wk 221  30.4 200  27.0 167  19.3 175  23.9
3 wk 234  16.8 235  25.6 156  13.3 196  22.9
6 wk 202  15.4 203  21.9 160  22.9 203  24.0
4 Y. Aubert et al.
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and chronic daily 8-OH-DPAT enhanced restraint-induced increase in plasma 
ACTH levels (Fig. 2A). 8-OH-DPAT increased ACTH levels at both 15 and 30 
minutes of restraint, while flibanserin increased ACTH at 30 minutes only. At 
210 min, or 3 h after the animals were returned to their home cages following 
Figure 2. Restraint test. Plasma concentrations of (A) ACTH (pg/ml; mean±SeM) and (B) 
cortisol (µg/dl; mean±SeM) at 0, 15, 30 and 210 min during and following 30-min restraint 
at 0-30 min at 9 weeks of daily flibanserin, 8-OH-DPAT (solid line) or corresponding vehicle 
(dotted line) treatment. ACTH flibanserin group (upper left graph): p=0.033 Treatment x Time 
interaction (F(3,21) = 3.5); ACTH 8-OH-DPAT group (upper right graph): p=0.041 Treatment 
effect (F(1,7) = 6.3), p=0.029 Treatment x Time interaction (F(3,21) = 3.6); cortisol flibanserin 
group (lower left graph): Treatment x Time interaction non-significant; cortisol 8-OH-DPAT 
group (lower right graph): p<0.001 Treatment x Time interaction (F(3,21) = 9.5); * p<0.05 vs. 
corresponding time point control; # p<0.05 vs. 0min (Time effect). ACTH, adrenocorticotropic 
hormone; 8-OH-DPAT, R-(+)-8-hydroxy-2-(di-n-propylamino)-tetralin.
female’s genital area, and allogrooming between pairmates.
In 8-OH-DPAT treated females, however, elevated ACTH
levels at 15 min of restraint were positively correlated to
female rejection of male mount attempts and mounts
(r = .830, p = .011; Fig. 3A), to unsuccessful male mount
attempts (r = .721, p = .044), and to aggressive interactions
between pairmates (r = .825, p = .012; Fig. 3B), while they
were negatively correlated to male investigation of the
female’s genital area (r = -.854, p = .007; Fig. 3C). Such
correlations were absent at 30 min of restraint.
Restraint also led to a stress-induced  release of cortisol
in all animals. 8-OH-DPAT chronic daily treatment, how-
ever, resulted in a significant Treatment  Time interac-
tion, indicating that chronic treatment with 8-OH-DPAT
maintained  elevated plasma cortisol levels at 210 min,
after animals had already been returned to their home
cages for 3 h, following cessation of restraint. Chronic
daily flibanserin treatment, in contrast, did not induce
prolonged elevation of cortisol following  cessation of
restraint (Fig. 2B). Significantly elevated cortisol levels
in 8-OH-DPAT treated females were not correlated to
any behavior altered by 8-OH-DPAT.
Estradiol supplementation, during both chronic daily fli-
banserin and 8-OH-DPAT administration, was without effect
on either ACTH or cortisol responses to 5-HTagonist challenge
or restraint.
4. Discussion
4.1. Comparisons to previous studies
Despite the prevalence of HSDD in women (Clayton, 2010),
little is known about the neural and endocrine bases of this
disorder. Flibanserin, a novel 5-HT1A agonist and 5-HT2A
antagonist, has demonstrated pro-sexual (humans and
rodents; Gelez et al., 2010; Kennedy, 2010; Stahl et al.,
2010) and pro-social (marmosets; Aubert et al., 2011) effects
on female behavior, while the classic 5-HT1A agonist 8-OH-
DPAT suppresses female sexual behavior in rodents and mar-
mosets (Uphouse et al., 1991; Aubert et al., 2011) and
increases aggressive interactions between male—female
pairmates of marmosets (Aubert et al., 2011).
In the present study, we demonstrate an increased respon-
siveness of the female marmoset HPA axis to restraint during
chronic flibanserin and 8-OH-DPAT treatments, suggesting
that selective manipulation of 5-HT1A receptors, with or
without respective 5-HT2A receptor manipulation, sensitizes
HPA reactivity. Morning basal cortisol levels, however, are not
affected by either treatment and contrast with a study in rats
that reports elevated basal plasma corticosterone levels
after 21 days of daily 8-OH-DPAT injections (Owens et al.,
1990). Differences in species (marmoset vs. rat), dosing
(0.1 mg/kg vs. 1.0 mg/kg), route of administration (SC vs.
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Fig. 2 Restraint test. Plasma concentrations of (A) ACTH (pg/mL; mean  SEM) and (B) cortisol (mg/dl; mean  SEM) at 0, 15, 30 and
210 min during and following 30-min restraint at 0—30 min at 9 weeks of daily flibanserin, 8-OH-DPAT (solid line) or corresponding
vehicle (dotted line) treatment. ACTH flibanserin group (upper left graph): p = 0.033 Treatment  Time interaction (F(3,21) = 3.5);
ACTH 8-OH-DPAT group (upper right graph): p = 0.041 Treatment effect (F(1,7) = 6.3), p = 0.029 Treatment  Time interaction
(F(3,21) = 3.6); cortisol flibanserin group (lower left graph): Treatment  Time interaction non-significant; cortisol 8-OH-DPAT group
(lower right graph): p < 0.001 Treatment  Time interaction (F(3,21) = 9.5); *p < 0.05 vs. corresponding time point control; #p < 0.05
vs. 0 min (Time effect). ACTH, adrenocorticotropic hormone; 8-OH-DPAT, R-(+)-8-hydroxy-2-(di-n-propyl mino)-tetralin.
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restraint, plasma ACTH levels in both flibanserin and 8-OH-DPAT treated 
females were comparable to respective vehicle treated controls.
In flibanserin treated females, elevated ACTH levels at 30 minutes of 
restraint (the only significantly different time point from vehicle control 
responses) were not correlated to any behavior altered by flibanserin, including 
female genital area self-grooming, male investigation of the female’s genital 
area, and allogrooming between pairmates. In 8-OH-DPAT treated females, 
however, elevated ACTH levels at 15 minutes of restraint were positively 
correlated to female rejection of male mount attempts and mounts (r = .830, 
p = .011; Fig. 3A), to unsuccessful male mount attempts (r = .721, p = .044), 
and to aggressive interactions between pairmates (r = .825, p = .012; Fig 3B), 
Figure 3. Behavioral correlates 
of enhanced ACTH response to 
restraint after 8-OH-DPAT. The 
magnitude of the 8-OH-DPAT-
induced elevation in ACTH responses 
at 15 min of restraint is positively 
correlated to female rejection of male 
mount attempts and mounts (A) and 
aggression between pairmates (B), 
and negatively correlated to male 
investigation of the female’s genital 
area (C). The graphs show the 
differential [8-OH-DPAT – vehicle; 
n=8] of both ACTH levels (x-axis) 
and behavior scores (y-axis). Each 
symbol indicates the same individual 
female marmoset receiving estradiol 
(solid symbols) or no estradiol (open 
symbols). ACTH, adrenocorticotropic 
hormone; 8-OH-DPAT, R-(+)-8-
hydroxy-2-(di-n-propylamino)-tetralin.
IP) and time of blood sampling in relation to diurnal/noctur-
nal rhythm (beginning vs. end of active phase in marmoset
and rat, respectively), however, make it difficult to directly
compare studies. There are no previous studies on flibanser-
in’s effects on HPA axis function. Both flibanserin and 8-OH-
DPAT are agonists on postsynaptic 5-HT1A receptors (Borsini
et al., 1995a; Palego et al., 2000), suggesting that the
sensitization of the HPA axis to restraint-type of stressors
may be mediated by chronic activation of the 5-HT1A receptor
in projection areas of 5-HT neurons.
Interestingly, enhanced ACTH responses to restraint corre-
late with increased aggression and reduced sexual receptivity
in 8-OH-DPAT treated female marmosets. In a study in female
rats, repeated exposure to a stressful environment is asso-
ciated with reduced sexual receptivity and increased aggres-
sive behavior (Yoon et al., 2005). ACTH and corticosteroid
levels, however, were not measured in the rodent study.
The lack of estradiol effects on HPA axis responses in both
flibanserin and 8-OH-DPAT treated marmosets might be some-
what surprising in light of well-documented interactions of
estrogens with the central serotonin system in female mam-
mals (Bethea et al., 2002). Estradiol replacement was also
without effects on sexual behavior (Aubert et al., 2012). This
is in line with our previous studies indicating that follicular
phase estradiol supplementation has no effect on circulating
cortisol levels (Saltzman et al., 2006) and marmoset female
sexual behavior (Barnett et al., 2006), but contrasts with a
study conducted by Kendrick and Dixson (1985). Kendrick and
Dixson (1985), however, applied mid-cycle levels of estradiol
supplementation equivalent to pre-ovulatory peak levels
(940 pg/mL). They also showed that pre-ovulatory estradiol
levels are associated with elevated cortisol levels and fre-
quent display of proceptive sexual behavior (Kendrick and
Dixson, 1984). The lower follicular phase circulating estradiol
levels in our study (396 pg/mL), chosen to facilitate a
modest baseline of sexual behavior, may be responsible for
the lack of obvious estradiol-induced HPA-axis and behavioral
changes in the present study.
4.2. Potential mechanisms of HPA axis
sensitization
A neuroendocrine 5-HT1A challenge test, serving as periph-
eral indicator of central 5-HT1A receptor function (Power and
Cowen, 1992; Van de Kar, 1997; Cowen, 2000), was applied to
test the responsiveness of the HPA axis to an acute activation
of hypothalamic 5-HT1A receptors. It is well known that
activation of hypothalamic 5-HT1A receptors stimulates the
HPA axis (Przegaliński et al., 1989; Raap et al., 2002; Osei-
Owusu et al., 2005). While we show that both circulating
ACTH and cortisol levels increase immediately following an
injection of 0.1 mg/kg 8-OH-DPAT (SC), neither chronic fli-
banserin nor chronic 8-OH-DPAT treatments alter ACTH and
cortisol responses in this neuroendocrine test (Fig. 1). Thus,
repeated administration of flibanserin and 8-OH-DPAT, both
agonists at post-synaptic 5-HT1A receptors, did not alter
sensitivity and function of hypothalamic 5-HT1A receptors
and the downstream HPA axis response.
Alterations in modulatory (descending) or activating
(ascending) systems that regulate CRH/AVP release from
the PVN may contribute to stress responses elicited by
restraint, as is the case for the limbic system comprising
amygdala and hippocampus (Van de Kar et al., 1991; De Kloet
et al., 1998), as well as the catecholaminergic system of the
brainstem comprising noradrenergic and adrenergic neurons
of the nucleus of the solitary tract (Pacák et al., 1993; Pacák
and Palkovits, 2001) and locus coeruleus (Vermetten and
Bremner, 2002). All of these brain areas express 5-HT1A
receptors (Azmitia et al., 1996; Wang et al., 1997; Popova
+ Models
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Fig. 3 Behavioral correlates of enhanced ACTH response to
restraint after 8-OH-DPAT. The magnitude of the 8-OH-DPAT-
induced elev tion in ACTH responses at 15 min of restrain  is
positively correlated to female rejection of male mount
attempts and mounts (A) and aggression between pairmates
(B), and negatively corre ated to male investigation of the
female’s genital area (C). The graphs show the differential [8-
OH-DPAT  vehicle; n = 8] of both ACTH levels (x-axis) and be-
havior scores (y-axis). Each symbol indicates the same individual
female marmoset receiving estradiol (solid symbols) or no estra-
diol (open symbols). ACTH, adrenocorticotropic hormone; 8-OH-
DPAT, R-(+)-8-hydroxy-2-(di-n-propylamino)-tetralin.
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while they were negatively correlated to male investigation of the female’s 
genital area (r = -.854, p = .007; Fig. 3C). Such correlations were absent at 30 
minutes of restraint.
Restraint also led to a stress-induced release of cortisol in all animals. 8-OH-
DPAT chronic daily treatment, however, resulted in a significant Treatment x 
Time interaction, indicating that chronic treatment with 8-OH-DPAT maintained 
elevated plasma cortisol levels at 210 min, after animals had already been 
returned to their home cages for 3 h, following cessation of restraint. Chronic 
daily flibanserin treatment, in contrast, did not induce prolonged elevation of 
cortisol following cessation of restraint (Fig. 2B). Significantly elevated cortisol 
levels in 8-OH-DPAT treated females were not correlated to any behavior 
altered by 8-OH-DPAT.
estradiol supplementation, during both chronic daily flibanserin and 8-OH-
DPAT administration, was without effect on either ACTH or cortisol responses 
to 5-HT1A agonist challenge or restraint.
DISCUSSION
Comparisons to previous studies
Despite the prevalence of HSDD in women (Clayton, 2010), little is known 
about the neural and endocrine bases of this disorder. Flibanserin, a novel 
5-HT1A agonist and 5-HT2A antagonist, has demonstrated pro-sexual (humans 
and rodents; Gelez et al., 2010; Kennedy 2010; Stahl et al., 2010) and pro-
social (marmosets; Aubert et al., 2011) effects on female behavior, while 
the classic 5-HT1A agonist 8-OH-DPAT suppresses female sexual behavior 
in rodents and marmosets (Uphouse et al., 1991; Aubert et al., 2011) and 
increases aggressive interactions between male-female pairmates of 
marmosets (Aubert et al., 2011).
In the present study, we demonstrate an increased responsiveness of the 
female marmoset HPA axis to restraint during chronic flibanserin and 8-OH-
DPAT treatments, suggesting that selective manipulation of 5-HT1A receptors, 
with or without respective 5-HT2A receptor manipulation, sensitizes HPA 
reactivity. Morning basal cortisol levels, however, are not affected by either 
treatment and contrast with a study in rats that reports elevated basal plasma 
corticosterone levels after 21 days of daily 8-OH-DPAT injections (Owens et 
al., 1990). Differences in species (marmoset vs. rat), dosing (0.1 mg/kg vs. 
1.0 mg/kg), route of administration (SC vs. IP) and time of blood sampling 
in relation to diurnal/nocturnal rhythm (beginning vs. end of active phase in 
marmoset and rat, respectively), however, make it difficult to directly compare 
studies. There are no previous studies on flibanserin’s effects on HPA axis 
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function. Both flibanserin and 8-OH-DPAT are agonists on postsynaptic 5-HT1A 
receptors (Borsini et al., 1995a; Palego et al., 2000), suggesting that the 
sensitization of the HPA axis to restraint-type of stressors may be mediated by 
chronic activation of the 5-HT1A receptor in projection areas of 5-HT neurons.
Interestingly, enhanced ACTH responses to restraint correlate with 
increased aggression and reduced sexual receptivity in 8-OH-DPAT treated 
female marmosets. In a study in female rats, repeated exposure to a stressful 
environment is associated with reduced sexual receptivity and increased 
aggressive behavior (yoon et al., 2005). ACTH and corticosteroid levels, 
however, were not measured in the rodent study.
The lack of estradiol effects on HPA axis responses in both flibanserin 
and 8-OH-DPAT treated marmosets might be somewhat surprising in light of 
well-documented interactions of estrogens with the central serotonin system 
in female mammals (Bethea et al., 2002). Estradiol replacement was also 
without effects on sexual behavior (Aubert et al., 2012). This is in line with our 
previous studies indicating that follicular phase estradiol supplementation has 
no effect on circulating cortisol levels (Saltzman et al., 2006) and marmoset 
female sexual behavior (Barnett et al., 2006), but contrasts with a study 
conducted by Kendrick and Dixson (1985). Kendrick and Dixson (1985), 
however, applied mid-cycle levels of estradiol supplementation equivalent to 
pre-ovulatory peak levels (~940 pg/mL). They also showed that pre-ovulatory 
estradiol levels are associated with elevated cortisol levels and frequent 
display of proceptive sexual behavior (Kendrick and Dixson, 1984). The lower 
follicular phase circulating estradiol levels in our study (~396 pg/mL), chosen 
to facilitate a modest baseline of sexual behavior, may be responsible for 
the lack of obvious estradiol-induced HPA-axis and behavioral changes in the 
present study. 
Potential mechanisms of HPA axis sensitization
A neuroendocrine 5-HT1A challenge test, serving as peripheral indicator 
of central 5-HT1A receptor function (Power and Cowen, 1992; Van de Kar, 
1997; Cowen, 2000), was applied to test the responsiveness of the HPA 
axis to an acute activation of hypothalamic 5-HT1A receptors. It is well known 
that activation of hypothalamic 5-HT1A receptors stimulates the HPA axis 
(Przegaliński et al., 1989; Raap et al., 2002; Osei-Owusu et al., 2005). While 
we show that both circulating ACTH and cortisol levels increase immediately 
following an injection of 0.1 mg/kg 8-OH-DPAT (SC), neither chronic flibanserin 
nor chronic 8-OH-DPAT treatments alter ACTH and cortisol responses in this 
neuroendocrine test (Fig. 1). Thus, repeated administration of flibanserin and 
8-OH-DPAT, both agonists at post-synaptic 5-HT1A receptors, did not alter 
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sensitivity and function of hypothalamic 5-HT1A receptors and the downstream 
HPA axis response. 
Alterations in modulatory (descending) or activating (ascending) systems 
that regulate CRH/AVP release from the PVN may contribute to stress responses 
elicited by restraint, as is the case for the limbic system comprising amygdala 
and hippocampus (Van de Kar et al., 1991; De Kloet et al., 1998), as well as 
the catecholaminergic system of the brainstem comprising noradrenergic and 
adrenergic neurons of the nucleus of the solitary tract (Pacák et al., 1993; 
Pacák and Palkovits, 2001) and locus coeruleus (Vermetten and Bremner, 
2002). All of these brain areas express 5-HT1A receptors (Azmitia et al., 1996; 
Wang et al., 1997; Popova et al., 1998) and project to the PVN (De Kloet et 
al., 1998; Pacák and Palkovits, 2001), thus becoming potential substrates 
to flibanserin- and 8-OH-DPAT-induced alterations that modulate HPA axis 
responsiveness to restraint. In rats, both flibanserin and 8-OH-DPAT have 
been shown to alter neuronal activity in addition to serotonin, norepinephrine 
and dopamine neurotransmitter levels in a brain region-specific manner 
(Lejeune and Millan, 2000; Allers et al., 2010). Chronic flibanserin and 8-OH-
DPAT treatments could sensitize the descending and ascending systems 
described above, leading to enhanced activation of CRH-containing neurons 
of the PVN during restraint and consequently to the observed exaggerated 
HPA axis response.
Flibanserin vs 8-OH-DPAT: Differences in pharmacological profiles and 
HPA responses to restraint
Although both flibanserin and 8-OH-DPAT enhance the excitability of the 
HPA axis during restraint, subtle differences in ACTH and cortisol response 
profiles exist between flibanserin and 8-OH-DPAT treated females. Both 
treatments enhance ACTH responses to the 30-minute restraint stressor, 
while chronic 8-OH-DPAT, but not flibanserin, also elevates cortisol levels. 
Increases in circulating ACTH levels relative to vehicle control values occur at 
both 15 and 30 minutes of restraint in 8-OH-DPAT-treated females, while only 
at 30 minutes in flibanserin-treated females, indicating a durational difference 
in the stress response distinguishing a more prolonged HPA axis activation 
during chronic 8-OH-DPAT compared to chronic flibanserin exposure.
Differences in HPA responses to restraint likely reflect the differences in 
pharmacological profiles between flibanserin and 8-OH-DPAT. Both flibanserin 
and 8-OH-DPAT are 5-HT1A agonists. 8-OH-DPAT, however, activates both 
pre- and postsynaptic 5-HT1A receptors (Palego et al., 2000), while flibanserin 
activates postsynaptic 5-HT1A receptors (Borsini et al., 1995b) without 
activating presynaptic 5-HT1A receptors in the raphé nuclei (Marazziti et al., 
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2002). Flibanserin thus lacks presynaptic inhibition of 5-HT neurotransmission 
(Borsini et al., 2002). Flibanserin is additionally an antagonist on 5-HT2A 
receptors and is possibly a weak partial agonist on dopamine D4 receptors 
(Borsini et al. 1995a; Borsini et al., 2002). 8-OH-DPAT is devoid of 5-HT2A 
(Borsini et al., 1995a) and dopaminergic (Arvidsson et al., 1981) actions, but 
shows additional 5-HT7 agonist properties (Shen et al., 1993).
These differences in receptor specificity result in fundamental differences 
in pharmacology and in abilities of flibanserin and 8-OH-DPAT to induce 
functional changes in a brain region-specific manner. For example, flibanserin 
inhibits forskolin-stimulated cAMP formation in the cortex, while 8-OH-DPAT 
does not affect cortical cAMP accumulation (Borsini et al., 1995a). Flibanserin 
decreases neuronal firing rate in the rat cortex regardless of whether the 
presynaptic receptor-containing dorsal raphé nucleus is intact, while the 
effects of 8-OH-DPAT are dependent upon intact raphé serotonergic neurons 
(Borsini et al., 1995b). Taken together, flibanserin and 8-OH-DPAT display 
different regional selectivity in the brain, and they differentially affect neuronal 
function in 5-HT projection sites.
It is unclear how differences in receptor binding profiles between flibanserin 
and 8-OH-DPAT translate into a prolongation of cortisol and acceleration of 
ACTH responses to restraint stress induced by 8-OH-DPAT compared to 
flibanserin. Additional activation of 5-HT7 receptors by 8-OH-DPAT may have 
a stimulatory effect on the HPA axis (Jørgensen et al., 1999), which could 
explain the increased efficacy in HPA activation by 8-OH-DPAT compared 
to flibanserin. Alternatively, differences in negative feedback mechanisms 
may account for the observed differences in hormone levels. The restoration 
of basal cortisol levels after a stress response is achieved by negative 
feedback mediated by cortisol binding to glucocorticoid receptors (GR) in 
limbic structures, PVN of the hypothalamus, and anterior pituitary (De Kloet 
et al., 1998). Onset of negative feedback, however, varies depending on the 
modulatory input from the limbic system to the PVN. Genomic GR effects 
in the hippocampus suppress excitatory β-adrenergic actions and enhance 
inhibitory effects of 5-HT on the HPA axis (De Kloet et al., 2008). Due to their 
distinct actions on 5-HT receptor subtypes, flibanserin and 8-OH-DPAT thus 
may differentially modulate the GR-mediated hippocampal input to the PVN. 
Indeed, activation of 5-HT7 increases GR expression in primary hippocampal 
cell cultures (Laplante et al., 2002), supporting the hypothesis that enhanced 
cortisol release after restraint may be mediated by chronic 5-HT7 activation 
in 8-OH-DPAT-treated females. Another explanation could involve peripheral 
mechanisms. It is suggested that systemic effects of 5-HT2A/2C agonists may be 
partially mediated by 5-HT2A receptors in the adrenal cortex (Rittenhouse et al., 
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1994; Welch and Saphier, 1994), or through a sympathetic catecholaminergic 
mechanism (Welch and Saphier, 1994). Flibanserin may reduce the sensitivity 
of peripheral 5-HT2A receptors to endogenous 5-HT during restraint, or may 
diminish sympathetic catecholaminergic stimulation of the adrenal cortex, 
thus preventing a comparable degree of cortisol elevation following restraint 
induced by 8-OH-DPAT.
Behavioral correlates of enhanced stress reactivity in 8-OH-DPAT-treated 
marmosets
The difference in ACTH response dynamics between flibanserin and 8-OH-
DPAT is of particular significance given the correlation analysis with behavior. 
8-OH-DPAT-treated females with the greatest ACTH response at the early 
measurement point of the restraint test (at 15 minutes) also experienced the 
most between-partner aggression, attracted the least genital investigation 
by their male pairmates, and most frequently rejected the pairmate’s sexual 
advances, causing an increased number of unsuccessful male mount 
attempts (Fig. 3). These associations were absent at the later measurement 
point of the restraint test (at 30 minutes). Thus, 8-OH-DPAT treated females 
that rapidly develop aggravated endocrine markers of stress (i.e. elevated 
ACTH beyond vehicle control values at 15 minutes) also display symptoms of 
aversive pair behavior proportional to the magnitude of 8-OH-DPAT-induced 
increase in ACTH responses. enhanced stress reactivity may thus contribute 
to decreased female sexual receptivity and heightened state of aggression in 
8-OH-DPAT-, but not in flibanserin-treated female marmosets.
While exposure to a stressful environment is associated with impaired 
sexual behavior and elevated aggression in female rats (Yoon et al., 2005), and 
personal distress and distress in partner relations are hallmarks of HSDD in 
women (DSM-IV-TR, 2000), the link between HPA axis activity and aggression 
is not clear. In some human studies high aggression is associated with low 
HPA axis activity (Gordis et al., 2006), but others do not confirm such an 
inverse relationship between aggression and stress hormone levels (Schulz 
et al., 1997). It is therefore not clear whether the behavioral associations with 
increased HPA responsiveness to restraint in the current study reflect HPA 
axis hormone-mediated changes in behavior, or whether both behavior and 
HPA hormones serve as separate and reliable biomarkers of 8-OH-DPAT-
mediated action. 
CONCLUSIONS
Our findings are the first to demonstrate enhanced HPA axis responsiveness 
to a restraint-type stressor after chronic serotonergic modulation in a nonhuman 
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primate. Considering the receptor binding profiles of flibanserin and 8-OH-
DPAT, similarities in their effects on HPA axis sensitization are likely mediated 
by their shared postsynaptic 5-HT1A agonist property. Chronic 8-OH-DPAT, 
but not flibanserin, however, leads to rapid aggravated ACTH responses to 
stress that may contribute to anti-sexual and anti-social behavior between the 
8-OH-DPAT-treated female and her male pairmate. Flibanserin, in contrast, 
dissociates such ACTH-marked stress reactivity from prolonged cortisol 
responses and aversive pair behavior possibly due to its unique regional 
selectivity in 5-HT1A receptor activation, combined with concurrent 5-HT2A 
antagonist activity. Thus, despite endocrine similarities in terms of enhanced 
ACTH responses to restraint stress, flibanserin-treated females show regular 
cortisol profiles and strengthening of the affiliative pair-bond with their male 
pairmates in contrast to the HPA axis and behavioral phenotypes of 8-OH-
DPAT-treated females.
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ABSTRACT
As part of a larger experiment investigating serotonergic regulation of 
female marmoset sexual behavior, this study was designed to (1) advance 
methods for PET imaging of common marmoset monkey brain, (2) measure 
normalized FDG uptake as an index of local cerebral metabolic rates for 
glucose, and (3) study changes induced in this index of cerebral glucose 
metabolism by chronic treatment of female marmosets with a serotonin 1A 
receptor (5-HT1A) agonist. We hypothesized that chronic treatment with the 
5-HT1A agonist 8-OH-DPAT would alter the glucose metabolism index in 
dorsal raphé (DR), medial prefrontal cortex (mPFC), medial preoptic area of 
hypothalamus (mPOA), ventromedial nucleus of hypothalamus (VMH), and 
field CA1 of hippocampus.
Eight adult ovariectomized female common marmosets (Callithrix jacchus) 
were studied with and without estradiol replacement. In a crossover design, 
each subject was treated daily with 8-OH-DPAT (0.1 mg/kg SC daily) or saline. 
After 42–49 days of treatment, the glucose metabolism radiotracer FDG was 
administered to each female immediately prior to 30 min of interaction with her 
male pairmate, after which the subject was anesthetized and imaged by PET. 
Whole brain normalized PeT images were analyzed with anatomically defined 
regions of interest (ROI). Whole brain voxelwisemappingwas also used to 
explore treatment effects and correlations between alterations in the glucose 
metabolism index and pairmate interactions.
The rank order of normalized FDG uptake was VMH/mPOA>DR>mPFC/
CA1 in both conditions. 8-OH-DPAT did not induce alterations in the glucose 
metabolism index in ROIs. Voxelwise mapping showed a significant reduction 
in normalized FDG uptake in response to 8-OH-DPAT in a cluster in medial 
occipital cortex as well as a significant correlation between increased rejection 
of mount attempts and reduced normalized FDG uptake in an overlapping 
cluster.
In conclusion, PeT imaging has been used to measure FDG uptake relative 
to whole brain in marmoset monkeys. Voxelwise mapping shows that 8-OH-
DPAT reduces this index of glucose metabolism in medial occipital cortex, 
consistent with alterations in female sexual behavior.
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INTRODUCTION
This is a study of the effects of chronic serotonergic manipulation in a 
nonhuman primate model of female sexual behavior (Barnett et al., 2006). 
This work applied positron emission tomography (PET) to marmoset brain 
imaging. The goals of this work involved methods development, determination 
of cerebral glucose metabolic indices, and measurement of the effect of 
chronic treatment with a serotonin 1A (5-HT1A) receptor agonist on brain 
regions implicated in female sexual interactions with a male pairmate.
5-HT is thought to play a central inhibitory role in regulating female sexual 
behavior by modulating satiety and balancing excitatory neuromodulators 
(Pfaus, 2009). In this marmoset study, the prototypical 5-HT1A receptor agonist 
R-(+)-8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) was used (Hjorth 
et al., 1982). In rats, 8-OH-DPAT acutely diminishes female sexual receptivity 
(Uphouse et al., 1991). Administration of 8-OH-DPAT (1 mg/kg IV) to male 
rats acutely alters glucose metabolism in a number of brain regions, including 
decreases in hippocampal areas and increases in motor regions, consistent 
with the “5-HT behavioral syndrome” (Kelly et al., 1988). Therapeutic efficacy 
of serotonergic treatments typically requires at least 2 weeks of administration 
perhaps due to adaptive changes, and therefore it is important to study the 
chronic effects of pharmacological treatment (Blier and de Montigny, 1994; Blier 
et al., 1987; Hensler, 2003). The effect of chronic 8-OH-DPAT administration 
on cerebral glucose metabolism in primates, including humans, has not been 
reported.
The current study’s focus on PET imaging of female marmoset neural 
responses to the 5-HT1A agonist 8-OH-DPAT, during male–female pair tests, 
arises from our interest in understanding the role of 5-HT in regulating 
female sexual behavior. An estimated 10% of women (Clayton, 2010) show 
marked distress and interpersonal difficulty because of unwanted, persistent 
or recurrent low sexual desire (hypoactive sexual desire disorder, HSDD 
(American Psychiatric Association, 2000)). Psychopathogenesis of HSDD, 
however, is not known, but neurotransmitter dysfunction has been proposed 
involving the excitatory regulators dopamine (DA) and norepinephrine 
(Ne), as well as inhibitory 5-HT (Clayton and Hamilton, 2010; Pfaus, 2009). 
Pharmacological manipulation of 5-HT commonly results in diminished female 
sexual satisfaction and activity, particularly in women prescribed selective 
serotonin reuptake inhibitors (SSRIs) for depression (Clayton and Montejo, 
2006; Clayton et al., 2002; Patterson, 1993; Rosen et al., 1999; Segraves, 
1998). Animal studies that apply 5-HT receptor subtype specific ligands 
permit mechanistic examination of 5-HT-mediated effects on sexual behavior. 
There are 7 known 5-HT receptor families, each with its own specific brain 
86
distribution, as well as effects on behavior and physiology (Barnes and Sharp, 
1999). We focused on 5-HT1A receptor activation in this study to explore 5-HT 
involvement in female sexual inhibition, since the sexually receptive female 
lordosis posture in rats is inhibited by 5-HT1A receptor activation (Ahlenius et 
al., 1986; Hebert et al., 1995; Uphouse et al., 1992).
Female marmoset monkeys present an opportunity to explore the sexually 
inhibitory properties of 8-OH-DPAT in a nonhuman primate model that readily 
translates to humans, as marmosets form stable, long-term, male–female 
relationships (Abbott et al., 2003) and display modest amounts of sexual 
behavior (Barnett et al., 2006). Unlike the multiple-mating social structures 
of rats and many nonhuman primates, such as macaques and baboons, 
marmoset sexual behavior most commonly occurs within stable male–female 
pairs (Abbott et al., 2003; evans and Poole, 1984; Saltzman et al., 2009). By 
acceptance or rejection of a pairmate’s sexual advances, female marmosets 
can readily promote, prevent or terminate sexual interactions (Kendrick and 
Dixson, 1986; Stevenson and Poole, 1976), and our recent development of 
a standardized behavioral testing paradigm permits repeatable, quantitative 
exploration of neurally active compounds that enhance or diminish female 
marmoset sexual behavior (Barnett et al., 2006).
Neuroimaging has furthered mechanistic understanding of neural regulation 
of sexual behavior in both humans and animals (Arnow et al., 2009; Rilling 
et al., 2004). Recent improvements in PET spatial resolution now permit its 
application to marmoset brain imaging (Haneda et al., 2007). PeT permits 
longitudinal measures of brain physiology that may be used to study individual 
differences in treatment response. In the current protocol, pair-bonded female 
marmosets are observed upon reunion with their male pairmates following a 
90-minute separation (Barnett et al., 2006). Measures were performed on the 
same individuals during chronic 8-OH-DPAT treatment as well as in a control 
saline treatment condition. To index glucose metabolism during behavioral 
interactions, we used the trapped tracer [18F]fluorodeoxyglucose (FDG) 
(Sokoloff et al., 1977). In this protocol, the rate of glucose metabolism during 
awake, freely moving behavior is reflected by subsequent imaging performed 
under anesthesia in the PeT scanner (Rilling et al., 2001; Tashiro et al., 2001). 
We identified anatomical location within the marmoset brain using template 
regions of interest (ROIs) similar to previous methods employed in studies 
of humans and rats (Lancaster et al., 2007; Rubins et al., 2003). Because 
template methods may be subject to error due to individual differences 
in anatomy not accounted for by the coregistration technique, we verified 
template ROI against individual ROI results.
The goals of this study were to (1) advance methods for PET imaging of 
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common marmoset monkey brain, (2) measure normalized FDG uptake as 
an index of local cerebral metabolic rates for glucose, and (3) study changes 
induced in this index of cerebral glucose metabolism by chronic treatment 
of female marmosets with a 5-HT1A agonist. We hypothesized that chronic 
treatment with the 5-HT1A agonist 8-OH-DPAT would yield altered glucose 
metabolism in the following five ROIs known to have high 5-HT1A density 
(Moller et al., 2007; Pazos et al., 1987) or to be involved in female proceptive 
or receptive sexual behavior (Pfaus, 2009): (1) dorsal raphé (DR), containing 
5-HT neurons with extensive projections to hypothalamic, limbic, hippocampal 
and cortical sites, and neurotransmission regulating 5-HT1A receptors 
(Kakeyama and yamanouchi, 1996); (2) medial prefrontal cortex (mPFC), 
involved in executive and inhibitory regulation of behavior, with sexual behavior-
relevant contributions from ventral tegmental area dopaminergic projections 
engaged in responses to sexual and incentive stimuli (Afonso et al., 2007); 
(3) medial preoptic area of the hypothalamus (mPOA), intimately involved 
in female proceptive sexual behavior (Dixson and Lloyd, 1988; Graham and 
Pfaus, 2010; Kendrick and Dixson, 1986), (4) ventromedial nucleus of the 
hypothalamus (VMH), regulating female sexual receptivity (Dixson and Lloyd, 
1988; Griffin and Flanagan-Cato, 2011; Kendrick and Dixson, 1986), and (5) 
field CA1 of the hippocampus, involved in sexually relevant memory processes 
(van Wingen et al., 2008).
MATeRIALS AND MeTHODS
Subjects
Female common marmosets were studied (Callithrix jacchus, n=8, 425±47 
g, age 4.5±0.6 years, mean±standard deviation). Subjects were pair housed 
with male pairmates at the Wisconsin National Primate Research Center 
(WNPRC) for 8–20 months before and throughout the duration of the study 
with lights on during 06:30–18:30 h, as previously described (Barnett et al., 
2006). Ovaries were removed and subcutaneous silastic capsules implanted 
to provide estradiol replacement in 4 of the subjects (serum estradiol during 
study weeks: 396±184 pg/mL, mid-follicular phase estradiol levels (Barnett 
et al., 2006)), while the remaining 4 subjects received empty capsules 
(serum estradiol 68±31 pg/mL, typical of ovariectomized female marmosets 
(Barnett et al., 2006)). This study was conducted in accordance with the 
recommendations of the Guide for the Care and Use of Laboratory Animals 
and the Animal Welfare Act and its subsequent amendments. All animal 
procedures were reviewed and approved by the Graduate School Animal Care 
and Use Committee of the University of Wisconsin-Madison. WNPRC, as part 
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of the University of Wisconsin-Madison Graduate School, is accredited by the 
Association for Assessment and Accreditation of Laboratory Animal Care.
Experimental protocol
A counterbalanced, cross-over study, that applied within-subject 
comparisons, was designed to examine the effects of chronic (15–16 weeks) 
daily (12:00 h–14:00 h) administration of 8-OHDPAT (0.1 mg/kg in 0.4 mL/kg 
saline, injected subcutaneously (SC); Sigma-Aldrich St. Louis, MO, USA), or 
0.4 mL saline SC, with an intervening 6-week washout period.
Behavioral observations of sexual behavior
In order to stimulate sexual interactions upon reunion (Barnett et al., 2006), 
females and males were separated for 90 min prior to each of four 30-min 
behavioral tests at 07:00 h–13:00 h (16–24 h after daily administration of 8-OH-
DPAT/saline), 5–6 weeks after treatment onset. At the start of each behavioral 
test, the male was introduced to the female by remote door operation and 
behavior was manually and digitally recorded by two observers from behind a 
one-way window (Barnett et al., 2006). Behavioral tests were reanalyzed from 
the digitally stored recordings in a random fashion by two observers, blinded 
with respect to treatment.
Brain imaging
Subjects were scanned with FDG PeT at 42–49 days following start of 
treatment with either 8-OH-DPAT or saline. On the day of the PeT scan, 
each female subject was removed from her home cage, placed alone in a 
test cage for 90 min, injected in the femoral vein with 31.1±6.4 MBq FDG 
(IBA Romeoville), reunited with her mate after 5.4±1.3 min in a behavioral 
test cage, and observed for 30 min during pair behavior, as described for 
behavioral observations above. The subject was then transported to the PET 
facility, anesthetized with ketamine (10 mg IM), intubated, and maintained on 
isoflurane (1–3% in O2) for the remaining procedures. Subjects were then 
positioned in the University ofWisconsin Inveon small animal PeT scanner 
(Siemens, Knoxville), which provides 127 mm axial and 100mm transaxial 
field of view, 5 μL volumetric resolution, and 6.8% sensitivity (Bao et al., 2009; 
Constantinescu and Mukherjee, 2009). Subjects were positioned prone and 
face forward with their heads taped to prevent motion and with their brains 
located at the center of the field of view. The subjects were warmed with blown 
air and monitored for heart rate, SpO2, exhaled CO2, and rectal temperature. 
emission data were acquired for 60 min in list mode with 350–650 keV energy 
and 3 ns timing windows. Scans started 82.5±6.3 min following FDG injection 
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and 26.4±5.7 min following ketamine injection. Following the emission scans, 
a 57Co transmission scan was acquired (120–125 keV).
To obtain anatomical images, each subject was scanned on a separate 
day under isoflurane anesthesia with the University of Wisconsin small animal 
4.7 T MRI (Varian, Palo Alto) using a Varian 72mm ID quadrature coil and 
a spin echo multi slice sequence (TR=2000 ms, TE=35ms, MA=128×128, 
FOV=40mm×40mm, slices=40, thickness=1.00 mm, in-plane pixel 
size=0.31mm×0.31mm).
Brain atlas
A brain atlas of an adult male common marmoset was used to aid 
anatomical identification (Palazzi and Bordier, 2008). The atlas comprises 48 
coronal sections sliced perpendicular to the anterior commissure—posterior 
commissure line. Uncertainty in the stereotaxic scale due to shrinkage is 
expected to be within 3% based on comparisons of medial–lateral and 
anterior–posterior measures of brains before and after freezing. Digital 2D 
images provided with the atlas were shifted left–right and dorsal–ventral to 
align the scales between slices (Adobe Illustrator). A slice missing at bregma 
+0 mm was replaced with a copy of bregma +0.56 mm resulting in 49 slices 
spaced at 620±45 μmbased on the labeled anteroposterior positions. These 
2D images were stacked into a 3D image of 589×584×59 voxels with in-plane 
pixel sizes of 53.3 μm×53.3 μm and slice thickness of 620.0 μm (ImageJ 
(Abramoff et al., 2004)).
MR image processing and ROIs
An MR template image was created as follows. The MR image from the first 
subject scanned (cj1074) was resliced to 0.5 mm cubic voxels and aligned 
manually (Spamalize, http://brainimaging.waisman.wisc.edu/~oakes) so 
as to appear symmetric in coronal and axial views and rotated in a sagittal 
orientation such that the anterior and posterior commissures of the corpus 
callosum (AC–PC) lay in the same axial plane. A preliminary whole brain mask 
was drawn on this image. The MR images of the remaining seven subjects 
were manually coregistered to that of the first subject, and all eight were 
whole brain normalized and averaged together. Each of the eight images was 
aligned to this mean image by automated rigid body (6 degrees of freedom, 
df) coregistration (FSL FLIRT v. 5.5; Oxford Centre for Functional MRI of 
the Brain) using a normalized mutual information cost function, and whole 
brain reference and input weights. The resulting eight images were averaged 
and each was then aligned to this new average by automated affine (9 df) 
coregistration. The mean of these eight images was taken as the 0.5 mm 
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cubic voxel MRI template and a whole brain mask was drawn on this template 
by tracing the inner boundary of the skull, which appears dark in the MRI.
To aid in delineation of ROIs, the 0.5 mm cubic voxel MRI template was 
resliced and translated manually to match the atlas image, and the same 
transformation was applied to the individual MRIs. Bilateral ROIs were 
drawn by two operators on the template and individual MRIs with reference 
to the atlas for DR, mPFC, mPOA, VMH, and CA1. Inter- and intra-operator 
comparisons of the drawn ROIs were made by calculating the ratio of the 
number of overlapping voxels to the average number of voxels between two 
versions of the same ROI. The second version drawn by the same operator 
was used for each of the template ROIs. PET scanner resolution effects for 
each ROI were estimated by smoothing the ROI and its inverse, i.e. Tissue 
outside the ROI, with a 1.71 mm FWHM Gaussian kernel.
PET image reconstruction
Reconstructions were performed using the scanner vendor’s software 
(Siemens Inveon Acquisition Workplace). Transmission events were sorted 
into a 2D sinogram (single-slice rebinning, 128 bins, 160 angles, 159 planes) 
and scaled by a blank sinogram. Emission events were sorted into a single 
3D sinogram (128 bins, 160 angles, 159 planes, span 3, ring difference 79, 
27 segments, hist.exe v. 2.3.3.8). Images were reconstructed by filtered 
backprojection with a ramp filter (recon.exe v. 2.222). The resulting images 
included corrections for accidental coincidences, detector sensitivity, 
attenuation, and radioactive decay. Consistent with the low scatter fraction 
expected from the approximately 25 mm diameter marmoset head, scatter 
correction was found to have a small effect on the whole brain normalized ROI 
values (e.g. <4% for mPOA), and scatter corrected whole brain normalized 
radioactivity values were linearly related across subjects to non-corrected 
values (e.g. r=0.996 for mPOA). Scatter correction was therefore not applied 
to avoid introducing additional noise. Image dimensions were 128×128×159 
with in-plane pixel size 0.776 mm×0.776 mm and slice thickness 0.796 mm.
PET image analysis
Alignment of the PET images to the 0.5 mm cubic voxel MRI template 
was performed in several steps as follows. The 16 static PET images (n=8 
subjects × 2 conditions) were resliced and manually aligned by translations 
to the MRI template. Each PET image was then automatically aligned to the 
version of the subject’s MRI prior to the final 9 df transformation of that MRI 
to the template space. This was done with 6 df using a correlation ratio cost 
function without reference image weighting and then again with weighting 
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by the template whole brain mask smoothed with a 2 mm Gaussian kernel. 
For each subject, the 8-OH-DPAT and Saline images were averaged, and 
the average was aligned by 6 df to the individual MRI. The 8-OH-DPAT and 
Saline images were again aligned to this aligned average image. As the final 
alignment step, the 9 df transformation that had been applied to the individual 
MRI was applied to the 8-OHDPAT and Saline PeT images. The PeT images 
were thus aligned within subject and between subject to the 0.5 mm cubic 
voxel MRI template. The whole brain mask (8601 μL) was trimmed to avoid 
radioactivity outside the brain by masking it at the edges with a thresholded 
version of an intermediate mean PET image (8 subjects × 2 conditions, whole 
brain normalized radioactivity >1.2, trimmed volume 8065 μL). The individual 
images were then whole brain normalized, i.e. each pixel value was divided 
by the average value for the individual in the trimmed whole brain mask. 
Subtraction images, 8-OH-DPAT minus Saline, were then created, and the 
trimmed whole brain mask was applied to all images.
ROI analysis was performed in the atlas space. All PET images were 
coregistered to the atlas using the same transformation that had been applied 
to the 0.5 mm cubic voxel MRI template. The ROIs drawn on the template 
and individual MRIs were then applied to the PET images. ROI methods were 
compared by calculating over the eight subjects the root mean square (RMS) 
differences of PET image values between operators and between individual 
MRI- and template-based ROIs. As described below in the Results section, 
template versus individual MRI differences were comparable to inter-operator 
differences. Use of template ROIs was therefore considered reliable, and 
template ROI results were used in the subsequent analyses. Paired 2-tailed 
Student’s t tests were performed on the ROI results in the Saline and 8-OH-
DPAT conditions. Significance at p<0.05 was required for testing the primary 
hypothesis of a treatment effect in any of the five bilateral ROIs.
Voxelwise whole brain analysis was also performed in the atlas space. To 
search for a treatment effect, a paired t test was performed between the 8-OH-
DPAT and Saline images. To search for correlations between the glucose 
metabolism index and behavioral response to 8-OH-DPAT (from quantitative 
observations made during weeks 5–6 described above), a linear regression 
with zero intercept was performed between the difference images and the 
behavioral difference scores (8-OH-DPAT minus Saline). In addition, linear 
regression was performed on the Saline condition images against sexual 
behavior in the Saline condition. Two-tailed t test or Pearson r thresholds 
were set corresponding to puncorrected<0.05 at each voxel, and clusters of voxels 
with significance pcorrected<0.05 2-tailed were identified by random field theory 
(SPM8) (Worsley et al., 1996).
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RESULTS
Image alignment and ROIs
As one goal of this study was methods development, we evaluated the 
image alignment and ROI delineation procedures. In each subject’s aligned 
MRI, visual inspection of the brain contour seen in every coronal slice 
demonstrated alignment with the mean MRI to within 0.5 mm (Suppl. Fig. 1). 
The resulting MRI template is shown in Fig. 1. The 16 aligned individual PeT 
images (8 subjects × 2 conditions) agreed to≤0.5 mm between individuals and 
to higher precision within subjects (Suppl. Fig. 2). There were visible differences 
between subjects and between conditions in relative FDG uptake in tissue 
outside the skull, but the trimmed whole brain mask prevented spillover into 
observed brain regions. Fig. 2 shows the MRI template and mean FDG image
Fig. 1. MRI template. Mean of aligned images (n=8) used as MRI template (Every fourth 0.5 
mm coronal slice shown). Whole brain mask is overlaid (red). The template is freely available 
upon request to the corresponding author.
 





Figure 1  MRI templ t . Mean of ligned i ages (n = 8) used as MRI 
emplate (Every fourth 0.5 mm coronal slice shown). Whole brain mask is 
overlaid (red). 
20 mm 
R       L
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(shown in greater detail in Suppl. Fig. 3) along with typical single subject MRI 
and FDG images in the two conditions. Representative slices of the template 
MRI aligned to the atlas and the ROIs are shown in Fig. 3.
Methods for delineating ROIs were compared, and resolution effects 
were estimated. Comparing ROIs delineated on individual MRIs (5 regions 
× 8 subjects), intra- and inter-operator overlap were 0.86±0.05 (n=40) and 
0.85±0.06 (n=40), respectively. Intra- and inter-operator overlap of the five 
template ROIs were 0.89±0.03 (n=5) and 0.84±0.06 (n=5), respectively. 
Degrees of differences in FDG values between operators and between 
methods were highly comparable: 8-OH-DPAT minus Saline values were 
compared across the eight subjects and the five bilateral ROIs, and the 
average (n=5) root mean square difference (n=8) was 0.0083±0.0034 for
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Figure 2  Aligned images. Axial, coronal, and sagittal slices of MRI 
template (A, n=8 subjects), MRI of one subject (B, cj1022), mean FDG 
image (C, n = 8 subjects x 2 conditions), and FDG image of one subject 
(cj1022) in Saline condition D and 8-OH-DPAT condition E. Contour is on 
whole brain mask trimmed to avoid contributions from radioactivity uptake 
outside of the brain. Color scale indicates whole brain normalized 
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Fig. 2. Aligned images. Axial, 
coronal, and sagittal slices of MRI 
template (A, n=8 subjects), MRI 
of one subject (B, cj1022), mean 
FDG image (C, n=8 subjects × 
2 conditions), and FDG image 
of one subject (cj1022) in Saline 
condition D and 8-OH-DPAT con-
dition E. Contour is on whole brain 
mask trimmed to avoid contribu-
tions from radioactivity uptake 
outside of the brain. Color scale 
indicates whole brain normalized 








inter-operator comparisons and 0.0092±0.0034 for individual MRI-determined 
versus template MRI-determined comparisons. Subsequent analyses were 
thus performed using only template MRI-determined ROIs. The template ROIs 
had the following bilateral volumes: DR 1.5 μL, mPFC 100.4 μL, mPOA 4.9 μL, 
VMH 5.2 μL, and CA1 46.8 μL. Upon simulating the PeT scanner resolution 
(5 μL) with assumed uniform distribution of radioactivity, the activity calculated 
in the ROI originating in the ROI itself was DR 14%, mPFC 66%, mPOA 29%, 
VMH 28%, and CA1 36%. No partial volume correction was applied to the 
measured data, and the reported results must, therefore, be considered best 
estimates for the delineated ROIs.
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Figure 3  Anatomical identification. Fusion image (center column) of 
coregistered brain atlas (left column) and MRI template (right column). 
Representative coronal slices showing regions of interest (ROIs) for 
edial prefrontal cortex (mPFC), medi l preoptic area of the 
hypothalamus (mPOA), ventromedial hypothalamic nucleus (VMH), field 
CA1 of the hippocampus (CA1), and dorsal raphe nucleus (DR). Atlas 
images courtesy of Springer Science+Business Media (Palazzi and 






Fig. 3. Anatomical iden-
tification. Fusion im-
age (center column) of 
coregistered brain atlas 
(left column) and MRI 
template (right column). 
Representative coronal 
slices showing regions of 
interest (ROIs) for medial 
prefrontal cortex (mPFC), 
medial preoptic area of the 
hypothalamus (mPOA), 
ventromedial hypotha-
lamic nucleus (VMH), field 
CA1 of the hippocampus 
(CA1), and dorsal raphe 
nucleus (DR). Atlas im-
ages courtesy of Springer 
Science+Business Me-
dia (Palazzi and Bordier, 
2008).
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Experimental conditions
Experimental conditions for the PET scans are presented in Table 1. There 
were no significant differences in parameters between treatment conditions. 
No significant effect of estradiol group was observed in the Saline condition in 
the ROIs or by voxelwise analysis, nor was there a significant estradiol × 8-OH-
DPAT interaction (two way ANOVA with repeated measures). Subsequent 
results were therefore calculated without reference to estradiol group.
Normalized FDG uptake during saline administration and response to 
treatment
In the Saline as well as the 8-OH-DPAT condition, mean FDG values ranked 
VMH / mPOA>DR>mPFC / CA1 (Suppl. Fig. 4). Paired t tests indicated no 
t tests indicated no 8-OH-DPAT-induced difference in the magnitude
of FDG uptake in any ROI (Table 2 and Fig. 4). Voxelwise mapping
of 8-OH-DPAT minus Saline revealed a single cluster in medial occip-
ital cortex of reduced activity (8-OH-DPATbSaline, puncorrectedb0.05,
extent=60 μL, pcorrected=0.004; Fig. 5 and Suppl. Fig. 5).
Behavior
To further confirm the significance of the finding of decreased nor-
malized FDG uptake in medial occipital cortex in response to 8-OH-
DPAT, we considered alterations in female rejection of male mounts
and mount attempts (the most significant 8-OH-DPAT-induced
behavioral finding) (Aubert et al., in press). The between-condition
difference in FDG uptake was therefore correlated voxelwise against
the difference in rejection of mount attempts. Two significant clusters
of voxels were found, in which altered normalized FDG uptake
correlated with altered rejection of mounts (Fig. 6 and Supp. Fig. 6;
puncorrectedb0.05; positive correlation: left ventral cerebellum,
extent=48 μL, pcorrected=0.017; negative correlation: medial occipi-







Fig. 2. Aligned images. Axial, coronal, and sagittal slices of MRI template (A, n=8 sub-
jects), MRI of one subject (B, cj1022), mean FDG image (C, n=8 subjects×2 condi-
tions), and FDG image of one subject (cj1022) in Saline condition D and 8-OH-DPAT
condition E. Contour is on whole brain mask trimmed to avoid contributions from
radioactivity uptake outside of the brain. Color scale indicates whole brain normalized






Fig. 3. Anatomical identification. Fusion image (center column) of coregistered brain
atlas (left column) and MRI template (right column). Representative coronal slices
showing regions of interest (ROIs) for medial prefrontal cortex (mPFC), medial preoptic
area of the hypothalamus (mPOA), ventromedial hypothalamic nucleus (VMH), field
CA1 of the hippocampus (CA1), and dorsal raphe nucleus (DR). Atlas images courtesy of
Springer Science+Business Media (Palazzi and Bordier, 2008).
Table 1
Experimental parameters. Mean±SD (n=8), p: paired t test 2-tailed. WB=mean
radioactivity concentration in whole brain (MBq/mL), ID=injected dose (MBq), and
BW=body weight (g).
Saline 8-OH-DPAT p
Age (years) 4.54±0.72 4.54±0.52 1.00
Weight (g) 427±54 422±42 0.44
Injected FDG (MBq) 32.1±7.3 29.9±5.4 0.51
Behavior start—FDG inject (min) 5.4±1.2 5.4±1.5 0.93
Scan start time 11:24±1:09 10:50±1:06 0.15
Scan start—last treatment (h) 22.6±1.3 21.9±1.1 0.14
Scan start—FDG inject (min) 83.1±6.6 82.0±6.3 0.73
Scan start—ketamine inject (min) 27.3±6.5 25.5±5.0 0.50
WB/(ID/BW) (g/mL) 1.06±0.17 0.99±0.13 0.27
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Table 1. Experimental parameters. Mean±SD (n=8), p: paired t test 2-tailed. WB=mean 
radioactivity concentration in whole brain (MBq/mL), ID=injected dose (MBq), and BW=body 
weight (g).
which decreased metabolism correlated with increased rejection of
mounts, overlapped 38% with the cluster of voxels described above
that exhibited reduced metabolism during 8-OH-DPAT treatment
(Fig. 7 and Suppl. Fig. 7). Subsequent exploration of the relation be-
tween normalized FDG uptake and rejection of mount attempts in
the Saline condition alone yielded three significant clusters (Table 3,
Suppl. Fig. 8), but the mean normalized FDG uptake in these clusters
did not reveal a significant response to 8-OH-DPAT (p>0.5, 2-tailed
paired t test).
Discussion
In this work, we (1) advanced methods for PET imaging of mar-
moset monkey brain, (2) measured whole brain normalized FDG up-
take as an index of local cerebral metabolic rates for glucose, and (3)
studied the effect of chronic treatment with a 5-HT1A receptor agonist
on brain regions implicated in regulating female sexual interactions.
Anatomical identification
In this work we implemented and validated a novel template-
based method of anatomical identification for PET imaging of marmo-
set brain. This relied on adequate alignment of the individual MR im-
ages to the template space and of PET images to MRIs (Figs. 1 and 2).
Alignment of the MRI template to the published histological atlas was
within 1 mm, a very satisfactory degree of agreement. While the
agreement between the MRI template and the atlas was not sufficient
to simply delineate ROIs on the atlas, it aided identification of regions
in the MRI by means of relative positions to common features seen in
each image (Fig. 3). Despite the excellent alignment between the in-
dividual MRIs, as judged by brain contours (Fig. 2), individual ana-
tomical differences in grey-white contrast within the brain may still
be significant. Inter-operator variances, however, in geometric over-
lap and in FDG measures using individual ROIs were comparable to
individual- versus template-determined differences. The template
ROI method may therefore provide anatomical identification as re-
producible as that obtained by delineating regions on individual
MRIs. While template ROI location was reliable between subjects,
measures attributed to the smaller regions, namely DR, mPOA, and
VMH, must be interpreted with caution because of the PET scanner
resolution.
Glucose metabolism index and behavior
This is the first report, to our knowledge, of the effect of chronic 8-
OH-DPAT administration on cerebral glucose metabolism in primates.
Despite relatively large differences in whole brain normalized radio-
activity measured between regions and between subjects, FDG
Table 2
FDG results. Whole brain normalized radioactivity measures in anatomically defined
ROIs for Saline condition, 8-OH-DPAT condition, and the difference 8-OH-DPAT
minus Saline. (p: paired t test, 2-tailed; n=8).
ROI V (μL) Saline 8-OH-DPAT 8-OH-DPAT minus saline p
DR 1.5 1.164±0.168 1.169±0.113 0.004±0.115 0.922
mPFC 100.4 0.988±0.055 0.981±0.050 −0.007±0.090 0.844
mPOA 4.9 1.292±0.245 1.324±0.249 0.031±0.096 0.387
VMH 5.2 1.349±0.310 1.359±0.232 0.010±0.134 0.832
CA1 46.8 0.987±0.037 0.983±0.045 −0.005±0.042 0.763
Fig. 4. ROI analysis of response to 8-OH-DPAT treatment. Scatter plot showing individual
ROI results (whole brain normalized radioactivity) in 8-OH-DPAT and saline conditions
(A). Bar plot shows difference in whole brain normalized radioactivity (8-OH-DPAT
minus saline) for each ROI and each subject (B). No ROI shows a significant response to
chronic 8-OH-DPAT treatment (p>0.3 for each region; paired t test, 2-tailed; n=8).
-0.1                                    +0.1 
L R
Δ FDG
Fig. 5. Glucose metabolism index decreases in medial occipital cortex in response to
chronic 8-OH-DPAT treatment. The color scale indicates the mean difference in
whole brain normalized radioactivity, ΔFDG=8-OH-DPAT minus Saline. White con-
tour marked by arrows delineates a significant negative 3D cluster in the correspond-
ing t map, shown at Bregma −11.2 mm (2-tailed paired t test, puncorrectedb0.05,
extent=60 μL, pcorrected=0.004). Mean difference arbitrarily thresholded at
0.02b |ΔFDG |b0.10.
Fig. 6. Rejection of mounts. Between-condition difference in normalized FDG uptake
(8-OH-DPAT - Saline) plotted against alteration in behavior for the eight subjects.
Voxelwise analysis found two significant clusters (Suppl. Fig. 6), one with a positive
correlation (◊ left ventral cerebellum) and one with a negative correlation (□ medial
occipital cortex).
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Table 2. FDG results. Whole brain normalized radioactivity measures in anatomically defined 
ROIs for Saline condition, 8-OH-DPAT condition, and the difference 8-OH-DPAT minus Saline. 
(p: paired t t t, 2-tailed; n=8).
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Figure 4  ROI analysis of response to 8-OH-DPAT treatment.  Scatter 
plot showing individual ROI results (whole brain normalized radioactivity) 
in 8-OH-DPAT and Saline conditions (A). Bar plot shows difference in 
whole brain normalized radioactivity (8-OH-DPAT minus Saline) for each 
ROI and each subject (B). No ROI shows a significant response to chronic 
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Figure 5  Glucose metabolism index decreases in medial occipital 
cortex in response to chronic 8-OH-DPAT treatment. The color scale 
indicates the mean difference in whole brain normalized radioactivity, 
FDG = 8-OH-DPAT minus Saline. White contour marked by arrows 
delineates a significant negative 3D cluster in the corresponding t map, 
shown at Bregma -11.2 mm (2-tailed paired t test, puncorrected < 0.05, extent 
= 60 L, pcorrected = 0.004). Mean difference arbitrarily thresholded at 0.02 
< |FDG | < 0.10.  
  
-0.1                                    FDG +0.1 
L                                         R
Fig. 4. ROI analysis of re-
sponse to 8-OH-DPAT treat-
ment. Scatter plot showing 
individual ROI results (whole 
brain normalized radioactivity) 
in 8-OH-DPAT and saline con-
ditions (A). Bar plot shows dif-
ference in whole brain normal-
ized radioactivity (8-OH-DPAT 
minus saline) for each ROI 
and each subject (B). No ROI 
shows a significant response to 
chronic 8-OH-DPAT treatment 
(p>0.3 for each region; paired 
t test, 2-tailed; n=8).
Fig. 5. Glucose metabolism 
index decreases in medial 
occipital cortex in response 
to chronic 8-OH-DPAT treat-
ment. The color scale indi-
cates the mean difference in 
whole brain normalized radio-
activity, ΔFDG = 8-OH-DPAT 
minus Saline. White contour 
marked by arrows delineates 
a significant negative 3D 
cluster in the corresponding t 
map, shown at Bregma −11.2 
mm (2-tailed paired t test, pun-
corrected<0.05, extent=60 μL, 
pcorrected=0.004). Mean differ-
ence arbitrarily thresholded at 
0.02<|ΔFDG |<0.10.
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8-OH-DPAT-induced difference in the magnitude of FDG uptake in any ROI 
(Table 2 and Fig. 4). Voxelwise mapping of 8-OH-DPAT minus Saline revealed 
a single cluster in medial occipital cortex of reduced activity (8-OH-DPAT < 
Saline, puncorrected<0.05, extent=60 μL, pcorrected=0.004; Fig. 5 and Suppl. Fig. 5).
Behavior
To further confirm the significance of the finding of decreased normalized 
FDG uptake in medial occipital cortex in response to 8-OHDPAT, we 
considered alterations in female rejection of male mounts and mount attempts 
(the most significant 8-OH-DPAT-induced behavioral finding) (Aubert et al., 
in press). The between-condition difference in FDG uptake was therefore 
correlated voxelwise against the difference in rejection of mount attempts. 
Two significant clusters of voxels were found, in which altered normalized 
FDG uptake correlated with altered rejection of mounts (Fig. 6 and Supp. 
Fig. 6; puncorrected<0.05; positive correlation: left ventral cerebellum, extent=48 
μL, pcorrected=0.017; negative correlation: medial occipital cortex, extent=72 
μL, pcorrected=0.001). The second cluster, in which decreased metabolism 
correlated with increased rejection of mounts, overlapped 38% with the 
cluster of voxels described above that exhibited reduced metabolism during 
8-OH-DPAT treatment (Fig. 7 and Suppl. Fig. 7). Subsequent exploration of 
the relation between normalized FDG uptake and rejection of mount attempts 
in the Saline condition alone yielded three significant clusters (Table 3, Suppl. 
Fig. 8), but the mean normalized FDG uptake in these clusters did not reveal 
a significant response to 8-OH-DPAT (p>0.5, 2-tailed paired t test).
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Figure 6  Rejection of mounts. Between-condition difference in 
normalized FDG uptake (8-OH-DPAT - Saline) plotted against alteration in 
behavior for the eight subjects. Voxelwise analysis found two significant 
clusters (Suppl. Fig. 6), one with a positive correlation (◊ left ventral 
cerebellum) and one with a negative correlation (□ medial occipital cortex). 
  
Fig. 6. Rejection of mounts. Between- ondition differe ce in normalized FDG uptake (8-OH-
DPAT - Saline) plotted against alteration in behavior for the eight subjects. Voxelwise analysis 
found two significant clusters (Suppl. Fig. 6), one with a positive correlation (◊ left ventral 
cerebellum) and one with a negative correlation (□ medial occipital cortex).
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Figure 7  Glucose metabolism index and behavior respond to 8-OH-
DPAT treatment in concert. Orthogonal views of MRI template at medial 
occipital cortex. Cluster of voxels with significant reduction in FDG 
radioactivity during 8-OH-DPAT condition compared to Saline condition 
(red; paired t test, 2-tailed puncorrected < 0.05, extent 60 L, pcorrected = 
0.004). Cluster of voxels with significant negative correlation between 
alterations of FDG radioactivity and rejection of mount attempts between 
conditions (blue; Pearson r; 2-tailed puncorrected < 0.05, extent 72 L, 
pcorrected = 0.001). The two clusters overlap (yellow). Part of significant 
cluster with positive correlation is seen in coronal view (light blue at ventral 
left edge of cerebellum).  
  
8-OH-DPAT < Saline
FDG = -b * Reject Mount
Overlap
L                  R
Fig. 7. Glucose metabolism index and behavior respond to 8-OH-DPAT treatment in concert. 
Orthogonal views of MRI template at medial occipital cortex. Cluster of voxels with significant 
reduction in FDG radioactivity during 8-OH-DPAT conditi n compar d to Saline condition 
(red; paired t test, 2-tailed puncorrected<0.05, extent 60 μL, pcorrected=0.004). Cluster of voxels 
with significant negative correlation between alterations of FDG radioactivity and rejection 
of mount attempts between conditions (blue; Pearson r; 2-tailed puncorrected<0.05, extent 72 
μL, pcorrected=0.001). The two clusters overlap (yellow). Part of significant cluster with positive 
correlation is seen in coronal view (light blue at ventral left edge of cerebellum).
Table 3. Significant clusters identified by voxelwise statistical mapping. Clusters in t maps 
above threshold at puncorrected=0.05 with extent shown in μL. pcorr.=p value of cluster corrected 
for familywise error (SPM8). Position of maximum absolute t value (max. |t|) within cluster 
indicated in atlas coordinates (mm) (Palazzi and Bordier, 2008): LR=right with respect to 
midline, AP=anterior w.r.t. bregma, and DV=dorsal w.r.t. interaural line. Atlas origin corresponds 
to voxel (x,y,z)=(298,30,111).
measures in the anatomically defined ROIs were generally stable be-
tween conditions. Indeed, none of the anatomically defined ROIs
exhibited a significant response to 8-OH-DPAT (Table 2 and Fig. 4).
On the other hand, voxelwise analysis of 8-OH-DPAT vers s Saline
identified a significant cluster of reduced metabolism in medial occip-
ital cortex (Fig. 5).
A limitation of this study was the lack of absolute quantification of
cerebral glucose metabolism. Because FDG uptake occurred during
freely moving behavior, blood sampling would have interfered with
the experiment, so normalized FDG uptake was used as an index of
glucose metabolism. The between condition measures reported here
ther for only index d alterations in metabolism relative to whole
brain, and interpreting the as changes in absolute glucose metabo-
lism is therefore complicated by potential changes in global cerebral
metabolism (Borghammer et al., 2009). The reduction in whole
brain normalized radioactivity observed in medial occipital cortex
(−5.9%, pcorrected=0.004) was supported by dimunition of radioac-
tivity in that region normalized to injected dose / body weight
(−13.2%, p=0.093, 2-tailed paired t test) suggestin a true reduction
in neural a tivity.
The observed 8-OH-DPAT induced red ction of normalized FDG
uptake in medial occipital cortex overlapped 38% with a brain region
showing a correlation between 8-OH-DPAT-i du ed increase in
female rejection of male mounts and 8-OH-DPAT-induced reduction
in FDG uptake (Figs. 6–7). Such an association between 8-OH-DPAT
induced changes in female sexual behavior and normalized FDG up-
take in occipital cortex is perhaps not surprising when considering
that primate occipital cortex receives considerable 5-HT innervation
(Morrison et al., 1982) associated with processing of visual informa-
tion involving 5-HT1A, 5-HT1B, and 5-HT2A receptors (Gebhard et al.,
1993; Watakabe et al., 2009; Yamamori, 2011).
Our detailed knowledge of within-neuron location of 5-HT recep-
tor subtypes within occiptal cortex derives from rodent studies, in
which hyperpolarizing 5-HT1A receptors are found on the soma and
axon hillock of layer 5 pyramidal (L5P) neurons (Moreau et al.,
2010). L5P neurons, after integrating thalamocortical inputs relayed
mostly from L2/3 visual cortex neurons, elaborate cortical outputs
from the visual cortex to multiple areas of the cortex (Thomson and
Bannister, 1998). Axon hillock 5-HT1A receptors on L5P neurons
have been shown to provide crucial inhibitory contributions in balan-
cing excitation and inhibition, possibly by regulating gain control
(enhancing weak signals and suppressing excessive responses)
(Amargos-Bosch et al., 2004; Moreau et al., 2010; Yamamori, 2011).
In this study, therefore, 8-OH-DPAT-mediated chronic overstimula-
tion of axon-hillock 5-HT1A receptors on L5P visual cortical neurons
may decrease the likelihood of L5P activity and potentially produce
an area-wide overall decrease in glucose metabolism. Such enhanced
5HT1A-mediated inhibition of female marmoset visual cortex L5P
synaptic output may thus distort visually-relevant signals required
for timely cortical processing. This disrupted cortical processing
could in turn contribute to the 8-OH-DPAT-mediated inhibition of fe-
male engagement in sexual behavior with their male pairmates, as
the visual cortex projects to, and receives input from, the amygdala
(Amaral, 2002) and frontal cortex (Catani et al., 2002; Nieuwenhuys
et al., 1988), 5-HT responsive regions that are intimately involved in
attributing salience, and directing visual attention, to negative emo-
tional stimuli (Surguladze et al., 2008).
To identify brain regions associated with female marmoset sexual
behavior, we subsequently correlated normalized FDG uptake with
female rejection of mounts in the Saline condition alone, which
yielded three significant clusters of voxels. A cluster encompassing bi-
lateral oribitofrontal cortex and right insular cortex exhibited increas-
ing FDG uptake across subjects with decreasing female rejection of
mounts. This result is consistent with those from human neuroimag-
ing studies, in which women were exposed to erotic visual stimuli
(Arnow et al., 2009) or to male faces (Rupp et al., 2009). There was
no significant change in FDG uptake observed in any of these three
clust rs of voxels in response to 8-OH-DPAT. The lack of 8-OH-DPAT
related changes in FDG uptake in these voxel clusters suggests that
individual differences in these regions are relatively stable and 8-
OH-DPAT induced alteration in female mount rejection is mediated
by o her brain regions, in particular the medial occipital region dis-
cussed above.
Taken togeth r, these observations support the notion that the
association between 8-OH-DPAT-related changes in behavior and oc-
cipi al cortex FDG uptake may indicate altered salience of, and visual
attention paid to, pairmate interactions contributing to diminished
female sexual receptivity. Further planned investigations of the
effects of chronic 8-OH-DPAT administration on the primate seroto-
nergic system, particularly upon 5-HT1A and SERT availability, may
shed light on this question.
Conclusions
This work implemented and validated a template method of mar-
moset brain PET analysis that yielded reliable measures of normalized
FDG uptake. Chronic treatment with 8-OH-DPAT (0.1 mg/kg SC daily
for 42–49 days) did not produce significant alterations in this glucose
metabolism index in the five anatomically defined regions examined
L R
Fig. 7. Glucose metabolism index and behavior respond to 8-OH-DPAT treatment in
concert. Orthogonal views of MRI template at medial occipital cortex. Cluster of voxels
with significant reduction in FDG radioactivity during 8-OH-DPAT condition compared
to Saline condition (red; paired t test, 2-tailed puncorrectedb0.05, extent 60 μL,
pcorrected=0.004). Cluster of voxels with significant negative correlation between alter-
ations of FDG radioactivity and rejection of mount attempts between conditions (blue;
Pearson r; 2-tailed puncorrectedb0.05, extent 72 μL, pcorrected=0.001). The two clusters
overlap (yellow). Part of significant cluster with positive correlation is seen in coronal
view (light blue at ventral left edge of cerebellum).
Table 3
Significant clusters identified by voxelwise statistical mapping. Clusters in t maps
above threshol at puncorrected=0.05 with exte t shown in μL. pcorr.=p value of cluster
corrected for familywise error (SPM8). Position of maximum absolute t value (max. |t|)
within cluster indicated in atlas coordinates (mm) (Palazzi and Bordier, 2008):
LR=right with respect to midline, AP=anterior w.r.t. br gma, and DV=dorsal w.r.t.
interaural line. Atlas origin corresponds to voxel (x,y,z)=(298,30,111).
Test Region μL pcorr. max. |t| LR AP DV
Contrast: 8-OH-DPAT minus saline
M dial occipital cortex 60 0.004 −14.4 0.6 −11.2 13.5
Correlation: ΔFDG vs Δreject mount
Medial occipital cortex 72 0.001 −15.4 1.0 −11.8 12.1
Left ventral cerebellum 48 0.017 9.7 −4.4 −8.1 0.5
Correlation: FDG vs reject mount (saline)
Bilateral ventral cerebellum 161 0.000 11.9 −2.6 −3.7 −1.9
Bilateral dorsal frontal cortex 115 0.001 16.2 −2.1 5.6 19.0
Bilateral orbitofrontal cortex 122 0.000 −8.8 8.5 7.4 10.2
453A.K. Converse et al. / NeuroImage 60 (2012) 447–455
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DISCUSSION
In this work, we (1) advanced methods for PET imaging of marmoset 
monkey brain, (2) measured whole brain normalized FDG uptake as an index 
of local cerebral metabolic rates for glucose, and (3) studied the effect of 
chronic treatment with a 5-HT1A receptor agonist on brain regions implicated 
in regulating female sexual interactions.
Anatomical identification
In this work we implemented and validated a novel templatebased method 
of anatomical identification for PeT imaging of marmoset brain. This relied 
on adequate alignment of the individual MR images to the template space 
and of PeT images to MRIs (Figs. 1 and 2). Alignment of the MRI template to 
the published histological atlas was within 1 mm, a very satisfactory degree 
of agreement. While the agreement between the MRI template and the atlas 
was not sufficient to simply delineate ROIs on the atlas, it aided identification 
of regions in the MRI by means of relative positions to common features seen 
in each image (Fig. 3). Despite the excellent alignment between the individual 
MRIs, as judged by brain contours (Fig. 2), individual anatomical differences 
in grey-white contrast within the brain may still be significant. Inter-operator 
variances, however, in geometric overlap and in FDG measures using individual 
ROIs were comparable to individual- versus template-determined differences. 
The template ROI method may therefore provide anatomical identification as 
reproducible as that obtained by delineating regions on individual MRIs. While 
template ROI location was reliable between subjects, measures attributed to 
the smaller regions, namely DR, mPOA, and VMH, must be interpreted with 
caution because of the PET scanner resolution.
Glucose metabolism index and behavior
This is the first report, to our knowledge, of the effect of chronic 8-OH-
DPAT administration on cerebral glucose metabolism in primates. Despite 
relatively large differences in whole brain normalized radioactivity measured 
between regions and between subjects, FDG measures in the anatomically 
defined ROIs were generally stable between conditions. Indeed, none of the 
anatomically defined ROIs exhibited a significant response to 8-OH-DPAT 
(Table 2 and Fig. 4). On the other hand, voxelwise analysis of 8-OH-DPAT 
versus Saline identified a significant cluster of reduced metabolism in medial 
occipital cortex (Fig. 5).
A limitation of this study was the lack of absolute quantification of cerebral 
glucose metabolism. Because FDG uptake occurred during freely moving 
behavior, blood sampling would have interfered with the experiment, so 
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normalized FDG uptake was used as an index of glucose metabolism. The 
between condition measures reported here therefore only indexed alterations 
in metabolism relative to whole brain, and interpreting them as changes in 
absolute glucose metabolism is therefore complicated by potential changes in 
global cerebral metabolism (Borghammer et al., 2009). The reduction in whole 
brain normalized radioactivity observed in medial occipital cortex (−5.9%, 
pcorrected=0.004) was supported by dimunition of radioactivity in that region 
normalized to injected dose / body weight (−13.2%, p=0.093, 2-tailed paired t 
test) suggesting a true reduction in neural activity.
The observed 8-OH-DPAT induced reduction of normalized FDG uptake 
in medial occipital cortex overlapped 38% with a brain region showing a 
correlation between 8-OH-DPAT-induced increase in female rejection of male 
mounts and 8-OH-DPAT-induced reduction in FDG uptake (Figs. 6–7). Such an 
association between 8-OH-DPAT-induced changes in female sexual behavior 
and normalized FDG uptake in occipital cortex is perhaps not surprising 
when considering that primate occipital cortex receives considerable 5-HT 
innervation (Morrison et al., 1982) associated with processing of visual 
information involving 5-HT1A, 5-HT1B, and 5-HT2A receptors (Gebhard et al., 
1993; Watakabe et al., 2009; yamamori, 2011).
Our detailed knowledge of within-neuron location of 5-HT receptor 
subtypes within occiptal cortex derives from rodent studies, in which 
hyperpolarizing 5-HT1A receptors are found on the soma and axon hillock of 
layer 5 pyramidal (L5P) neurons (Moreau et al., 2010). L5P neurons, after 
integrating thalamocortical inputs relayed mostly from L2/3 visual cortex 
neurons, elaborate cortical outputs from the visual cortex to multiple areas 
of the cortex (Thomson and Bannister, 1998). Axon hillock 5-HT1A receptors 
on L5P neurons have been shown to provide crucial inhibitory contributions 
in balancing excitation and inhibition, possibly by regulating gain control 
(enhancing weak signals and suppressing excessive responses) (Amargos-
Bosch et al., 2004; Moreau et al., 2010; yamamori, 2011). In this study, 
therefore, 8-OH-DPAT-mediated chronic overstimulation of axon-hillock 5-HT1A 
receptors on L5P visual cortical neurons may decrease the likelihood of L5P 
activity and potentially produce an area-wide overall decrease in glucose 
metabolism. Such enhanced 5HT1A-mediated inhibition of female marmoset 
visual cortex L5P synaptic output may thus distort visually-relevant signals 
required for timely cortical processing. This disrupted cortical processing could 
in turn contribute to the 8-OH-DPAT-mediated inhibition of female engagement 
in sexual behavior with their male pairmates, as the visual cortex projects 
to, and receives input from, the amygdala (Amaral, 2002) and frontal cortex 
(Catani et al., 2002; Nieuwenhuys et al., 1988), 5-HT responsive regions that 
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are intimately involved in attributing salience, and directing visual attention, to 
negative emotional stimuli (Surguladze et al., 2008).
To identify brain regions associated with female marmoset sexual behavior, 
we subsequently correlated normalized FDG uptake with female rejection of 
mounts in the Saline condition alone, which yielded three significant clusters of 
voxels. A cluster encompassing bilateral orbitofrontal cortex and right insular 
cortex exhibited increasing FDG uptake across subjects with decreasing 
female rejection of mounts. This result is consistent with those from human 
neuroimaging studies, in which women were exposed to erotic visual stimuli 
(Arnow et al., 2009) or to male faces (Rupp et al., 2009). There was no 
significant change in FDG uptake observed in any of these three clusters of 
voxels in response to 8-OH-DPAT. The lack of 8-OH-DPAT related changes 
in FDG uptake in these voxel clusters suggests that individual differences 
in these regions are relatively stable and 8-OH-DPAT induced alteration in 
female mount rejection is mediated by other brain regions, in particular the 
medial occipital region discussed above.
Taken together, these observations support the notion that the association 
between 8-OH-DPAT-related changes in behavior and occipital cortex FDG 
uptake may indicate altered salience of, and visual attention paid to, pairmate 
interactions contributing to diminished female sexual receptivity. Further 
planned investigations of the effects of chronic 8-OH-DPAT administration 
on the primate serotonergic system, particularly upon 5-HT1A and SERT 
availability, may shed light on this question.
CONCLUSIONS
This work implemented and validated a template method of marmoset 
brain PeT analysis that yielded reliable measures of normalized FDG uptake. 
Chronic treatment with 8-OH-DPAT (0.1 mg/kg SC daily for 42–49 days) did 
not produce significant alterations in this glucose metabolism index in the five 
anatomically defined regions examined (DR, mPFC, mPOA, VMH, and CA1) 
in awake, behaving, ovariectomized adult female marmosets with or without 
estradiol replacement. Parametric mapping revealed a significant reduction in 
the glucose metabolism index in response to 8-OH-DPAT in medial occipital 
cortex, consistent with alterations in female sexual behavior.
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Supplementary Figure 1  Alignment of individual MRIs.  The first eight 
images show axial, coronal, and sagittal slices in each subject's aligned 
MRI at the same position.  Individual images have been aligned to the 
target (cj1074) by 6 degrees of freedom (rigid body) and then by 9 
degrees of freedom (rigid body plus zooms).  The last image shows the 
mean image, used as the MRI template.  The whole brain contour is the 
same in all views and demonstrates the quality of the alignments. 
mean (n=8)
Supplementary Figure 1. Alignment of individual MRIs. The first eight images show axial, 
coronal, and sagittal slices in each subject's aligned MRI at the same position. Individual 
images have been aligned to the target (cj1074) by 6 degrees of freedom (rigid body) and then 
by 9 degrees of freedom (rigid body plus zooms). The last image shows the mean image, used 
as the MRI template. The whole brain contour is the same in all views a d demonstrates the 
quality of the alignments.
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Supplementary Figure 2  Individual FDG images.  Each row shows 
axial, coronal, and sagittal slices of FDG image for one subject in Saline 
condition (left) and DPAT condition (right). Contour is on whole brain 
mask modified to avoid contributions from FDG uptake outside of brain. 
Supplementary Figure 2. Individual FDG images. Each row shows axial, coronal, and 
sagittal slices of FDG image for one subject in Saline condition (left) and DPAT condition (right). 
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Supplementary Figure 3  Mean FDG Image.   Average of 16 (8 subjects 
x 2 conditions) whole brain normalized images.  Every fourth 0.5 mm slice 
shown. 
0.0                          FDG                           2.0
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Supplementary Figure 4  No ROI shows a significant response to 
chronic 8-OH-DPAT treatment. Mean whole brain normalized 
radioactivity in each condition (Saline, 8-OH-DPAT) for each ROI and all 






































Supplementary Figure 3. Mean FDG Image. Average of 16 (8 subjects x 2 conditions) whole 
brain normalized images. Every fourth 0.5 mm slice shown.
Supplementary Figure 4. 
No ROI show  a signifi-
cant response to chronic 
8-OH-DPAT treatment. Mean 
whole brain normalized ra-
dioactivity in each condition 
(Saline, 8-OH-DPAT) for each 
ROI and all subjects (p>0.3 
for each region; paired t test, 
2-tailed; n = 8).
109
8-OH-DPAT-MEDIATED CHANGES IN CEREBRAL GLUCOSE  METABOLISM
4
 
\ref\converse\ConverseAK(MS)Neuroimage_marm_FDG_DPAT_current.doc  5 Oct 2011 54/57 
 
 
Supplementary Figure 5  Glucose metabolism index decreases in 
medial occipital cortex in response to chronic 8-OH-DPAT treatment.  
The color scale indicates the mean difference in whole brain normalized 
radioactivity, FDG = 8-OH-DPAT minus Saline, thresholded at 0.02 < 
|FDG | < 0.10. The white contour marked by arrows delineates a 
significant negative cluster (2-tailed paired t test, puncorrected < 0.05, extent = 
60 L, pcorrected = 0.004). Every fourth 0.62 mm coronal slice shown. 
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Supplementary Figure 5. Glucose metabolism index decreases in medial occipital cortex 
in response to chronic 8-OH-DPAT treatment. The color scale indicates the mean difference 
in whole brain normalized radioactivity, ΔFDG = 8-OH-DPAT minus Saline, thresholded at 
0.02 < |ΔFDG | < 0.10. The white contour marked by arrows delineates a significant negative 
cluster (2-tailed paired t test, puncorrected < 0.05, extent = 60 μL, pcorre ted = 0.004). Every fourth 0.62 
mm coronal slice shown.
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Supplemenatary Figure 6  Changes in glucose metabolism index 
correlate with alterations in female rejection of mounts. Between-
condition difference in normalized FDG uptake (8-OH-DPAT minus Saline) 
correlated against alteration in behavior. Color scale corresponds to slope 
of linear correlation through the origin, FDG = b * (Reject Mount), 
thresholded at 0.01 < |b | < 0.08. For Pearson r, 2-tailed puncorrected < 0.05, 
two significant clusters were identified, one with a positive correlation (left 
ventral cerebellum; extent = 47 L; pcorrected = 0.017) and one with a 
negative correlation (medial occipital cortex; extent = 72 L; pcorrected = 
0.001; indicated by arrows). Every fourth 0.62 mm coronal slice shown.  
R                    L
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Supplementary Figure 6. Changes in glucose metabolism index correlate ith alterations 
in female rejection of mounts. Between-condition difference in normalized FDG uptake 
(8-OH-DPAT minus Saline) correlated against alteration in behavior. Color scale corresponds 
to slope of linear correlation through the origin, ΔFDG = β * Δ(Reject Mount), thresholded at 
0.01 < |β| < 0.08. For Pearson r, 2-tailed puncorrected < 0.05, two significant clusters were identified, 
one with a positive correlation (left ventral cerebellum; extent = 47 μL; pcorrected = 0.017) and one 
with a negative correlation (medial occipital cortex; extent = 72 μL; pcorrected = 0.001; indicated by 
arrows). Every fourth 0.62 mm coronal slice shown.
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Supplementary Figure 7  Overlap between contrast and correlation 
clusters shown in Supplementary Figures 5 and 6. Cluster of voxels 
with significant reduction in FDG radioactivity during 8-OH-DPAT condition 
compared to Saline condition (red; paired t test, 2-tailed puncorrected < 0.05, 
extent 60 L, pcorrected = 0.004). Cluster of voxels with significant negative 
correlation between alterations of FDG radioactivity and rejection of mount 
attempts between conditions (green; Pearson r; 2-tailed puncorrected < 0.05, 
extent 72 L, pcorrected = 0.001). The two clusters overlap (yellow; 23 L). 
Significant cluster with positive correlation is seen as well in left ventral 
cerebellum (blue; Pearson r; 2-tailed puncorrected < 0.05, extent 47 L, 
pcorrected = 0.017). Every fourth 0.62 mm coronal slice shown. This image 
shown in orthogonal views in Fig. 7. 
R                    L
8-OH-DPAT < Saline
FDG = -b * Reject Mount
Overlap
FDG = +b * Reject Mount
Supplementary Figur  7. Overlap between contrast and correlation clusters show  in 
Supplementary Figures 5 and 6. Cluster of voxels with significant reductio  in FDG radioactivity 
during 8-OH-DPAT condition compared to Saline condition (red; paired t test, 2-tailed puncorrected 
< 0.05, extent 60 μL, pcorrected = 0.004). Cluster of voxels with significant negative correlation 
between alterations of FDG radioactivity and rejection of mount attempts betw en conditions 
(green; Pearson r; 2-tail d puncorrected < 0.05, extent 72 μL, pcorrected = 0.001). The two clusters 
overlap (yellow; 23 μL). Significant cluster with positive correlation is seen as well in left ventral 
cerebellum (blue; Pearson r; 2-tailed puncorrected < 0.05, extent 47 μL, pcorrected = 0.017). Every 
fourth 0.62 mm coronal slice shown. This image shown in orthogonal views in Fig. 7.
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Supplementary Figure 8  Glucose metabolism index correlated 
against female rejection of mounts in Saline condition. Three 
significant clusters indicated by numbers and arrows. Negative correlation 
(blue), i.e. less rejection of mounts with increasing FDG uptake: (1) 
bilateral orbitofrontal cortex and right insular cortex (Pearson r; 2-tailed 
puncorrected < 0.05, extent 122 L, pcorrected = 0.000). Positive correlation 
(red): (2) bilateral ventral cerebellum (161 L, pcorrected = 0.000) and (3) 
bilateral dorsal frontal cortex (115 L, pcorrected = 0.001). FDG = b * Reject 
Mount + b. Arbitrarily thresholded at 0.02 < |b | < 0.2. Every fourth 0.62 
mm coronal slice shown.  
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Supplementary Figure 8. Glucose metabolism index correlated against female rejection 
of mounts in Saline condition. Three significant clusters indicated by numbers and arrows. 
Negative correlation (blue), i.e. less rejection of mounts with increasing FDG uptake: (1) 
bilateral orbitofrontal cortex and right insular cortex (Pearson r; 2-tailed puncorrected < 0.05, 
extent 122 μL, pcorrected = 0.000). Positive correlation (red): (2) bilateral ventral cerebellum 
(161 μL, pcorrected = 0.000) and (3) bilateral dorsal frontal cortex (115 μL, pcorrected = 0.001). 
FDG = β1 * Reject Mount + β2. Arbitrarily thresholded at 0.02 < |β1| < 0.2. Every fourth 0.62 mm 
coronal slice shown.
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Introduction. In a marmoset model of hypoactive female sexual function, 
we have shown that chronic administration of the serotonin (5-HT)-1a agonist 
8-OH-DPAT inhibits sexual receptivity in female marmoset monkeys and 
increases aggression towards the male pairmate. 
Aim. To investigate gene expression changes induced by 8-OH-DPAT in 
laser-microdissected brain areas that regulate female sexual function, and to 
identify genes, functional gene classes and pathways associated with 8-OH-
DPAT-mediated inhibition of female sexual receptivity.
Methods. Gene expression was measured in the medial prefrontal cortex 
(mPFC), medial preoptic area (mPOA), CA1 area of the hippocampus (CA1) 
and dorsal raphé nucleus (DRN) of four chronically 8-OH-DPAT-treated 
(0.1 mg/kg) and four vehicle-treated female marmosets using a marmoset-
specific microarray (eUMAMA) and validated by Real-time quantitative PCR 
(RTqPCR). Enriched functional gene classes were determined. In a parallel 
candidate gene approach, the expression of serotonergic candidate genes, 
i.e. the 5-HT1A, 5-HT2A, 5-HT7 receptors and the 5-HT transporter (5-HTT), was 
measured by RTqPCR.
Main outcome measures. Differential expression of genes between 8-OH-
DPAT- and vehicle-treated marmosets.
Results. 8-OH-DPAT affected gene classes important to neural 
development (mPFC, mPOA and DRN), neurotransmission (mPOA), energy 
production (mPFC and mPOA), learning and memory (CA1), and intracellular 
signal transduction (DRN). Oxytocin (OxT) in the mPOA and 5-HTT in the 
DRN were strongly increased by 8-OH-DPAT. 5-HT1A tended to increase in the 
mPFC, while 5-HT7 was decreased in the CA1. 
Conclusions. Brain region-specific alterations of gene expression 
regulating neural circuitries, energy demands and learning processes are 
associated with 8-OH-DPAT-induced decrease in female sexual receptivity 
and increase in pairmate aggression. Whether enhanced OxT expression in 
the mPOA disrupts the oxytocinergic regulation of social and sexual behavior, 
or presents a pharmacotherapeutic opportunity for the treatment of hypoactive 
sexual desire disorder (HSDD) in women, remains to be investigated.
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INTRODUCTION
Personally distressing hypoactive sexual desire disorder (HSDD) is 
reported in an estimated 10% of women, but its psychopathogenesis is 
largely unknown. Causes for HSDD are multifactorial, including hormonal, 
neurobiological and psychosocial factors [1]. A twin/sibling study investigating 
the contributions of genetic and environmental influences on domains of the 
Female Sexual Function Index (FSFI) suggests a modest genetic influence 
on female sexual function, including desire [2]. Animal research, and a few 
clinical studies employing novel pharmacological targets to treat HSDD in 
women, point towards potential genes involved in female sexual function. 
Such candidates include genes encoding serotonin-1a and -2a receptors 
(5-HT1A/5-HT2A) [3, 4], dopamine [5] and dopamine D4 receptor [6], oxytocin 
(OxT) [7] and oxytocin receptor (OTR) [8], vasopressin and AVP-1a receptor 
[8], estrogen (E2) and estrogen receptor alpha [9], gonadotropin-releasing 
hormone II [10], and melanocortin receptors [11]. Genetic research in female 
sexual dysfunction, including HSDD, however, lags far behind genetic research 
in other biomedical areas [12], and to the best of our knowledge, neither large-
scale gene expression studies nor genome-wide association studies (GWAS) 
have been undertaken to investigate the genetic substrate of female sexual 
function and dysfunction.
Female marmoset monkeys (Callithrix jacchus) present an opportunity to 
explore sexually stimulatory or inhibitory pharmacological manipulations in a 
nonhuman primate model that readily translates to humans. Marmosets form 
long-term sexual relationships between male-female pairs [13, 14], in contrast 
to multiple-mating social structures of rats [15] and many nonhuman primates, 
including macaques [16]. By the display of species-specific proceptive 
behaviors, and by acceptance or rejection of a pairmate’s sexual advances, 
female marmosets can influence male sexual behavior and readily promote, 
prevent or terminate sexual interactions [17, 18].
We have established a marmoset model for female sexual function that 
employs a standardized behavioral testing paradigm, permitting repeatable, 
quantitative exploration of neurally active compounds that enhance or diminish 
female marmoset sexual behavior [4, 10]. We have shown that repeated, daily 
administration of the 5-HT1A/7 agonist R-(+)-8-hydroxy-2-(di-n-propylamino)
tetralin (8-OH-DPAT) diminishes female sexual receptivity and increases 
aggression with a male pairmate, as well as modulating other behavioral, 
endocrine and brain activity parameters, which correlate to the changes 
observed in sexual receptivity (Table 1; [4, 19, 20]).
We have previously developed a marmoset-specific DNA microarray 
(eUMAMA), the first microarray designed for this species, representing 
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more than 1,500 transcripts [21]. Using the EUMAMA microarray we have 
shown that specific marmoset brain regions isolated by laser microdissection 
(LMD) technology show highly divergent expression profiles, underscoring 
the importance of characterizing gene expression in precisely isolated brain 
subregions of interest [21].
In the present study, we take advantage of the well-characterized effects 
of chronic 8-OH-DPAT administration on marmoset female sexual function to 
gain insight into 8-OH-DPAT-induced transcriptomic changes that may underlie 
the observed decrease in female sexual receptivity. Here, we present a gene 
expression study using large-scale expression profiling on brain tissue of the 
same female marmosets that were studied for sexual behavior. We applied 
LMD to isolate discrete brain regions relevant to female sexual behavior [22] or 
that have high 5-HT1A density [23]. The selected brain regions comprised: (1) 
medial prefrontal cortex (mPFC), involved in executive and inhibitory regulation 
of behavior and receiving dopaminergic projections from the ventral tegmental 
area that are relevant to sexual behavior [24]; (2) medial preoptic area of the 
hypothalamus (mPOA), intimately involved in female sexual behavior [17, 22]; 
(3) CA1 field of the hippocampus (CA1), involved in sexually relevant memory 
processes [25]; and (4) dorsal raphé nucleus (DRN), containing 5-HT neurons 
Table 1. The effects of chronic 8-OH-DPAT administration on behavioral, endocrine and brain 














Increased Negatively correlated [4]
Endocrine
ACTH levels at 15 
min of restraint 
stress
Increased Negatively correlated [19]
Cortisol levels 3 h 
after restraint stress




Reduced Positively correlated [20]
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with extensive projections to cortical, hypothalamic and hippocampal sites, 
and auto-regulating presynaptic 5-HT1A receptors [26].
Parallel to the large-scale microarray study, we followed a candidate gene 
approach using Real-time quantitative PCR (RTqPCR) to measure expression 
levels of genes not present on the EUMAMA microarray, but of high relevance 
to the serotonergic pharmacology of 8-OH-DPAT. The candidate genes 
included the 5-HT1A, 5-HT2A and 5-HT7 receptors, and the 5-HT transporter 
(5-HTT). Combining this candidate gene approach with the large-scale 
microarray experiment, we expect to determine a general transcriptomic 
response to chronic 8-OH-DPAT, mediated by altered expression of specific 
serotonergic markers that may underlie sexual rejection and aggression in 
female marmoset monkeys.
AIMS
The aim of the present study was to investigate the transcriptomic changes 
induced by chronic 8-OH-DPAT in brain areas that play a key role in regulating 
female sexual function and 5-HT neurotransmission. Identification of genes, 
functional gene classes and pathways associated with 8-OH-DPAT-mediated 
inhibition of female marmoset sexual receptivity may reveal neural molecular 
mechanisms involved in female sexual dysfunction.
MeTHODS
Animals and treatment
Animal experiments were conducted in accordance with the 
recommendations of the Guide for the Care and Use of Laboratory Animals 
and the Animal Welfare Act and its subsequent amendments. All animal 
procedures were reviewed and approved by the Graduate School Animal Care 
and Use Committee of the University of Wisconsin-Madison. The Wisconsin 
National Primate Research Center (WNPRC) is accredited by the Association 
for Assessment and Accreditation of Laboratory Animal Care as part of the 
University of Wisconsin-Madison Graduate School. eight adult (age 2-5 yr) 
nulliparous captive-born common marmoset (Callithrix jacchus) females were 
pair housed with similarly aged male partners at the WNPRC for 8-20 months 
before onset of this study. Females were housed with the same male partner 
for the entire study and were ovariectomized and primed with mid-follicular 
phase estradiol levels for the entire duration of this study using estradiol 
capsule implants. Estradiol priming and surgical procedures were performed 
as described in Barnett et al [10].
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Four of the eight females received daily subcutaneous (SC) injections 
of 8-OH-DPAT (N=4; 0.1 mg/kg in 0.4 ml/kg saline) for 16 weeks, while the 
remaining four females received daily SC injections of vehicle (N=4; 0.4 ml/
kg saline). Animals were euthanized 15-19 hours after the last 8-OH-DPAT 
or vehicle injection, when circulating 8-OH-DPAT levels were low to absent 
[4]. Harvesting of neural tissue at a time when circulating 8-OH-DPAT levels 
were minimal permitted assessment of changes in gene expression induced 
by repeated dosing of 8-OH-DPAT, while avoiding potential immediate effects 
of elevated 8-OH-DPAT on transcription. Thus, transcriptomic changes were 
likely consequences of long-term treatment; effects of single dosing were not 
assessed in this study. 
Between 08:30h-10:30h on the day of tissue harvest, marmosets were 
anesthetized with an intramuscular (IM) injection of 15 mg/kg ketamine within 
1-3 minutes (1.5 min ± 0.3 min) of cage entry, and received a lethal injection of 
pentobarbital (50 mg/kg) administered intravenously (IV) within 7-13 minutes 
(10.1 min ± 0.7 min) of cage entry. The brains were snap-frozen in isopentane 
(-78.5°C) within 6-16 minutes (9.1 min ± 1.1 min) of euthanasia and stored at 
-80°C until further use.
Laser microdissection (LMD)
Laser microdissection was performed as previously described [27].  Briefly, 
coronal cryosections (8 μm) containing 1) mPFC, 2) mPOA, 3) CA1, and 4) 
DRN were prepared according to available marmoset brain atlases [28, 29] 
at A16.0 – A17.5 (16.0 – 17.5 mm anterior to the interaural level) for mPFC, 
A10.0 for mPOA, A5.0 – A6.0 for CA1, and A1.5 – A2.0 for DRN samples [28]. 
Cryosections were mounted on PEN-membrane slides (1440-1000, PALM, 
Bernried, Germany) and stored at -80 °C. Before use, the sections were stained 
with hematoxylin and brain regions of interest were laser microdissected 
(PALM MicroBeam, Bernried, Germany; Figure 1). Per sample, an area of 1.5 
– 6.0 x 106 μm2 of the relevant brain region was excised from several slices 
and pooled.
In one of the four 8-OH-DPAT treated brains, the DRN was damaged, likely 
due to brain collection/freezing procedures, and not further analyzed, leading 
to a N=3 8-OH-DPAT vs. N=4 Vehicle comparison for the DRN.
RNA isolation and linear amplification
Total RNA was isolated as described in [27]. 7.5 ng (if 28S/18S ratio >0.7) 
or 12.5 ng (if 28S/18S ratio <0.7) of total RNA was used as input to the Ovation 
Pico WTA System kit (NuGeN Technologies, San Carlos, CA, USA) and was 
subjected to reverse transcription using a mix of random and poly(T) primers, 
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followed by one round of linear amplification. 1.5 µl of amplified cDNA was 
analyzed and quantified on a NanoDrop ND-1000 spectrophotometer (Isogen 
Life Science, De Meern, The Netherlands). A total of 3.45 µg of amplified 
cDNA was fragmented and biotinylated using the Encore Biotin Module kit 
Figure 1. examples of coronal sections containing mPFC (A), mPOA (B), CA1 (C) and DRN (D) 
before and after laser-microdissection. mPFC, medial prefrontal cortex; mPOA, medial preoptic 
area; CA1, CA1 field of the hippocampus; DRN, dorsal raphé nucleus.
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(NuGEN Technologies, San Carlos, CA, USA) and subsequently hybridized to 
our custom eUMAMA marmoset-specific microarray (Affymetrix, Santa Clara, 
USA; [21]) at the MicroArray Department of the University of Amsterdam, 
The Netherlands, using an adapted protocol from NuGEN based on the 
manufacturer’s recommendations (Affymetrix, Santa Clara, USA). A total of 
31 microarrays were hybridized: four 8-OH-DPAT and four vehicle controls for 
each mPFC, mPOA and CA1, and three 8-OH-DPAT and four vehicle controls 
for the DRN.
Data Analysis
Microarray cell intensity files (CeL-files) were subjected to the Affymetrix 
Expression Console software (Affymetrix, Santa Clara, USA) to estimate 
signal intensities and signal reliabilities. All microarrays were background-
corrected and normalized by a MAS5 statistical algorithm.
A separate probe set-level summarized data file was created for each brain 
region and analyzed using BRB-Array Tools version 4.2, an integrated package 
for the visualization and statistical analysis of DNA microarray gene expression 
data that operates as an add-in to Microsoft excel [30]. Prefiltering of data was 
performed to exclude probe sets with unreliable detection in more than 50% of 
the samples and yielded 1241 (mPFC), 1268 (mPOA), 1221 (CA1) and 1160 
(DRN) probe sets that were included in the statistical analysis. Differentially 
expressed genes between 8-OH-DPAT and vehicle treatment groups were 
identified per brain region using a univariate two-sample T-test (with random 
variance model). To increase the information that can be derived from the 
data regarding patterns of genes and pathways, rather than focusing on single 
genes, we chose a moderate statistical stringency of analysis, applying a 
maximal nominal significance level of P < 0.05 and no correction for multiple 
testing. Consequently, individual genes require independent follow-up.
Gene lists containing all significant genes at P < 0.05 or a trend towards 
altered expression (P < 0.1), were evaluated using the DAVID 6.7 Functional 
Annotation Tool [31], particularly suited to determine enriched Gene Ontology 
(GO) terms and signaling pathways associated with a given gene list.
Validation of microarray results
Real-time quantitative PCR (RTqPCR) was performed to confirm 
differential expression of genes indicated by the microarray analysis. Primers 
were designed in the same region of the transcript harboring the Affymetrix 
probe sets using Primer3 freeware. Primers were checked for specificity using 
BLAST (NCBI, Bethesda, MD, USA) and for hairpins and self-complementary 
using oligo 7 (MBI, Cascade, CO, USA; see Table 2, for RTqPCR primer pair 
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sequences).
A selection of responsive genes was validated in the same experimental 
cDNA samples that were used to hybridize to the microarray, using RTqPCR 
on a 7900 HT Fast Real-Time PCR System (Applied Biosystems, Life 
Technologies, Carlsbad, CA, USA) and SYBR Green I dye (Applied Biosystems, 
Bleiswijk, The Netherlands). Standard curves were generated by performing 
PCR reactions on a serial dilution of the cDNA corresponding to 100%, 25%, 
6.25%, 1.56%, 0.39% and 0.10% of 12 ng input cDNA. A negative control (no 
template control; NTC) was included in all PCR runs, and all samples were 
measured in triplicates. 
Table 2. RTqPCR primer pair sequences of normalization genes, validated genes and 
serotonergic candidate genes.
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A suitable normalization gene for each individual brain region was selected 
from the microarray data based on high and stable expression in both 
treatment groups. Stability in expression in controls and 8-OH-DPAT treated 
animals was confirmed by RTqPCR (data not shown). Talin 2 (TLN2) was 
used for the mPFC, x-ray repair complementing defective repair in Chinese 
hamster cells 6 (xRCC6) for the mPOA, and beta actin (ACTB) for both 
CA1 and DRN. Expression levels of the validated genes were normalized 
against the expression levels of the respective normalization gene. To test the 
directionality of the gene expression change predicted by the microarray, a 
one-tailed, independent-samples T-test was used.  
Candidate gene approach by RTqPCR
Gene expression of the main pharmacological targets of 8-OH-DPAT, 5-HT1A 
and 5-HT7, as well as other serotonergic genes that may alter expression in 
response to chronic 8-OH-DPAT, 5-HT2A, 5-HTT, were measured by RTqPCR 
and analyzed as described above. None of these candidate genes are present 
on the EUMAMA microarray. Primers were designed in the coding region of 
the transcripts using the same criteria as mentioned above.
RESULTS
Effects of chronic 8-OH-DPAT on transcriptome in mPFC, mPOA, CA1 
and DRN
The transcriptional response to chronic 8-OH-DPAT was the largest in the 
mPOA, with 68 genes significantly (P < 0.05) altered, followed by DRN (61), 
mPFC (55) and CA1 (45). There was only a small overlap of genes altered by 
8-OH-DPAT between brain regions (Figure 2), indicating mostly brain region-
specific effects of 8-OH-DPAT at the molecular level.
Figure 2. Number of 
genes per brain region 
that were significantly 
altered by 8-OH-DPAT. P 
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In addition, 8-OH-DPAT-induced differential gene expression was most 
pronounced in the mPOA in terms of magnitude of gene expression change 
(Figure 3). Approximately 30% of genes altered by 8-OH-DPAT displayed >2-
fold changes in expression, while only 20% had fold changes <1.5 (Figure 
3B). expression fold-changes were more moderate in the CA1 (Figure 3C), 
and even more subtle in the mPFC and DRN (Figures 3A and 3D). A full list 
of significantly altered genes will be made available online as Supplementary 
Materials.
Validation of microarray results
A total of 33 genes (7 – 10 genes per brain region) were selected for 
RTqPCR validation to confirm the 8-OH-DPAT-induced differential expression 
Figure 3. The magnitude of the transcriptional response to 8-OH-DPAT in the mPFC (A), mPOA 



































































predicted by the microarray. Ten genes (30%) were successfully validated by 
RTqPCR at a significance level of P < 0.05. Applying a less stringent criterion 
(P < 0.1), the number of validated genes increased to 17 (52%). There were 
clear differences between brain regions in terms of validation success rate. 
While validation was most successful in the mPOA and DRN (57% – 90%; 
P < 0.1), it was less obvious for mPFC and CA1 (25%; P < 0.1). A validation 
summary is presented in Table 3. Overall, microarray and RTqPCR results 
from the combined analyses of all four brain regions correlated strongly in 
terms of fold-changes (r = 0.897, p < 0.001; Figure 4A). When only successfully 
validated genes (P < 0.1) were included, the correlation coefficient was similar 
(r = 0.918, p < 0.001; Figure 4B). The successfully validated genes covered a 
wide range of different functions, ranging from regulation of gene transcription, 
protein phosphorylation and metabolism to regulation of neurogenesis, 
cognition and behavior. Oxytocin (OxT), however, clearly stood out from all 
other successfully validated genes in terms of comparative magnitude of the 
8-OH-DPAT-induced change in expression. Microarray analysis predicted 
a >10-fold increase in OxT expression, and this magnitude difference was 
confirmed by RTqPCR. A full list of the validated genes with their associated 
functions is presented in Table 4.
Gene ontology classes enriched in the differentially expressed genes 
8-OH-DPAT induced changes in gene expression (p<0.1) were analyzed 
using the DAVID 6.7 Functional Annotation Tool. Table 5 lists a selection of 






mPFC 13% (1/8) 25% (2/8)
mPOA 50% (5/10) 90% (9/10)
CA1 0% (0/8) 25% (2/8)
DRN 57% (4/7) 57% (4/7)
All 30% (10/33) 52% (17/33)
Table 3. Overview of validation of microarray predictions by RTqPCR. The numbers between 
parentheses indicate the number of genes validated.
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Figure 4. Linear regression analysis of fold-changes from microarray and RTqPCR data of all 
four brain regions combined, including (A) all genes tested, or (B) successfully validated genes 
only. FC, fold-change; MA, microarray.
Gene ID Region
P FC
Dir. Gene name Gene Function
qPCR MA qPCR MA
Casp9 mPFC 0.03 0.001 3.4 2.0 ↓ Caspase 9 Induction of apoptosis
Brpf3 mPFC 0.06 0.005 2.0 2.1 ↑
Bromodomain and PHD finger 
containing, 3
DNA-dependent regulation of  transcription
Lgi1 mPOA 0.01 <0.001 1.9 2.0
↓ Leucine-rich repeat LGI family, 
member 1
Predisposes to epilepsy; expression reduced in brain tumors 
(metastasis suppressor?)
Oxt mPOA 0.03 0.015 10.2 18.8 ↑ Oxytocin-neurophysin
Involved in cognition, tolerance, adaptation and complex social, 
sexual and maternal behavior
Dyrk3 mPOA 0.09 0.001 1.7 2.2 ↑
Dual-specificity tyrosine-
(Y-)phosphorylation regulated kinase 3
Peptidyl-tyrosine phosphorylation
Fads3 mPOA 0.06 0.002 1.7 2.6 ↑ Fatty acid desaturase 3 Fatty acid biosynthesis
P4hb mPOA 0.02 0.010 1.6 1.6 ↑ Prolyl 4-hydroxylase, beta polypeptide Protein folding; electron carrier activity
Dnpep mPOA 0.10 0.011 1.9 1.6 ↑ Aspartyl aminopeptidase Proteolysis




Gatad2a mPOA 0.04 0.002 2.2 1.9 ↑ GATA zinc finger domain containing 2A Negative regulation of  transcription; transcription factor activity
N-pac mPOA 0.07 0.009 1.9 1.8 ↑ Cytokine-like nuclear factor n-pac Phosphogluconate dehydrogenase (decarboxylating) activity
Mtmr6 CA1 0.09 0.005 1.4 5.9 ↓ Myotubularin related protein 6
Protein amino acid dephosphorylation; protein tyrosine 
phosphatase activity
Adcy1 CA1 0.10 0.004 1.6 2.0 ↑ Adenylate cyclase 1 (brain)
cAMP biosynthesis; intracellular signaling; calmodulin binding; 
overexpression enhances recognition memory and LTP in mouse
Gmpr2 DRN 0.01 0.004 1.5 1.3 ↑
Guanosine monophosphate reductase 
2
GMP catabolism; GMP reductase activity
Enc1 DRN <0.01 0.006 5.2 3.6 ↑ Ectodermal-neural cortex 1
Proteolysis; actin binding; cysteine-type endopeptidase activity;  
expression strongly induced by p53; interacts with Rb1
Map1lc3b DRN <0.01 0.004 1.7 1.3 ↑
Microtubule-associated protein 1  light 
chain 3 beta
Ubiquitin cycle; autophagy; microtubule-based process; 
neurogenesis
Vdac1 DRN 0.01 0.006 1.5 1.2 ↑ Voltage-dependent anion channel 1
Ion transport; apoptosis; synaptic transmission; learning; 
behavioral fear response; voltage-gated ion-selective channel 
activity
Table 4. List of validated genes. P, p-value; FC, fold-change; MA, microarray; Dir, direction of 
change.
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GO Term ID GO Term Description mPFC mPOA CA1 DRN
Energy production
GO:0006091 (BP)
Generation of precursor metabolites and 
energy
0.004 0.010
GO:0045333 (BP) Cellular respiration 0.025 0.003
GO:0006099 (BP) Tricarboxylic acid cycle 0.010 0.008
Mitochondrion
GO:0005739 (CC) Mitochondrion 0.029 0.009
Neural development
GO:0000902 (BP) Cell morphogenesis 0.028 0.009
GO:0043005 (CC) Neuron projection 0.020 0.043 0.022
GO:0007409 (BP) Axonogenesis 0.009
GO:0030424 (CC) Axon 0.018 0.012
Neurotransmission
GO:0032844 (BP) Regulation of homeostatic process 0.030
GO:0050804 (BP) Regulation of synaptic transmission 0.047
Protein transport
GO:0015031 (BP) Protein transport 0.005 0.028
Intracellular signal transduction
GO:0010627 (BP) Regulation of protein kinase cascade 0.001
GO:0009967 (BP) Positive regulation of signal transduction 0.003
GO:0080135 (BP) Regulation of cellular response to stress 0.030
GO:0043408 (BP) Regulation of MAPKKK cascade 0.035
Ion channel activity
GO:0022836 (MF) Gated channel activity 0.024
Learning and memory
GO:0007611 (BP) Learning or memory 0.006
Table 5. A selection of GO terms and genes, grouped into functionally related clusters that were 
altered by 8-OH-DPAT (p-values calculated by DAVID 6.7 Functional Annotation Tool). GO, 
gene ontology; BP, biological process; CC, cellular compartment.
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GO Term ID GO Term Description mPFC mPOA CA1 DRN
Energy production
GO:0006091 (BP)
Generation of precursor metabolites and 
energy
0.004 0.010
GO:0045333 (BP) Cellular respiration 0.025 0.003
GO:0006099 (BP) Tricarboxylic acid cycle 0.010 0.008
Mitochondrion
GO:0005739 (CC) Mitochondrion 0.029 0.009
Neural development
GO:0000902 (BP) Cell morphogenesis 0.028 0.009
GO:0043005 (CC) Neuron projection 0.020 0.043 0.022
GO:0007409 (BP) Axonogenesis 0.009
GO:0030424 (CC) Axon 0.018 0.012
Neurotransmission
GO:0032844 (BP) Regulation of homeostatic process 0.030
GO:0050804 (BP) Regulation of synaptic transmission 0.047
Protein transport
GO:0015031 (BP) Protein transport 0.005 0.028
Intracellular signal transduction
GO:0010627 (BP) Regulation of protein kinase cascade 0.001
GO:0009967 (BP) Positive regulation of signal transduction 0.003
GO:0080135 (BP) Regulation of cellular response to stress 0.030
GO:0043408 (BP) Regulation of MAPKKK cascade 0.035
Ion channel activity
GO:0022836 (MF) Gated channel activity 0.024
Learning and memory
GO:0007611 (BP) Learning or memory 0.006
complete list of terms will be published online. A significant P-value indicates 
that genes related to a given term are overrepresented in the list of differentially 
expressed genes.
Both in mPFC and mPOA, 8-OH-DPAT affected the expression of gene 
classes important to energy production and neural development. In the 
mPOA, the GO term generation of precursor metabolites and energy 
includes genes such as fatty acid desaturase 3 (FADS3) and oxoglutarate 
dehydrogenase (OGDH), which were both validated by RTqPCR. Additional 
gene classes altered in the mPOA, but not in the mPFC, are related to 
neurotransmission and protein transport. Altered expression of both OxT, 
implicated in neurotransmission [32] and complex sexual and social behaviors 
[33], and leucine-rich, glioma inactivated 1 (LGI1), which plays a role in the 
regulation of synaptic transmission, was validated in the mPOA by RTqPCR.
8-OH-DPAT-induced changes in gene expression in the CA1 were 
mostly unique to this brain region and included gene classes important to 
mitochondrial function, ion channel activity and learning and memory. The 
expression change of myotubularin related protein 6 (MTMR6, validated by 
RTqPCR), part of the GO term ion channel activity, and of adenylate cyclase 
1 (ADCY1), encoding an important enzyme that is activated by G-protein 
signaling and related to the overrepresented GO term learning or memory, 
were confirmed by RTqPCR.
Similar to mPFC and mPOA, 8-OH-DPAT affected gene classes related 
to neural development in the DRN. Other gene classes altered by 8-OH-
DPAT in the DRN are related to mitochondrial function (including the validated 
gene voltage-dependent anion channel 1; VDAC1), protein transport and 
intracellular signal transduction. While mitochondrial function and protein 
transport were also affected in other brain regions (see Table 5), changes in 
intracellular signal transduction were specific to the DRN.
Expression of candidate genes
expression of 5-HT1A, 5-HT2A, 5-HT7 and 5-HTT was measured in all four 
brain regions and compared between treatments (Figure 5). There was a trend 
for an increase in 5-HT1A transcripts in the mPFC (p<0.06), while expression 
of 5-HT1A autoreceptors in the DRN was not altered after chronic 8-OH-DPAT 
treatment. There was also a trend for decreased 5-HT7 expression in the CA1 
(p<0.08). 8-OH-DPAT elevated the expression of 5-HTT in the DRN (p<0.05). 
The increased 5-HTT expression was pronounced (approx. 15x), particularly 
considering the relatively subtle changes in expression in other genes. 5-HT2A 
expression was not altered in any of the brain regions analyzed.
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DISCUSSION
Despite the relative prevalence of personally distressing HSDD, nonhuman 
primate studies targeting potential genomic mechanisms of female sexual 
dysfunction are lacking. Studies using novel pharmacotherapeutic targets have 
so far only provided indirect evidence for potential candidate genes involved 
in HSDD, such as serotonin and dopamine receptors [3, 5]. To the best of our 
knowledge, we present the first large-scale transcriptomic study to investigate 
the sexually suppressive effects of a pharmacological manipulation on gene 
expression of more than 1500 genes in the nonhuman primate brain.
In rodents, microarray experiments have focused on the estrogenic 
regulation of gene expression in the hypothalamus [34]. Estrogen function 
in female rodents is intimately linked to sexual behavior. Estrogen facilitates 
sexually proceptive (appetitive) and receptive (consummatory) behavior in 
both rodents [35, 36] and nonhuman primates [37]. The studies show that 
estrogen priming in female rats leads to activation of genes that code for 
neurotransmitter receptors (α1B adrenoreceptor and muscarinic receptors) or 
facilitate neuronal growth in the ventromedial hypothalamic nucleus (VMH) 
[38]. Female rat estrogen priming also increases OxT receptor density in the 
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Figure 5. The expression profiles of 5-HT1A (in the mPFC), 5-HT7 (in the CA1) and 5-HTT (in 
the DRN) in response to chronic 8-OH-DPAT, as measured by RTqPCR. The expression levels 
are normalized to brain area specific normalization genes and are presented relative to those 
in the vehicle group (100%).
131
TRANSCRIPTOMIC MARKERS OF SEROTONIN-1A RECEPTOR ACTIVATION
5
in the mPOA/medial basal hypothalamus [41] and magnocellular neurons of 
the paraventricular and supra-optic nuclei [40, 42]. The translation of rodent 
findings to humans, however, is difficult in light of the strict hormonal control of 
female sexual function in rodents [34] compared to humans [43]. In contrast 
to rodents, but in line with human studies, marmosets permit studies of female 
sexual behavior in the context of pair-bonds [4, 10]. Moreover, marmosets 
emulate humans in demonstrating a degree of emancipation of female sexual 
behavior from estrogen determination [10, 44].
Hypothalamic oxytocin is over-expressed after chronic 8-OH-DPAT
Probably the most intriguing result of this study is the strong increase in 
OxT mRNA expression in the mPOA after chronic 8-OH-DPAT. This finding 
is of particular interest as the function of hypothalamic OxT has been closely 
associated with social and sexual behavior in rodents, non-human primates 
and humans [45-47]. OxT expression in the paraventricular (PVN) and 
supraoptic nuclei (SON) of the hypothalamus can be induced by activation 
of 5-HT1A receptors [42]. While the mPOA samples collected in the present 
study contain neither PVN nor SON, oxytocin expression in areas overlapping 
with the mPOA has previously been demonstrated in the female marmoset 
monkey [48]. The magnitude of the OxT increase in the present study (greater 
than 10-fold) is particularly striking, considering that the magnitude of 8-OH-
DPAT induced changes in gene expression was mostly below 2-fold. 
There is strong evidence for functional interaction of the serotonergic and 
oxytocinergic systems. Immunocytochemical and double-immunofluorescent 
techniques reveal that the density of 5-HTT fibers follows the distribution 
of OxT-containing neurons in the PVN and SON in macaques [49]. The 
5-HT1A agonist alnespirone [50], the 5-HT releasers p-choloroamphetamine 
and fenfluramine [51] as well as acute and chronic SSRI administration [52] 
stimulate OxT secretion in rats. Collectively, these studies support the notion 
that OxT synthesis and release is stimulated by 5-HT via 5HT1A receptors.
Interestingly, there is an apparent discrepancy between the present 
marmoset data, which associates overexpression of hypothalamic OxT with 
reduced female sexual receptivity, increased aggression and increased stress 
responsiveness, and the large body of literature that reports OxT function as 
supporting pro-social and pro-sexual behavior, and reducing stress reactivity 
[46, 53-54]. A possible explanation might be that while chronic 8-OH-DPAT 
treated females exhibit increased OxT expression in the mPOA, as well as 
likely increased estradiol-supported, 8-OH-DPAT-induced OxT release from 
the dendrites or soma of oxytocinergic neurons in the PVN and SON [42], such 
OxT increases may be part of a compensatory mechanism for 8-OH-DPAT-
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mediated sexual and social impairment. evidence for increased OxT action, 
however, such as increased social or sexual behavior, is absent, suggesting 
diminished OxT signaling through OTR. In rodents, estrogen depletion due 
to ovariectomy reduces or even abolishes OTR density in a brain region-
specific manner [39, 55], which might not be fully restored by the low, mid-
follicular phase level estradiol replacement used in our marmoset model. In 
addition, chronic 8-OH-DPAT diminishes estradiol receptor expression in the 
hippocampus of ovariectomized rats [56]. Estrogen priming is indeed necessary 
for OxT-induced facilitation of female sexual receptivity, at least in rodents 
[57]. Thus, with minimal expression of its receptor due to chronic 8-OH-DPAT 
in combination with relatively low circulating estradiol levels compared to mid-
cycle and luteal phase levels in ovary-intact females, enhanced hypothalamic 
OxT expression may have little functional impact. Validation of this hypothesis 
requires further studies of OTR expression and binding in the marmoset 
brain. The potential for pharmacotherapeutic treatment of HSDD, however, 
may arise through development of a serotonergic compound that increases 
hypothalamic OxT without impairing OTR function. We recently reported that 
female marmosets chronically treated with flibanserin, a 5-HT1A agonist and 
5-HT2A antagonist, attract more male sexual interest and show increased social 
grooming between partners, contrasting the behavioral effects of 8-OH-DPAT 
[4]. In this context, it would be of particular interest to investigate whether the 
pro-sexual and pro-social effects of flibanserin in the female marmoset are 
mediated by increased hypothalamic OxT release that is not diminished by 
impaired action.
An alternative explanation for the paradoxical association of increased 
hypothalamic OxT expression and reduced sexual receptivity, increased 
aggression and stress responsiveness may come from the magnitude of the 
OxT elevation in the mPOA. While studies that link increased social behavior 
to elevated OxT mRNA levels report small fold-changes, typically below 1.5-
fold [42, 58], the more than 10-fold increase in hypothalamic OxT transcription 
in 8-OH-DPAT treated marmosets might reflect a major disruption of a finely 
tuned balance in the oxytocinergic regulation of female social and sexual 
behavior, and stress responsiveness. OxT furthermore binds with a low affinity 
to vasopressin-1a receptors (AVP-1a) [59], including marmosets [60] and 
humans [61]. A more than 10-fold increased OxT expression might thus lead 
to enhanced AVP-1a activity in the mPOA of 8-OH-DPAT, but not in vehicle 
treated animals, and result in sexual rejection [62] and aggression [63].
Brain region-specific effects of chronic 8-OH-DPAT
In agreement with Figure 1, the effect of 8-OH-DPAT on the expression 
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of individual genes is mostly region-specific, with only a small number of 
differentially expressed genes overlapping between brain regions. This 
finding was expected, given the vast differences in basal molecular make-up 
of different brain regions [27], including differential 5-HT1A densities that likely 
underlie the region-specific, 8-OH-DPAT induced transcriptomic changes. 
The regional specificity of 8-OH-DPAT-induced transcriptomic changes is also 
reflected in brain region-specific alterations of several classes of functionally 
related genes (Table 3), such as a mPOA-specific change in neurotransmission 
(GO term regulation of synaptic transmission), CA1-specific changes in ion 
channel activity (GO term gated channel activity) and learning and memory 
(GO term learning or memory), and a DRN-specific change in intracellular 
signal transduction (GO terms regulation of protein kinase cascade, positive 
regulation of signal transduction and regulation of MAPKKK cascade).
Not surprisingly, 8-OH-DPAT-induced alteration of the GO term learning or 
memory was restricted to the hippocampal CA1 subregion, a structure that is 
intimately implicated in episodic and semantic memory processes [64, 65]. 
In mice, overexpression of ADCY1 leads to elevated long-term potentiation 
(LTP), increased recognition memory and slower rates of extinction of 
contextual memory [66]. 8-OH-DPAT increased transcription of ADCy1 in the 
marmoset CA1, suggesting that memory function could play a role in altered 
pairmate interaction dynamics. These changes might be caused by 8-OH-
DPAT-induced downregulation of 5-HT7 receptors in the CA1 (Figure 4), a 
hypothesis that is supported by rodent studies that implicate 5-HT7 function in 
contextual learning [67] and memory consolidation [68].
Brain region-overlapping effects of chronic 8-OH-DPAT
Interestingly, and despite the small number of overlapping genes between 
brain regions, 8-OH-DPAT affected several gene classes that are similar 
between brain regions and comprise identical or closely related GO terms. 
Energy production, for example, including the GO terms generation of 
precursor metabolites and energy, cellular respiration and tricarboxylic acid 
cycle, was affected by 8-OH-DPAT in mPFC and mPOA, which are both major 
postsynaptic projection areas of serotonergic neurons originating from the 
raphé nuclei [69]. Changes in energy production may reflect altered energy 
demands due to a changed state of brain activation in the mPFC and mPOA 
following 8-OH-DPAT [20, 70], which may be mediated by OxT [71] and may 
underlie the observed changes in sexual and social behavior after chronic 
8-OH-DPAT.
As another example of a more global effect of 8-OH-DPAT, alterations of 
gene classes related to neural development in mPFC, mPOA and DRN, and to 
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neurotransmission in the mPOA, implicate that chronic administration of 8-OH-
DPAT leads to a global modification of neural circuitries and communication 
between neurons. The GO terms axon/axonogenesis and neuron projection 
were significantly altered in all three regions. Increased expression of genes 
involved in axon formation, axon guidance and neuron migration in the 
mPFC and mPOA, including OxT, suggests that chronic activation of 5-HT1A 
receptors by 8-OH-DPAT likely leads to a structural reorganization of neural 
circuits within the serotonergic projection areas. In rodents, altered expression 
of genes involved in neuronal growth has been described and linked to altered 
sociosexual behaviors [72].
Candidate gene approach: Changes in serotonin receptor and 
transporter expression may underlie altered signal transduction, neural 
development and oxytocin function
The 5-HT1A and 5-HT7 receptors are the primary pharmacological targets of 
8-OH-DPAT and are both coupled to G-proteins to induce intracellular signal 
transduction cascades upon activation [73]. The DRN is characterized by high 
presynaptic 5-HT1A and moderate 5-HT7 density [74, 75]. It is therefore not 
surprising that 8-OH-DPAT affected GO terms associated with intracellular 
signal transduction in the DRN. The 5-HT1A receptor couples negatively via 
G-proteins (αi) to adenylate cyclase and promotes inward rectifying K
+ currents 
producing hyperpolarization [76], while the 5-HT7 receptor couples to Gαs and 
activates both Gs-sensitive and Gs-insensitive adenylate cyclase isoforms. 
5-HT1A receptors in transfected cell lines decrease intracellular Ca
2+ and 
activate phospholipase C, while 5-HT7 receptors increase intracellular Ca
2+ 
(reviewed in [73]). Given the high density of 5-HT1A receptors on the presynaptic 
soma of serotonergic neurons, the present results indicate that 8-OH-DPAT 
may alter MAPKKK cascades in the DRN via inhibition of adenylate cyclase 
to modify downstream mitochondrial function (GO term mitochondrion), 
protein transport [77] and neural development (GO terms cell morphogenesis, 
neuron projection and axonogenesis). Changes in the postsynaptic projection 
areas (mPFC, mPOA and CA1) could either be indirect results of diminished 
serotonergic neurotransmission due to altered DRN function, or due to direct 
activation of postsynaptic 5-HT1A and 5-HT7 receptors by 8-OH-DPAT.
8-OH-DPAT drastically increased 5-HTT expression in the DRN, and tended 
to increase 5-HT1A expression in the mPFC (Figure 4). Activation of 5-HT1A 
autoreceptors in the DRN by 8-OH-DPAT likely suppresses serotonergic 
activity [73], which might trigger a compensatory upregulation of 5-HTT in the 
DRN and of 5-HT1A in the mPFC to restore the serotonergic tone. In contrast, 
the expression of 5-HT7 in the CA1 tended to be decreased by chronic 8-OH-
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DPAT, indicating a brain region-specific desensitization of 5-HT7 receptors. 
Repeated, 8-OH-DPAT induced stimulation of normally expressed 5-HT1A 
receptors in the mPOA might present a direct mechanism for increased 
hypothalamic OxT expression [42].
Methodological considerations
The current study presents a transcriptomic conclusion of a long-term 
marmoset experiment designed to explore the effects of chronic serotonergic 
manipulation on female sexual and social behavior [4], endocrine function [19] 
and neural activity parameters [20]. In contrast to our previous in vivo studies in 
which different treatments were administered to the same subjects, the nature 
of this transcriptomic study requires a between-subject comparison. Due to 
small group sizes (n=4), and to decrease variation in expression profiles, we 
did not experimentally explore the potential effects of contrasting 8-OH-DPAT 
induced changes in gene expression in females with and without estradiol 
replacement, as we provided estradiol replacement to all test subjects for the 
entire duration of the study. The estradiol regimen chosen for this study provides 
the ovariectomized female marmosets with estradiol levels comparable to the 
physiological levels previously reported for female marmosets in the mid-
follicular phase of the ovarian cycle, supporting modest expression of female 
marmoset sexual behavior [10]. Estradiol priming in rodents is necessary for 
the full expression of female sexual behavior [36], including oxytocin-induced 
facilitation of sexual receptivity [57], and is also required for the activation of 
genes coding for oxytocin, norepinephrine and acetylcholine receptors [38, 
39, 55]. Thus, estradiol replacement was the regimen of choice for this study, 
despite that it has surprisingly been without effects on in vivo results in the 
female marmoset [4].
Validation of microarray predictions by RTqPCR was successful in 52% of 
the measured genes (including seven genes that were just below significance), 
with notable differences between brain regions. Given the small responses with 
the majority below two-fold, validation success rates were reasonably high for 
mPOA and DRN (57 – 90%). Validation was however low at 25% for mPFC and 
CA1, indicating that microarray data should be cautiously interpreted for these 
two regions. A 1.5 – 2-fold change is commonly considered as cutoff, below 
which microarray and RTqPCR data begin to lose correlation [78]. Despite 
the small changes, the correlation between microarray and RTqPCR data in 
this study was very strong (r = 0.897, including non-validated genes, all four 




In a marmoset model of hypoactive female sexual function, we 
demonstrate that chronic 5-HT1A activation leads to lasting, brain region-
specific transcriptomic changes. Analysis of classes of functionally related 
genes revealed that modification of neural circuitries in the mPFC, mPOA and 
DRN, altered energy demands in the mPFC and mPOA, and altered learning 
and memory may underlie 8-OH-DPAT-induced decrease in sexual receptivity, 
increase in aggression towards the male pairmate, and higher stress 
reactivity. 5-HTT expression in the DRN is increased, possibly via alterations 
in intracellular signal transduction within the DRN induced by chronic 5-HT1A 
autoreceptor activation. Chronic post-synaptic 5-HT1A activation in the mPOA 
could be responsible for augmented hypothalamic OxT expression in 8-OH-
DPAT treated female marmosets. enhanced OxT expression in the mPOA 
may disrupt the oxytocinergic regulation of social and sexual behavior.
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The main goal of this thesis is to investigate serotonergic (5-HT) regulation 
of female sexual behavior in marmoset monkeys using the 5-HT1A agonist/
5-HT2A antagonist flibanserin and the 5-HT1A agonist 8-OH-DPAT. The specific 
objectives are to assess the effects of chronic flibanserin and 8-OH-DPAT 
treatments on (1) sexual and social behavior, (2) hypothalamic-pituitary-
adrenal (HPA) axis function, (3) brain activity, and (4) gene transcription in the 
brain.1
1. OVeRVIeW OF THe eFFeCTS OF FLIBANSeRIN AND 8-OH-
DPAT IN THe FeMALe MARMOSeT MONKey
Table 1 presents an overview of the effects of repeated daily administration 
of flibanserin (15 mg/kg, PO) and 8-OH-DPAT (0.1 mg/kg, SC) on 
ovariectomized female marmosets. More detailed information regarding 
the timing of experiments with respect to treatment duration and regarding 
estradiol supplementation is shown in Chapter 1, Figure 7, study design.
1.1 Sexual and social behavior
The main objective in Chapter 2 was to quantify the effects of chronic 
flibanserin and 8-OH-DPAT on sexual and social interactions between treated 
females and their untreated male pairmates. Repeated observations of the 
pairmates’ interactions at reunion following a 90 minute separation revealed 
remarkable and contrasting differences between flibanserin and 8-OH-
DPAT on marmoset pair behavior, despite the drugs’ shared 5-HT1A agonist 
properties.
Chronic flibanserin treatment increased the female’s sexual attractiveness 
to her male pairmate (more frequent male inspection of the female’s genital 
area) and grooming between pairmates. While increased grooming indicates 
a flibanserin-induced strengthening of the pair bond between marmoset 
partners, female sexual behavior per se was not altered by flibanserin. Chronic 
flibanserin also enhanced female genital and non-genital self-grooming. 
Notably, flibanserin administration did not cause an acute occurrence of the 
serotonin (5-HT) behavioral syndrome, commonly induced by other 5-HT1A 
agonists, as well as by 5-HT2A/2C agonists [1-3]. 
In contrast to flibanserin, 8-OH-DPAT (0.1 mg/kg, SC, 4-16 weeks) 
transiently induced an acute 5-HT behavioral syndrome, which persisted 
during the course of chronic administration. Chronic 8-OH-DPAT decreased
1 Flibanserin data are not available for brain activity (analyses ongoing) and gene transcrip-
tion (not assessed as per agreement with Boehringer Ingelheim, proprietor and developer of 
flibanserin).
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Parameter Flibanserin 8-OH-DPAT Chapter
Behavior 2
Female sexual proceptivity --- ---
Female sexual receptivity ---   ↓*
Female attractiveness to male ↑   (↓)*
Allogrooming ↑ (↓)
Aggression ---   ↑*
Female self-grooming ↑ ---
Serotonin behavioral syndrome --- ↑
HPA axis 3
Morning basal cortisol --- ---
5-HT1A agonist challenge ACTH --- ---
Cortisol --- ---
Restraint test ACTH 15 min ---  ↑*
ACTH 30 min ↑ ↑
ACTH 210 min --- ---
Cortisol 15 min --- ---
Cortisol 30 min --- ---
Cortisol 210 min --- ↑






mOCC n/a  ↓*
Gene transcription in the brain 5
5-HT1A in mPFC n/a (↑)
5-HT1A in mPOA, CA1, DRN n/a ---
5-HT2A in mPFC, mPOA, CA1, DRN n/a ---
5-HT7 in CA1 n/a (↓)
5-HT7 in mPFC, mPOA, DRN n/a ---
5-HTT in DRN n/a ↑
5-HTT in mPFC, mPOA, CA1 n/a ---
OXT in mPOA n/a ↑
OXT in mPFC, CA1, DRN n/a ---
Molecular functions 5
Neural development n/a mPFC, mPOA, DRN
Neurotransmission n/a mPOA
Energy production n/a mPFC, mPOA
Mitochondrial function n/a CA1, DRN
Protein transport n/a mPOA, DRN
Learning and memory n/a CA1
Ion channel activity n/a CA1
Intracellular signal transduction n/a DRN
Table 1. Summary of chronic flibanserin and 8-OH-DPAT actions in the female marmoset 
monkey (cumulated data from Chapters 2-5). ↑, increased function; ↓, decreased function;
---, not changed; n/a, data not available; *, parameter correlated with female sexual receptivity; 
8-OH-DPAT, R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin; 5-HT1A, serotonin-1A receptor; 
5-HT2A, serotonin-2A receptor; 5-HT7, serotonin-7 receptor; 5-HTT, serotonin transporter; OxT, 
oxytocin; mPFC, medial prefrontal cortex; mPOA, medial preoptic area; VMH, ventromedial 





Parameter Flibanserin 8-OH-DPAT Chapter
Behavior 2
Female sexual proceptivity --- ---
Female sexual receptivity ---   ↓*
Female attractiveness to male ↑   (↓)*
Allogrooming ↑ (↓)
Aggression ---   ↑*
Female self-grooming ↑ ---
Serotonin behavioral syndrome --- ↑
HPA axis 3
Morning basal cortisol --- ---
5-HT1A agonist challenge ACTH --- ---
Cortisol --- ---
Restraint test ACTH 15 min ---  ↑*
ACTH 30 min ↑ ↑
ACTH 210 min --- ---
Cortisol 15 min --- ---
Cortisol 30 min --- ---
Cortisol 210 min --- ↑






mOCC n/a  ↓*
Gene transcription in the brain 5
5-HT1A in mPFC n/a (↑)
5-HT1A in mPOA, CA1, DRN n/a ---
5-HT2A in mPFC, mPOA, CA1, DRN n/a ---
5-HT7 in CA1 n/a (↓)
5-HT7 in mPFC, mPOA, DRN n/a ---
5-HTT in DRN n/a ↑
5-HTT in mPFC, mPOA, CA1 n/a ---
OXT in mPOA n/a ↑
OXT in mPFC, CA1, DRN n/a ---
Molecular functions 5
Neural development n/a mPFC, mPOA, DRN
Neurotransmission n/a mPOA
Energy production n/a mPFC, mPOA
Mitochondrial function n/a CA1, DRN
Protein transport n/a mPOA, DRN
Learning and memory n/a CA1
Ion channel activity n/a CA1
Intracellular signal transduction n/a DRN
female sexual receptivity and increased aggressive interactions between male-
female pairmates, while tending to decrease female sexual attractiveness and 
grooming between pairmates.
The data described in Chapter 2 resemble studies performed in female 
rodents that show that flibanserin increases the female’s sexual attractiveness 
and display of proceptive and receptive sexual behavior [4], while 8-OH-DPAT 
inhibits lordosis [5], an indicator of female sexual receptivity in rodents. Chapter 
2 thus presents the first study to confirm the sexual attractiveness-enhancing 
effects of flibanserin and sexually inhibitory effects of 8-OH-DPAT in a non-
human primate. In humans, flibanserin improved satisfying sexual events, 
desire and the female sexual function index, and reduced sexual distress [6, 
7]. While flibanserin did not alter the frequency of female sexual behavior 
in the marmoset, enhanced female sexual attractiveness and strengthened 
pair-bond between marmoset pairmates suggest that the observed beneficial 
effects of flibanserin on female sexual function in humans might be rooted on 
improved partner interactions and intimacy in the relationship between long-
term sexual partners.
1.2 HPA axis function
In Chapter 3, the impact of chronic flibanserin and 8-OH-DPAT on HPA axis 
function was investigated to delineate the possibility of a HPA axis-mediated 
mechanism in the serotonergic regulation of female sexual behavior.
Chronic flibanserin neither affected circulating morning basal cortisol 
levels, nor ACTH and cortisol responses to an acute 5-HT1A agonist challenge. 
Flibanserin treated females, however, displayed an increased ACTH response 
at 30 minutes during a restraint test, while cortisol levels were not altered 
during the 30 minutes of restraint, nor at 3 hours after return to the home cage.
Similar to flibanserin, neither circulating morning basal cortisol levels nor 
ACTH and cortisol responses to an acute 5-HT1A agonist challenge were 
altered by chronic 8-OH-DPAT. The restraint-induced increase in ACTH was 
enhanced by chronic 8-OH-DPAT at both 15 and 30 minutes, while cortisol 
was elevated at 3 hours after return to the home cage, in comparison to 
vehicle control treatment. In 8-OH-DPAT, but not in flibanserin treated females, 
exaggerated ACTH responses at 15 minutes of restraint were associated 
with reduced female sexual receptivity, reduced sexual attractiveness and 
increased aggression between pairmates.
Importantly, enhanced ACTH responses to restraint were correlated with 
increased aggression and reduced sexual receptivity in 8-OH-DPAT treated 
female marmosets, supporting the hypothesis that increased stress reactivity 
might contribute to inhibition of sexual behavior. Such correlations were 
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absent in flibanserin treated females, suggesting no inhibitory role of HPA axis 
reactivity on female sexual function.
1.3 Cerebral glucose metabolism
In Chapter 4, a PET/MRI functional brain imaging experiment was described 
that was designed to measure cerebral glucose metabolism, an indicator of 
neural activity, in chronic 8-OH-DPAT or vehicle treated female marmosets 
during sexual and social interactions after a 90 minute separation from their 
male pairmates. Radiolabeled [18F]fluorodeoxyglucose (FDG) was infused 
to the femoral vein immediately prior to a 30 minute pair test. The females 
were subsequently imaged by PeT under isofluorane anesthesia. Structural 
MRI scans were recorded and overlaid on the PET images to improve the 
visualization of anatomical structures. PeT scans using 5-HT1A- and 5-HTT-
specific radiotracers were also performed. Data processing and analysis of 
the latter scans are still ongoing, and the results are not within the scope of 
this thesis.
8-OH-DPAT decreased glucose metabolism, an indicator of neural activity, 
in the females’ medial occipital cortex (mOCC) while interacting with their 
male partners. Decreased neural activity in the mOCC was associated with 
reduced female sexual receptivity, suggesting 8-OH-DPAT induced altered 
female perception of interactions with their male pairmate. However, glucose 
metabolism in pre-defined regions of interest (ROI), the medial prefrontal 
cortex (mPFC), medial preoptic area (mPOA), ventromedial hypothalamic 
nucleus (VMH), CA1 field of the hippocampus (CA1) and dorsal raphé nucleus 
(DRN), hypothesized to play a central role in sexual function and serotonin 
neurotransmission, were not altered.
1.4 Gene transcription in the marmoset brain
In Chapter 5, the transcriptomic effects of chronic 8-OH-DPAT 
administration to female marmoset monkeys were reported, complementing 
an open, hypothesis-generating microarray approach using the marmoset-
specific eUMAMA microarray, with a candidate gene approach using real-time 
quantitative PCR (RT-qPCR) to measure serotonin receptor and transporter 
transcripts. In keeping experimental parameters consistent between chapters, 
the same brain regions of interest (mPFC, mPOA, CA1, DRN) as in Chapter 4 
were selected, with exception of the VMH, which was not analyzed in Chapter 
5.
Chronic 8-OH-DPAT, in a brain region-specific fashion, altered the 
expression of gene clusters linked to neural development (mPFC, mPOA, 




mitochondrial function (CA1, DRN), protein transport (mPOA, DRN), learning 
and memory (CA1), ion channel activity (CA1), and intracellular signal 
transduction (DRN), suggesting global changes in gene regulation of neuronal 
function induced by 8-OH-DPAT that involve changes in cellular metabolism, 
communication between neurons and axonal growth.
Furthermore, 8-OH-DPAT increased 5-HT transporter (5-HTT, or SeRT) 
mRNA expression in the DRN and oxytocin (OxT) mRNA expression in the 
mPOA. There was a statistical trend towards increased 5-HT1A expression in 
the mPFC and towards reduced 5-HT7 expression in the CA1. Activation of 
5-HT1A autoreceptors in the DRN by 8-OH-DPAT likely suppressed serotonergic 
activity [8], which may have triggered a compensatory upregulation of 5-HTT 
in the DRN and of 5-HT1A in the mPFC to restore the serotonergic tone. In 
contrast, decreased 5-HT7 expression in the CA1 may reflect a brain region-
specific desensitization of 5-HT7 receptors. As 8-OH-DPAT directly interacts 
with 5-HT1A and 5-HT7 receptors, their brain region-specific expression 
changes may present the most upstream molecular mechanisms underlying 
sexual and affiliative suppression induced by chronic 8-OH-DPAT.
While resolution was a limiting factor in the brain imaging study (Chapter 
4), the gene expression experiments described in Chapter 5 benefitted from 
high anatomical precision provided by laser-microdissection techniques, 
which were used to dissect the ROIs prior to RNA isolation. Both Chapter 
4 and Chapter 5, however, indicate that the selected ROIs (mPFC, mPOA, 
CA1 and DRN) may not comprehensively cover the brain areas involved in 
8-OH-DPAT induced modulation of female sexual and social behavior. For 
example, Chapter 5 highlights increased oxytocin expression in the mPOA, 
but does not investigate expression levels in oxytocin-rich areas such as the 
paraventricular and supraoptic nuclei of the hypothalamus. Future studies 
should also target the expression of oxytocin receptor in marmoset brain areas 
with high receptor densities, including the basal forebrain cholinergic nuclei, 
nucleus basalis of Meynert, the diagonal band of Broca, and the amygdala [9, 
10], areas that were not part of the pre-selected ROIs.
2. POTeNTIAL MeCHANISMS OF ACTION OF FLIBANSeRIN 
AND 8-OH-DPAT IN THe ReGULATION OF FeMALe SexUAL 
AND SOCIAL BeHAVIOR
In assessing how flibanserin and 8-OH-DPAT may affect female sexual 
function, the data collected in Chapters 2-5 point towards a complex, multi-
modal mechanism of serotonergic regulation of female sexual function. Thus, 
flibanserin’s and 8-OH-DPAT’s potential modes of action in regulating female 
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sexual behavior will be discussed in the framework of a model that involves 
four distinct, but interactive modules (Figure 1).
The core component of this model entails a hypothalamic unit, referred 
to as the regulatory module of female sexual and social behavior, which 
integrates relevant sensory information and produces sexual and social 
behavioral responses. Sexual and social behaviors are joined into a single unit, 
consistent with the results obtained in Chapter 2 that highlight the significance 
of pair-bond quality for female sexual behavior. This module is influenced by 
the other three modules. A monoamine regulatory module can exert either 
excitatory or inhibitory leverage, as outlined in Chapter 1, Figure 3: Excitatory-
Inhibitory model of female sexual behavior (adapted from [11]). A HPA axis 
module accounts for the potential influence of stress hormones on female 
sexual behavior, while a pair-bond, experience and memory module applies 
a more integrative, holistic approach and emphasizes the important findings










































sexual behavior, social behavior
Figure 1. Four interacting modules through which flibanserin and 8-OH-DPAT modulate 
female sexual and social behavior. Circle and arrow size indicate relative impact of the 
respective module on female sexual and social behavior according to the observations described 
in Chapters 2-5 and additional data reported in [12, 13]. HPA, hypothalamus-pituitary-adrenal; 
mPFC, medial prefrontal cortex; DRN, dorsal raphé nucleus; VTA, ventral tegmental area; LC, 
locus coeruleus; PVN, paraventricular hypothalamic nucleus; mPOA, medial preoptic area; 




of Chapters 2, 4 and 5 that implicate relationship dynamics and cognitive 
processes in the regulation female sexual behavior. The four modules are 
briefly described in the following sections.
2.1 Monoamine regulatory module
Pharmacological approaches based on manipulation of serotonin receptors, 
particularly of the 1A and 2A subtypes, have recently emerged in animal models 
of female sexual dysfunction [4, 14, 15] and as putative treatments for HSDD in 
women [6, 7]. The monoamine regulatory module integrates evidence derived 
from rodent studies, as modified from Stahl et al [16], in which flibanserin and 
8-OH-DPAT selectively alter serotonergic, dopaminergic and noradrenergic 
neurotransmission in a brain region-specific manner. Pyramidal neurons in 
the prefrontal cortex (PFC) process sensory and cognitive inputs to the PFC 
and send glutamatergic projections to, among others, brainstem monoamine 
centers for 5-HT (DRN), for DA (ventral tegmental area, VTA) and for Ne 
(locus coeruleus, LC). These connections can either be direct, resulting in 
monoamine release, or indirect via inhibitory GABAergic (γ amino butyric acid) 
interneurons, in which case monoamine release decreases.
Flibanserin activates 5-HT1A and inhibits 5-HT2A receptors on PFC 
pyramidal neurons, leading to increased DA and Ne, but decreased 5-HT 
levels in the mPFC [12], purportedly by selective inhibition of pyramidal 
neurons that excite brainstem serotonergic neurons (decrease in 5-HT) 
and GABAergic interneurons in the VTA and LC (increase in DA and NE) 
[16]. Interestingly, we found that neural activity was indeed decreased in 
the mPFC of flibanserin treated female marmosets [AK Converse and DH 
Abbott, personal communication], consistent with the hypothesized inhibition 
of pyramidal neurons by flibanserin.
In contrast to flibanserin, 8-OH-DPAT preferentially binds to 5-HT1A 
receptors located on GABAergic interneurons, but not pyramidal neurons of 
the PFC, causing enhanced pyramidal cell firing in the PFC [17]. Increased 
activation of dopaminergic and noradrenergic neurons in the VTA and LC 
through these pyramidal neurons would explain the cortical increase in DA 
and Ne that is observed after systemic administration of 8-OH-DPAT [18]. 
Compared to flibanserin, however, the increase in DA is more modest [11]. 
5-HT levels have been shown to remain unaltered [13, 18], possibly due to 
direct activation of counteractive presynaptic 5-HT1A autoreceptors in the 
DRN, or due to upregulated 5-HTT function in the DRN in response to chronic 
5-HT1A activation, as suggested by the marmoset data described in Chapter 5.
As proposed by the Excitatory-Inhibitory model of female sexual behavior 
(Chapter 1, Figure 3, [11]), DA and Ne activate the regulatory module of 
152
female sexual and social behavior (section 2.4) to facilitate sexual behavior, 
while 5-HT has an inhibitory effect. Increased DA and Ne and decreased 5-HT 
after flibanserin is thus consistent with increased sexual attractiveness and 
affiliative behavior observed in flibanserin treated female marmosets (Chapter 
2). 8-OH-DPAT likely increases excitatory DA and Ne inputs to the regulatory 
module of female sexual and social behavior, but more moderately compared 
to flibanserin, without affecting the inhibitory 5-HT input. The expected net 
effect of 8-OH-DPAT on sexual and social behavior in the female marmoset 
would thus be slightly pro-sexual and pro-social, which contrasts the results 
shown in Chapter 2. This discrepancy will be discussed in section 2.4 below.
Projected module effect on sexual and social behavior:
Flibanserin ↑; 8-OH-DPAT (↑) 2
2.2 HPA axis module
Pharmacological manipulations of serotonin receptors commonly 
activate the HPA axis. The HPA axis is a key neuroendocrine component 
in the physiological response to stress that generally suppresses female 
reproductive function [19]. Cortisol interacts with the hippocampus and 
amygdala which indirectly regulate the HPA axis by modulating the processing 
of stressful information, involving inhibitory GABAergic neuron projections to 
the PVN [20]. Adrenergic and noradrenergic projections from the nucleus of 
the solitary tract (NTS) [21, 22] and from the LC [23] can modulate the HPA 
axis responsiveness to stress.
In Chapter 3, evidence was presented for flibanserin and 8-OH-DPAT 
induced HPA axis sensitization in response to a stressor. In 8-OH-DPAT, but 
not in flibanserin treated females, increased ACTH responses to restraint 
were positively correlated with increased sexual rejection. Furthermore, only 
8-OH-DPAT, but not flibanserin, elevated cortisol levels several hours after 
termination of the stressor. 
Chronic flibanserin might enhance the HPA axis response to a stressor by 
inhibiting the modulatory, inhibitory GABAergic inputs from the hippocampus 
or amygdala, or by activating the stimulatory noradrenergic inputs from the 
NTS and LC, causing exaggerated ACTH release to restraint stress. Chronic 
8-OH-DPAT might enhance the ACTH response to restraint stress in a similar 
way as flibanserin by changing modulatory and/or activating inputs to the 
PVN. Such stress-induced rises in ACTH are likely independent from acute 
2 Upwards pointing arrows indicate that the module exerts pro-sexual and pro-social influence, 





5-HT1A actions of flibanserin and 8-OH-DPAT [24]. In contrast to flibanserin, 
8-OH-DPAT also elevates cortisol levels following a stressor. elevated cortisol 
might suppress female sexual receptivity and induce aggression, consistent 
with the observation that exaggerated ACTH responses to a stressor correlate 
with agonistic and sexual rejection behavior in 8-OH-DPAT treated female 
marmosets (Chapter 3).
Projected module effect on sexual and social behavior:
Flibanserin unaltered; 8-OH-DPAT ↓
2.3 Pair-bond, experience and memory module
In humans, psychosocial factors such as partnership quality, previous 
sexual experiences and personal, social and cultural expectations [25-31] are 
important determinants of women’s sexuality (see Chapter 1). Interpersonal 
distress is in fact a central component in the diagnosis of hypoactive sexual 
desire disorder (HSDD) in women [32]. It is in this context that marmoset data 
on flibanserin’s actions, outlined in Chapters 2-5, may add the most important 
contribution to understanding flibanserin’s action on HSDD in women. The 
pair-bond, experience and memory module links the effects of flibanserin 
and 8-OH-DPAT on female sexual behavior to experimental evidence that 
partner interactions (Chapter 2), stress reactivity (Chapter 3), cortical glucose 
metabolism (Chapter 4) and learning and memory processes (Chapter 5) may 
all partake in regulating female sexual function.
In Chapter 2, it was demonstrated that both flibanserin and 8-OH-DPAT 
not only affected the treated female’s behavior towards her partner, but also 
altered the untreated male’s social behavior towards the female, clearly 
implicating altered relationship dynamics between the partners. As outlined 
in Chapter 1, sexual behavior in women entails a complex interplay between 
psychosocial, hormonal and neural factors and requires hypothalamic, limbic 
and cortical brain structures for its regulation [11].
Similar factors may play a role in the female marmoset monkey. For 8-OH-
DPAT, such psychosocial, hormonal and neural factors were determined in 
Chapters 2-5. Reduced female sexual receptivity was associated with more 
frequent agonistic interactions between pairmates (Chapter 2), increased 
endocrine stress reactivity (Chapter 3) and reduced glucose metabolism in 
the occipital cortex (Chapter 4). Reduced glucose metabolism in the occipital 
cortex suggests an 8-OH-DPAT-induced impairment in the perception of visual 
salience in social interactions with the long-term sexual partner. Agonistic 
social interactions, as well as increased stress reactivity, may cause sexual 
signals from the male partner to be negatively interpreted and rejected, 
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thus establishing a negative association with the sexual partner. Chapter 5 
highlights that 8-OH-DPAT affects the expression of hippocampal genes that 
are linked to learning and memory. Learning negative associations with the 
sexual partner and remembering previous agonistic interactions could indeed 
impair the pair-bond between marmoset pairmates and negatively affect 
female sexual function.
For flibanserin, behavioral data indicate a positive shift in social and sexual 
behavior that is built on improved pair bonds (Chapter 2). Brain activity and 
transcriptomic data, however, are not yet available.
Projected module effect on sexual and social behavior:
Flibanserin ↑; 8-OH-DPAT ↓
2.4 Regulatory module of female sexual and social behavior
This module relates to a key finding described in Chapter 5, that 8-OH-DPAT 
affects the transcription of hypothalamic oxytocin, to a previous marmoset 
study employing the same study design [33], and places it in context of a 
theoretical framework proposed by Choleris et al [34], the four-gene micronet 
of social behavior regulation, described below.
The hypothalamus, specifically the mPOA and VMH, plays a central role 
in the regulation of female sexual behavior by integrating sexually-relevant 
sensory inputs with excitatory and inhibitory neurotransmitter and sex 
hormone signals, thus controlling female sexual behavior (reviewed in [11, 
35]. The essential function of the mPOA and VMH in the generation of sexual 
behavior in female and male marmoset monkeys is confirmed by lesion and 
functional imaging studies [36-39]. In rodents, oxytocin immunoreactivity and 
mRNA expression in the mPOA has been associated with social behavior 
[40, 41], and infusion of oxytocin into the mPOA increases female sexual 
receptivity [42]. It is however possible that the detection of oxytocin mRNA 
in the mPOA may reflect mRNA molecules stored in dendritic projections of 
oxytocin neurons located in the PVN [43].
The mPOA receives a large number of projections from the PVN, which 
also sends efferents to the amygdala [44]. The PVN is a major site of oxytocin 
production, which can act centrally as a neuropeptide through oxytocin 
receptors expressed in the mPOA and amygdala to regulate maternal, social 
and sexual behavior [45-49]. Oxytocin thus serves as a prominent connection 
between the pair-bond, experience and memory module (Section 2.3), and 
the regulatory module of female sexual and social behavior presented in this 
section.




oxytocin receptor and the estrogen receptors alpha and beta (eRα, eRβ), in 
the regulation of social recognition and ultimately in the regulation of affiliation, 
pair bonds, aggression and sex [50]. In this model, estradiol plays a crucial 
role in the expression of oxytocin in the PVN and PVN dendrites that extend to 
other hypothalamic areas, and of oxytocin receptors in the amygdala. Signaling 
through the oxytocin receptor initiates a cascade of events (described in [35, 
51]) that facilitate social recognition and promote or prevent the display of 
sexual behavior.
Chronic 8-OH-DPAT increases the expression of oxytocin in the mPOA 
(Chapter 5) and likely in the PVN [52]. 8-OH-DPAT, however, downregulates 
the expression of estrogen receptors [53], which are essential for oxytocin 
receptor function in the amygdala [34]. Ovariectomy may further impair 
oxytocin receptor expression [54]. Thus, and despite elevated hypothalamic 
oxytocin expression, the cumulative effects of chronic administration and 
ovariectomy might suppress oxytocin signaling through its receptor and cause 
sexual rejection and aggression between marmoset pairmates (Chapter 2; 
discussion in Chapter 5). Furthermore, the impact of increased excitatory 
input from the monoamine regulatory module on the regulatory module of 
sexual and social behavior, proposed in Section 2.1, may also be without 
functional consequence due to the lack of downstream mediators.
Although no molecular data are available for the effect of flibanserin on 
oxytocin and oxytocin receptor expression, there is ample indirect evidence that 
flibanserin, similar to 8-OH-DPAT, may increase oxytocin in the hypothalamus. 
Flibanserin supports pro-social and pro-sexual behavior in female marmosets 
(Chapter 2), behaviors that are strongly associated to increased central 
oxytocin function [55-57]. Flibanserin also increases genital and non-genital 
self-grooming in female marmosets (Chapter 2), a behavior that is induced by 
central oxytocin administration in female rats [58]. Furthermore, flibanserin 
increases norepinephrine (Ne) levels in the mPFC and mPOA in female rats 
[59]. Oxytocin induces Ne release in the VMH [60], while Ne conversely induces 
oxytocin release in the PVN and the supraoptic hypothalamic nucleus (SON) 
[41]. Unlike 8-OH-DPAT, flibanserin has not been reported to impair oxytocin 
receptor function. Thus, according to Choleris’ model [34], flibanserin-induced 
increases in oxytocin in the mPOA and PVN could lead to enhanced activation 
of the amygdala and promote pro-social [41] and pro-sexual behavior [11, 61].
A flibanserin-induced increase in oxytocin signaling may also stimulate 
sexual and social behavior through the release of gonadotropin-releasing 
hormone (GnRH). Oxytocinergic neurons in the mPOA and PVN project to 
GnRH containing neurons in the mPOA to stimulate GnRH release [62]. In 
the marmoset monkey, GnRH II has been shown to stimulate female sexual 
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behavior by binding to the GnRH receptor type II, which is expressed in the 
mPOA and VMH [33]. Noradrenergic, dopaminergic and serotonergic afferents 
from the brainstem monoamine centers play an important regulatory role on 
oxytocin and GnRH release in the hypothalamic nuclei [60, 62] and serve thus 
as interface between the monoamine regulatory module described in Section 
2.1, and the regulatory module of female sexual and social behavior.
Net effect on sexual and social behavior:
Flibanserin ↑; 8-OH-DPAT ↓
3. FLIBANSeRIN AND HyPOACTIVe SexUAL DeSIRe 
DISORDeR (HSDD) IN WOMeN: WHeRe NexT?
Parallel to the marmoset study presented in this thesis, flibanserin 
underwent large Phase III clinical trials termed the BOUQUET Study Program, 
conducted by Boehringer Ingelheim [63]. The seven trials involved over 5,000 
pre-menopausal women with HSDD and were conducted in North America 
and europe, with the aim to evaluate the efficacy and safety of flibanserin. 
Trial participants suffered from primary generalized acquired HSDD for a 
period of more than 24 weeks. Inclusion criteria were, among others, that the 
participants lived in a stable, communicative, heterosexual relationship of at 
least one year, with a sexually functioning partner and that they experienced 
major personal distress due to sexual dysfunction.
The co-primary endpoints of the BOUQUET studies were the change 
from baseline to study end in the number of satisfying sexual events (SSE) 
in all trials and a sexual desire score measured using a daily electronic diary 
(eDiary). Sexual desire was measured using both the daily eDiary and the 
desire domain of the Female Sexual Function Index (FSFI). Secondary 
endpoints assessed to provide data on sexual functioning and the alleviation 
of distress, a hallmark of HSDD, using the Female Sexual Function Index 
(FSFI) and Female Sexual Distress Scale (FSDS-R).
The North American trials demonstrated significantly increased numbers 
of sexually satisfying events at the highest flibanserin dose of 100 mg/day 
(from 2.7/month to 4.5/month) compared to 2.7/month versus 3.7/month, 
respectively, in the placebo group. Flibanserin also improved the secondary 
endpoints (FSFI, FSDS-R) and was thus effective in decreasing interpersonal 
distress. The eDiary desire scores were, however, not significantly increased 
by flibanserin, when compared to placebo treatment [6, 7]. The latter result, 
together with some reported adverse events (sleepiness, dizziness and 




for flibanserin by an advisory panel of the US Food and Drug Administration 
(FDA) in August 2010. Boehringer Ingelheim, as a consequence, withdrew the 
drug from development in October 2010. Controversy regarding the usability 
of eDiary and SSE as suitable primary endpoints remains after the withdrawal 
of flibanserin, as the development of meaningful and valid end points that 
capture the complexity of women’s sexual responses is unsolved [64].3
The marmoset flibanserin data presented in this thesis suggest the possibility 
that flibanserin might indirectly affect female sexual function by improving 
the relationship with a partner. Increased female sexual attractiveness and 
strengthened pair-bond between marmoset pairmates reflect improved partner 
interactions and intimacy in the relationship between long-term sexual partners. 
Allogrooming in nonhuman primates is essential to lasting social bonding 
and the creation of a psychological environment of trust between partners 
[66], likely involving central actions of oxytocin. Flibanserin’s main effect in 
the marmoset study was to increase allogrooming in established, long-term 
marmoset pairs, while its main effect in the clinical BOUQUET trials was to 
increase sexual satisfaction and decrease distress in women in a relationship 
with a long-term sexual partner. Considering these main outcomes, it seems 
plausible that flibanserin’s therapeutic effect in the treatment of HSDD may 
be mediated by improving relationship quality and reducing sexual distress 
between partners. Flibanserin-induced improvements in sexual, social and 
emotional bonding between partners may underlie the efficacy of flibanserin in 
increasing sexual satisfaction and decreasing interpersonal distress in women 
suffering from HSDD.
For future clinical HSDD trials, the marmoset findings suggest that it 
would be valuable to consider parameters that characterize the intimacy of a 
relationship and emphasize on the role of the partner as trial end-points, thus 
exploring novel perspectives in the pharmacotherapeutic treatment of HSDD. 
In addition, the role of hypothalamic oxytocin in the regulation of female sexual 
behavior merits special attention in future studies of flibanserin. It would be 
of great interest to measure oxytocin and oxytocin receptor expression in 
the available brain tissues of chronic flibanserin treated female marmoset 
monkeys. Regions of interest should entail PVN, mPOA and amygdala, as well 
as other brain regions with high oxytocin and oxytocin receptor expression. A 
large-scale microarray study using the EUMAMA microarray would provide 
the transcriptomic correlates of the behavioral findings. Furthermore, 
3 On July 13, 2012, it was reported that the startup company Sprout Pharmaceuticals, who 
acquired flibanserin from Boehringer Ingelheim in 2011, plans to resubmit a flibanserin drug 
application to the FDA in early 2013 without additional clinical studies.  Flawed metrics  in 
looking at the data were cited that led the FDA to deny flibanserin approval [65].
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neuroimaging tools for oxytocin receptor binding are currently being developed 
[67] and may soon provide the opportunity to detect oxytocin receptors in vivo 
in both marmoset and human flibanserin trials.
4. THe BOUQUET FINALe
A bouquet of concluding statements highlights new insights gained from 
experiments conducted as part of this thesis and their added value to the 
flibanserin pivotal phase-III clinical trials (BOUQUET Study Program).
• Pair bond quality determines sexual attractiveness and activity in female 
marmoset monkeys (Chapter 2).
• Chronic 5-HT1A activation by 8-OH-DPAT causes a phenotype characterized 
by reduced female sexual receptivity and attractiveness, increased 
aggression between pairmates, increased stress reactivity and reduced 
neural activity in the medial occipital cortex (Chapters 2, 3, 4).
• Oxytocin may be the pivot of serotonergic regulation of female sexual 
behavior, pair-bond and pharmacotherapy of HSDD (Chapters 2, 5).
• Marmoset data suggest that flibanserin-induced improvements in partner 
interactions may underlie increased sexual satisfaction and reduced 
interpersonal distress in the BOUQUET studies, thus presenting unexplored 
perspectives to investigate HSDD and its future pharmacotherapy.
5. DISCLAIMER
Experiments described in the thesis were sponsored by Boehringer 
Ingelheim, proprietor and developer of flibanserin. Selection of experiments, as 
well as experimental design, was under full control of the Principal Investigators 
of the studies. Experiments described in Chapters 2, 3 and 4 were conceived 
and designed by Prof. David Abbott (PI), Dr. Alexander Converse and Yves 
Aubert. Experiments described in Chapter 5 were conceived and designed by 
Dr. Nicole Datson (PI) and Yves Aubert.
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Sexual dysfunctions in women are highly prevalent. Hypoactive sexual 
desire disorder (HSDD), as the most frequently diagnosed condition, is found in 
approximately 1 out of 10 women, causing distress and interpersonal difficulty 
that arise from unwanted, persistent or recurrent low sexual desire. Etiology 
and underlying neurobiological mechanisms of HSDD are not well understood, 
but neurotransmitter dysfunction has been proposed involving the excitatory 
regulators dopamine and norepinephrine, as well as inhibitory serotonin (5-
HT). The objective of the research described in this thesis was to investigate 
the serotonergic regulation of female sexual behavior in a nonhuman primate 
model of female sexual function. Due to its pairmate social setting comparable 
to humans, the common marmoset monkey (Callithrix jacchus) was the animal 
model of choice. Marmosets form stable male-female relationships that are 
strengthened by partner-directed social interactions, including grooming 
behavior. Females can signal interest for sexual interactions (proceptivity) 
and control the occurrence of sexual intercourse by accepting (receptivity) or 
rejecting the pairmate’s sexual advances.
A behavioral testing paradigm was developed to quantitatively assess 
the behavioral expression of proceptive and receptive sexual states of the 
female marmoset, as well as other parameters of pairmate interactions that 
give information about the pair-bond quality between the sexual partners. This 
paradigm was used to test the chronic effects of the serotonergically active 
substances flibanserin, a 5-HT1A agonist and 5-HT2A antagonist, and 8-OH-
DPAT, a 5-HT1A agonist. Flibanserin is currently being developed as a potential 
pharmacotherapeutic treatment of HSDD in women.
Chapter 1 introduced female sexuality and provided an overview of the 
classification of female sexual dysfunctions. The current knowledge of the 
neurobiology of female sexual function and dysfunction in both humans 
and animal models was presented. A concept was introduced that sexual 
behavior is centrally regulated by both excitatory and inhibitory factors. Such 
factors include steroid hormones, neuropeptides and neurotransmitters. 
On the excitatory side, estradiol, testosterone, oxytocin, melanocortin, 
dopamine and norepinephrine play an important role, while on the inhibitory 
side, opioids, cannabinoids and serotonin exert a suppressive function. The 
central serotonin neurotransmitter system was introduced in more detail, and 
the stimulatory or inhibitory function of different serotonin receptor subtypes 
was highlighted. The effects of flibanserin and 8-OH-DPAT on female sexual 
behavior in rodents (8-OH-DPAT) and in humans (flibanserin, 8-OH-DPAT) 
were described in this context. Chapter 1 also outlined how female sexuality 




particularly suitable model species to explore female sexual behavior and 
to test the chronic effects of flibanserin and 8-OH-DPAT on behavior and its 
underlying neurobiological substrate.
The main objective of Chapter 2 was to quantify the effects of chronic 
flibanserin and 8-OH-DPAT on sexual and social interactions between treated 
females and their untreated male pairmates. Repeated observations of the 
pairmates’ interactions at reunion following a 90 minute separation revealed 
remarkable and contrasting differences between flibanserin and 8-OH-
DPAT on marmoset pair behavior, despite the drugs’ shared 5-HT1A agonist 
properties. While pairmates with flibanserin-treated females were more 
frequently engaged in sexually-related and affiliative, pro-social interactions, 
the pair-bond between 8-OH-DPAT-treated females and their male partners 
was impaired as evidenced by increased female rejection of male sexual 
advances, a tendency for diminished female sexual attractiveness, reduced 
affiliative and increased agonistic interactions. We proposed that the drugs’ 
effects on social interactions and pair-bond between the pairmates play an 
important role in determining female sexual behavior in the marmoset. Chapter 
2 furthermore described the pharmacokinetic 24-hour profiles of circulating 
flibanserin and 8-OH-DPAT levels during chronic administration. The results 
showed that blood levels of flibanserin and 8-OH-DPAT were low or absent 
during the time of behavioral tests, as well as during endocrine, brain imaging 
and gene expression experiments described below.
In Chapter 3, the impact of chronic flibanserin and 8-OH-DPAT on HPA axis 
function was investigated to delineate the possibility of an HPA axis-mediated 
mechanism in the serotonergic regulation of female sexual behavior. Chronic 
flibanserin and 8-OH-DPAT neither altered circulating morning basal cortisol 
levels nor ACTH and cortisol responses to an acute 5-HT1A agonist challenge. 
Activation of hypothalamic 5-HT1A receptors stimulates the HPA axis, and a 
neuroendocrine 5-HT1A challenge can thus serve as peripheral indicator of 
central 5-HT1A receptor function. In response to 30 minute restraint stressor, 
the ACTH response was enhanced by flibanserin and 8-OH-DPAT, suggesting 
sensitized HPA axis reactivity to stress after chronic flibanserin and 8-OH-DPAT 
treatment. Cortisol was elevated after 8-OH-DPAT, but not after flibanserin 
treatment. enhanced ACTH responses to restraint were correlated with 
increased aggression and reduced sexual receptivity in 8-OH-DPAT treated 
female marmosets, supporting the hypothesis that increased stress reactivity 
may have contributed to inhibition of sexual behavior. Such correlations were 
absent in flibanserin treated females, suggesting no inhibitory effect of HPA 
axis reactivity on female sexual function after flibanserin.
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Chapter 4 described the results of a PET/MRI functional brain imaging 
experiment that was designed to measure cerebral glucose metabolism, an 
indicator of neural activity, in chronic 8-OH-DPAT or vehicle treated female 
marmosets during sexual and social interactions with their male pairmates. 
Radiolabeled [18 F]fluorodeoxyglucose (FDG) was infused immediately prior to 
a 30 minute pair test, and the females were subsequently imaged by PET under 
isofluorane anesthesia. Structural MRI scans were recorded and overlaid on the 
PeT images to improve the visualization of anatomical structures. In predefined 
regions of interest that were chosen for their involvement in mediating female 
sexual behavior and their high 5-HT1A density (mPFC, mPOA, VMH, CA1 and 
DRN), chronic 8-OH-DPAT was without effect on FDG uptake. Whole brain 
voxel-wise mapping, however, showed significantly reduced neural activity 
in a cluster located in the medial occipital cortex (mOCC), overlapping with 
a cluster derived from correlations of behavioral scores of female rejection 
behavior with FDG signals. This finding suggests that reduced neural activity 
in the mOCC may underlie the 8-OH-DPAT induced reduction in female sexual 
receptivity.
Chapter 5 described a large-scale gene expression experiment using 
the marmoset-specific eUMAMA microarray, as well as a candidate gene 
approach using real-time quantitative PCR that targeted mRNA expression of 
the 5-HT1A, 5-HT2A, 5-HT7 and 5-HTT genes. The same brain regions of interest 
were targeted as those studied in the PET imaging experiment (Chapter 4), 
with exception of the VMH, which was not analyzed.
Functional annotation clustering of microarray data showed that chronic 
8-OH-DPAT specifically altered genes associated with neurotransmission in 
the mPOA, while gene clusters associated to ion channel activity and learning 
and memory were affected in the CA1. Genes involved in intracellular signal 
transduction were affected in the DRN. Gene clusters involved in neural 
development were altered in the mPFC, mPOA and DRN, energy production 
was affected in the mPFC and mPOA, mitochondrial function in the CA1 and 
DRN, and protein transport in the mPOA and DRN. We thus proposed that 
transcriptomic changes related to neural plasticity, energy production and 
learning and memory processes in cortical, hippocampal and hypothalamic 
brain areas may have contributed to sexual impairment in response to chronic 
8-OH-DPAT administration. The microarray analysis also revealed a greater 
than 10-fold increased expression of oxytocin (OxT) in the mPOA of 8-OH-
DPAT treated females. This finding is of particular interest as the function of 
hypothalamic OxT has been closely associated with social and sexual behavior 
in rodents, nonhuman primates and humans. Serotonergic regulation of 




OxT. However, increased hypothalamic oxytocin is normally attributed to pro-
sexual and pro-social behavior, contrasting the finding reported in Chapter 5. 
Assessment of oxytocin receptor expression and signaling will be essential to 
shed more light into this apparent contradiction.
The candidate gene approach revealed that the serotonin transporter 
gene (5-HTT) was strongly upregulated in the DRN. The expression of 5-HT1A 
autoreceptors in the DRN was not altered by chronic 8-OH-DPAT, but there 
was a trend to increased 5-HT1A expression in the mPFC. expression of 5-HT2A 
was not affected by 8-OH-DPAT in any of the investigated brain regions, 
while there was a trend for decreased 5-HT7 expression in the CA1 area of 
the hippocampus. We proposed that activation of 5-HT1A autoreceptors in 
the DRN by 8-OH-DPAT likely suppressed serotonergic activity, triggering a 
compensatory upregulation of 5-HTT in the DRN and of 5-HT1A in the mPFC 
to restore the serotonergic tone.
In Chapter 6, a synthesis of the experimental findings described in Chapters 
2-5 was proposed. Contrasting effects of flibanserin and 8-OH-DPAT on 
female sexual and social behavior (Chapter 2) were discussed in context with 
enhanced HPA axis responsiveness to stress (Chapter 3), and brain region-
specific alterations in glucose metabolism (Chapter 4) and gene transcription 
(Chapter 5). In light of the discipline-spanning data set presented in this thesis 
and the multifactorial etiology of female sexual dysfunctions (see Chapter 1), 
we proposed that flibanserin and 8-OH-DPAT regulate female sexual behavior 
through four separate, but interactive modules.
In a monoamine regulatory module (i), flibanserin and 8-OH-DPAT alter 
serotonergic, dopaminergic and noradrenergic neurotransmission, causing 
altered excitatory or inhibitory input on female sexual behavior. Through this 
module, flibanserin was proposed to exert both an excitatory and dis-inhibitory 
influence on female sexual behavior. An HPA axis module (ii) accounts for 
sexually inhibitory effects due to enhanced activation of the endocrine stress 
system. This module could play a role in increased sexual rejection behavior 
of chronic 8-OH-DPAT treated female marmosets. A pair-bond, experience 
and memory module (iii) was proposed as impactful mechanism through 
which flibanserin and 8-OH-DPAT may exert their pro-sexual and pro-social 
(flibanserin), or anti-sexual and anti-social (8-OH-DPAT) actions. Oxytocin 
might play a key role in linking this module to a regulatory module of female 
sexual and social behavior (iv), which integrates the inputs from modules 
(i)-(iii) and ultimately determines the expression of female sexual and social 
behavior.
In conclusion, the synthesis of experimental data within the proposed 
theoretical framework highlighted the importance of pair-bond quality on the 
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expression of female sexual behavior and called for further investigation of 
the role of oxytocin in the serotonergic regulation of female sexual function. 
The thesis was concluded by suggesting that flibanserin’s therapeutic effect 
in women with HSDD may be rooted on improvements in sexual, social and 
emotional bonding between partners. In translating the marmoset findings to 
humans, the thesis also suggested that future HSDD trials should consider 
the inclusion of parameters that characterize the intimacy of a relationship and 









Sexueel dysfunctioneren komt bij vrouwen veel voor. Bij ongeveer 1 op 
de 10 vrouwen is er sprake van “Hypoactive sexual desire disorder (HSDD)”, 
een aandoening waarbij het libido regelmatig of aanhoudend sterk verlaagd 
is, hetgeen voor problemen zorgt in de persoonlijke en relationele sfeer. Hoe 
HSDD ontstaat en wat de onderliggende neurobiologische mechanismen 
zijn, is nog grotendeels onbekend, maar mogelijk speelt dysfunctie van de 
excitatoire neurotransmitters dopamine en norepinephrine en de inhibitoire 
neurotransmitter serotonine (5-HT) een rol. Doel van het onderzoek beschreven 
in dit proefschrift was om de rol te onderzoeken van het serotonine systeem in 
de regulatie van vrouwelijk sexueel gedrag. Hierbij werd gebruik gemaakt van 
het penseelaapje (Callithrix jacchus) als diermodel, omdat de paarvorming in 
penseelaapjes sociaal gezien veel lijkt op die van de mens. Penseelaapjes 
vormen namelijk stabiele man-vrouw koppels waarin sociaal gedrag tussen 
de partners, zoals bijvoorbeeld elkaar vlooien, een belangrijke rol speelt. 
Vrouwtjes geven hun interesse in sexuele interactie aan en reguleren ook 
wanneer dit plaatsvindt door actief sexuele avances te accepteren of af te 
wijzen. 
Een gedragstest is ontwikkeld waarmee de belangstelling van het vrouwtje 
voor en het toelaten of afwijzen van de sexuele avances van het mannetje 
kwantitiatief bepaald kan worden. Daarnaast meet deze gedragstest ook 
andere parameters die informatie geven over de interactie tussen beide 
partners van een koppel en de kwaliteit van deze interacties. Deze gedragstest 
werd vervolgens gebruikt om de chronische effecten te bepalen van twee 
verschillende serotonerge stoffen: flibanserin (een 5-HT1A agonist en 5-HT2A 
antagonist) en 8-OH-DPAT (een 5-HT1A agonist). Momenteel is flibanserin in 
ontwikkeling als potentieel geneesmiddel voor de behandeling van HSDD in 
vrouwen.
Hoofdstuk 1 gaf een inleiding in vrouwelijke sexualiteit en een overzicht van 
de indeling van vrouwelijk sexueel dysfunctioneren. De huidige stand van zaken 
van kennis van de neurobiologie van sexueel functioneren en dysfunctioneren 
in vrouwen, zowel in de mens als in diermodellen, kwam aan bod. Sexueel 
gedrag wordt centraal gereguleerd door zowel excitatoire en inhibitoire 
factoren, o.a. steroïd hormonen, neuropeptiden en neurotransmitters. Aan de 
excitatoire kant van de balans spelen oestrogenen, testosteron, oxytocine, 
melanocortine, dopamine en norepinephrine een belangrijke rol, terwijl aan 
de inhibitoire kant opioïden, cannabinoïden en serotonine een onderdrukkend 
effect hebben. Het centrale serotonine neurotransmitter systeem werd in 
meer detail besproken en de stimulerende en remmende werking van de 




van flibanserin en 8-OH-DPAT op vrouwelijk sexueel gedrag in knaagdieren 
(8-OH-DPAT) en in de mens (flibanserin, 8-OH-DPAT) werd beschreven. In 
Hoofdstuk 1 kwam ook aan bod waarom het penseelaapje een zeer geschikt 
diermodel is voor het bestuderen van vrouwelijke sexualiteit en voor het testen 
van de chronische effecten van flibanserin en 8-OH-DPAT m.b.t. gedrag en de 
onderliggende neurobiologische substraten.
De doelstelling van Hoofdstuk 2 was om de effecten te bestuderen van 
chronische behandeling met flibanserin en 8-OH-DPAT op sexuele en sociale 
interacties tussen behandelde vrouwtjes en hun onbehandelde partners. 
Er waren opvallende verschillen en tegengestelde effecten waarneembaar 
van flibanserin enerzijds en 8-OH-DPAT anderzijds op de interacties 
tussen het vrouwtje en mannetje van een koppel bij hun weerzien na een 
scheidingsperiode van 90 minuten, ondanks het feit dat beide stoffen 5-HT1A 
agonist eigenschappen gemeen hebben. Terwijl koppels met daarin flibanserin-
behandelde vrouwtjes vaker sexueel-gerelateerde en toenaderende, 
pro-sociale interacties vertoonden, was de band tussen 8-OH-DPAT-
behandelde vrouwtjes en hun partner verstoord. Dit was zichtbaar als een 
toename van afwijzing van sexuele avances door het vrouwtje, verminderde 
aantrekkelijkheid van het vrouwtje, minder toenaderende interacties en 
een toename van agonistische interacties. Dit suggereert dat beide stoffen 
(flibanserin en 8-OH-DPAT) een belangrijke rol spelen in het bepalen van 
vrouwelijk sexueel gedrag van het penseelaapje. Verder werd in Hoofdstuk 2 
de farmacokinetische 24-uurs profielen beschreven van flibanserin en 8-OH-
DPAT spiegels in de circulatie tijdens chronische toediening.  Dit toonde aan 
dat flibanserin en 8-OH-DPAT spiegels in het bloed laag of afwezig waren 
op het moment dat de gedragstesten werden uitgevoerd, en ook tijdens de 
endocriene studies, hersen imaging en gen expressie experimenten die 
hieronder worden beschreven.  
In Hoofdstuk 3 werd de impact van chronische flibanserin en 8-OH-DPAT 
behandeling op HPA-as functie onderzocht en gekeken of de HPA-as een rol 
speelde in de serotonerge regulatie van vrouwelijk sexueel gedrag. Zowel 
chronische flibanserin als 8-OH-DPAT behandeling gaven geen verandering 
in basale ochtend cortisol spiegels, en hadden ook geen effect op de 
ACTH en cortisol respons in reactie op een acute 5-HT1A agonist challenge. 
Activatie van hypothalamische 5-HT1A receptoren stimuleerden de HPA-
as, en een neuroendocriene 5-HT1A challenge kan dus dienst doen als een 
perifere indicator van centrale 5-HT1A receptor functie. Blootstelling aan 30 
minuten immobilisatie stress resulteerde in een verhoogd ACTH respons 
na flibanserin en 8-OH-DPAT behandeling, wat wijst op een sensitisatie 
van HPA-as reactiviteit op stress na chronische flibanserin en 8-OH-DPAT 
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behandeling. Cortisol was verhoogd na 8-OH-DPAT, maar niet na flibanserin 
behandeling. er bleek een correlatie te zijn tussen toename van de ACTH 
respons op immobilisatie en toegenomen aggressie en verminderde sexuele 
ontvankelijkheid in 8-OH-DPAT behandelde vrouwtjes, wat consistent is met 
de hypothese dat toegenomen stress reactiviteit bijdraagt aan de inhibitie 
van sexueel gedrag. Dergelijke correlaties waren afwezig in flibanserin-
behandelde vrouwtjes, wat  suggereert dat er geen remmend effect is van 
HPA-as reactiviteit op vrouwelijk sexueel gedrag na flibanserin behandeling. 
In Hoofdstuk 4 werden de resultaten beschreven van een PET/MRI 
functionele imaging experiment gericht op het meten van cerebrale glucose 
metabolisme, een indicator van neurale activiteit, in chronische 8-OH-
DPAT of vehicle-behandelde vrouwelijke penseelaapjes tijdens sexuele 
en sociale interacties met hun mannelijke partners. Radioactief gelabeled 
[18 F]fluorodeoxyglucose (FDG) werd aan de vrouwtjes toegediend direkt 
voorafgaand aan een 30 minuten durende interactie na hereniging  met 
hun partner, waarna de vrouwtjes onder isofluorane narcose een PeT 
scan ondergingen. Structurele MRI scans werden met de PET beelden 
gecombineerd om de visualisatie van anatomische structuren te verbeteren. 
In vooraf bepaalde hersengebieden, gekozen op basis van hun rol in 
vrouwelijk sexueel gedrag en een hoge 5-HT1A dichtheid (mPFC, mPOA, 
VMH, CA1 en DRN), bleek chronische 8-OH-DPAT geen effect te hebben op 
FDG opname. echter, voxel-wise mapping van de gehele hersenen liet een 
significante afname van neurale activiteit zien in een cluster gelegen in de 
mediale occipitale cortex (mOCC). Deze cluster vertoonde overlap met een 
cluster verkregen uit correlaties van scores van vrouwelijk afwijzingsgedrag 
en FDG signalen. Dit resultaat wijst erop dat verminderde neurale activiteit 
in de mOCC mogelijk ten grondslag ligt aan de 8-OH-DPAT geïnduceerde 
afname in vrouwelijke sexuele ontvankelijkheid.
In Hoofdstuk 5 werden de resultaten van een grootschalig genexpressie 
experiment beschreven waarbij gebruik gemaakt werd van een microarray 
met specifieke sequenties afkomstig van het penseelaapje (marmoset-specific 
microarray EUMAMA). Daarnaast werd de expressie van diverse kandidaat-
genen van het serotonine systeem gemeten m.b.v. real-time kwantitatieve 
PCR, namelijk 5-HT1A, 5-HT2A, 5-HT7 en 5-HTT. Dezelfde hersengebieden als 
in de PeT imaging studie (Hoofdstuk 4) werden onderzocht, met uitzondering 
van de VMH.   
Clustering van microarray data op basis van functionele annotatie liet zien 
dat chronische 8-OH-DPAT in de mPOA specifiek de expressie van genen 
geassocieerd met neurotransmissie beïnvloedde, terwijl de expressie van 




het CA1 gebied veranderd was. Expressie van genen die een rol spelen in 
intracellulaire signaal overdracht was met name in de DRN veranderd. Gen 
clusters betrokken bij neurale ontwikkeling waren veranderd in de mPFC, 
mPOA and DRN, gen clusters betrokken bij energie productie in de mPFC 
en mPOA, gen clusters voor mitochondriele functie in de CA1 en DRN, en 
tenslotte gen clusters voor eiwit transport in de mPOA en DRN. Op basis hiervan 
postuleerden wij dat transcriptoom veranderingen gekoppeld aan neurale 
plasticiteit, energie productie en leren en geheugen processen in corticale, 
hippocampale en hypothalamische hersengebieden mogelijk bijgedragen 
hebben aan de sexuele remming door chronische 8-OH-DPAT toediening. De 
microarray analyse detecteerde ook een meer dan 10-voudige toename in 
oxytocine (OxT) expressie in de mPOA van 8-OH-DPAT-behandelde vrouwtjes. 
Deze vondst is van belang, aangezien hypothalamische OxT functie in nauw 
verband gebracht is met sociaal en sexueel gedrag in knaagdieren, primaten 
en mensen. Serotonerge regulatie van sexueel en sociaal gedrag van het 
penseelaapje wordt dus mogelijk gemedieerd door hypothalamische OxT. 
Echter, doorgaans wordt aan een toename van hypothalamische oxytocine 
een pro-sexuele en pro-sociale werking toegeschreven, wat in tegenstelling 
is met de waarneming in Hoofdstuk 5. Verder onderzoek naar de expressie 
van oxytocine receptoren en signalering is essentieel om meer inzicht te 
verschaffen in deze ogenschijnlijke paradox.   
De kandidaat-gen aanpak liet een sterkte toename zien van expressie 
van het serotonine transporter gen (5-HTT) in de DRN. De expressie van 
5-HT1A autoreceptoren in de DRN was niet veranderd door chronische 8-OH-
DPAT toediening, maar er was wel een trend in de richting van toegenomen 
HT1A expressie in de mPFC. expressie van 5-HT2A werd niet beïnvloed door 
8-OH-DPAT in alle onderzochte hersengebieden, maar er was wel een trend 
waarneembaar richting een afname van 5-HT7 expressie in het CA1 gebied 
van de hippocampus. Mogelijk resulteert activatie van 5-HT1A autoreceptoren 
in de DRN door 8-OH-DPAT in een onderdrukking van serotonerge activiteit, 
wat een compensatoire upregulatie induceert van 5-HTT in de DRN en van 
5-HT1A in de mPFC om de serotonerge tonus te herstellen.
In Hoofdstuk 6 werd een synthese gegeven van de experimentele 
bevindingen beschreven in Hoofdstukken 2-5. Contrasterende effecten van 
flibanserin en 8-OH-DPAT op vrouwelijk sexueel en sociaal gedrag (Hoofdstuk 
2) werden besproken in de context van toegenomen HPA-as responsiviteit 
op stress (Hoofdstuk 3), en hersengebied-specifieke veranderingen in 
glucose metabolisme (Hoofdstuk 4) en genexpressie (Hoofdstuk 5). In het 
licht van de discipline-overstijgende data set beschreven in dit proefschrift 
en de multifactoriele etiologie van sexuele dysfunctie in vrouwen  (Hoofdstuk 
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1), postuleren wij dat flibanserin en 8-OH-DPAT vrouwelijk sexueel gedrag 
reguleren via een viertal individuele maar interactieve modules. 
In de monoamine regulatoire module (i), veranderen flibanserin en 
8-OH-DPAT serotonerge, dopaminerge en noradrenerge neurotransmissie, 
resulterend in een verandering in excitatoir of inhibitoir input op vrouwelijk 
sexueel gedrag. Via deze module zou flibanserin zowel een excitatoire en dis-
inhibitoire invloed hebben op vrouwelijk sexueel gedrag. De HPA-as module 
(ii) is verantwoordelijk voor sexueel remmende effecten vanwege verhoogde 
activatie van het endocriene stress systeem. Deze module speelt mogelijk een 
rol in de toegenomen sexuele afwijzing van de partner door chronisch 8-OH-
DPAT behandelde vrouwelijke penseelaapjes. De paarvorming, ervaring en 
geheugen module (iii) werd voorgesteld als mechanisme via welk flibanserin 
en 8-OH-DPAT mogelijk hun pro-sexuele and pro-sociale (flibanserin), of anti-
sexuele en anti-sociale (8-OH-DPAT) werking uitoefenen. Oxytocine speelt 
mogelijk een sleutelrol bij het verbinden van deze module aan een regulatoire 
module voor vrouwelijk sexueel en sociaal gedrag (iv), die input ontvangt van 
modules (i)-(iii), deze integreert en uiteindelijk vertaalt naar vrouwelijk sexueel 
en sociaal gedrag. 
Concluderend, uit de experimenten beschreven in dit proefschrift komt 
het belang van de kwaliteit van de band tussen de twee partners van een 
koppel voor de expressie van vrouwelijk sexueel gedrag sterk naar voren. De 
rol van oxytocine in de serotonerge regulatie van vrouwelijk sexueel gedrag 
moet verder onderzocht worden. Het therapeutisch effect van flibanserin voor 
vrouwen met HSDD zou kunnen berusten op verbeteringen in de sexuele, 
sociale en emotionele band tussen partners. Bij het extrapoleren van de 
bevindingen in het penseelaapje, beschreven in dit proefschrift, naar de mens 
zouden toekomstige klinische studies op het terrein van HSDD er goed aan 
doen als klinische uitleesparameters maten voor de intimiteit van een relatie 
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